Abbreviated Title:  Ph2Sunitinib Thymoma/Thymic Ca CTEP Protocol #: 9174  
Version Date:  04/30/2020  
 
1 
 Abbreviated Title: Ph2Sunitinib-Thymoma/Thymic Ca 
CTEP  Protocol #:  9174   
CC Protocol #:  12-C-0118 Study ID: [REMOVED] 
  Title:  A Phase II Study of Sunitinib in Patients with Advanced Relapsed or Refractory 
Thymoma or Thymic Carcinoma with at Least One  Prior Line of Platinum- Based Systemic 
Chemotherapy  Coordinating Center:  Center for Cancer Research / National Cancer Institute  
10 Center Drive Bethesda, MD 20892   
NCI Principal Investigator:  Arun Rajan , MD 
A-F 
Thoracic and GI  Malignancies  Branch/CCR/NCI  
Bldg 10- CRC RM 4 -5330 MSC 1465 
10 Center Drive Bethesda, MD 20892-1465 Telephone: 240 760-6236 Email: rajana@mail.nih.gov
  
  NCI Lead Associate Investigator: 
Anish Thomas, MD DTB /CCR/NCI
 A- F 
Bldg 10- CRC RM 4 -5330 MSC 1465 
10 Center Drive Bethesda, MD 20892-1465 Telephone: 240-760-6241  E-mail: anish.thomas@nih.gov
   
  NIH Associate Investigators:  
Jane Trepel, DTB , CCR, NCI F 
10 Center Drive, Room  12C432A 
Bethesda, MD 20814  
Phone: 301-496-1547 
Email: trepelj@mail.nih.gov  Corrine Keen, RN, OCD, CCR, NCI A, B, C 
10 Center Drive, Room  8D44B 
Bethesda, MD 20814  
Phone: 240-760-6097 
Email: ck232s@nih.gov  
Raffit Hassan, MD, TGMB , CCR, NCI A-F 
Building  10, Room 4-5330 
Bethesda, MD 20892  
Phone: 240-760-6232 
Email: hassanr@mail.nih.gov  Arlene Berman, RN, OCD, CCR, NCI A, B, C 
10 Center Drive, Room  8D44 
Bethesda, MD 20814  
Phone: 240-760-6096 
Email: arleneb@mail.nih.gov  
 
Abbreviated Title:  Ph2Sunitinib Thymoma/Thymic Ca CTEP Protocol #: 9174  
Version Date:  04/30/2020  
 
2 
 Paul Meltzer, MD, GB, CCR, NCI F 
37 Convent Drive 
Building 37, Room 6138 
Bethesda, MD 20814  
Phone: 240-760-6136 
Email: pmeltzer@mail.nih.gov  Linda Sciuto, RN, OCD, CCR, NCI A, B, C 
10 Center Drive, Room 13N230 
Bethesda, MD, 20814  
Phone: 240-760-6117 
Email: lsciuto@mail.nih.gov  
Eva Szabo, MD, DCP, NCI A- F 
9609 Medical Center Drive, Room 5E102 
Bethesda, MD 20852 
Phone: 240-276-7011 
Email: azaboe@mail.nih.gov  Christine Alewine, MD, LMB , CCR, NCI A-F 
37 Convent Drive, Room  
Bethesda, MD, 20814  
Phone: 240-760-6146 
Email: alewinecc@mail.nih.gov  
 
         
Statistician :                            Seth M. Steinberg, PhD OCD/CCR/NCI  F 
9609 Medical Center Drive, Room 2W334 MSC 9716 Rockville, MD 20850-9716 Telephone: 240-276-5563  
E-mail: steinbes@mail.nih.gov
  
 Referral Contact and 
Study Coordinator :              Arlene Berman, RN
 A, B, C 
10 Center Drive, Room 12N226 Bethesda, MD 20814 Phone: 240-760-6096 Fax: 301-480-2590 Email: arleneb@mail.nih.gov
  
 Investigator Role Code Key 
A. Obtain information by intervening or interacting with living individuals for research purposes 
B. Obtaining identifiable private information about living individuals 
C. Obtaining the voluntary informed consent of individuals to be subjects 
D. Makes decisions about subject eligibility  
E. Studying, interpreting, or analyzing identifiable private information or data/specimens for 
research purposes 
F. Studying, interpreting, or analyzing coded, linked data or specimens for research purposes  
G. Some/all research activities performed outside NIH  
  
Abbreviated Title:  Ph2Sunitinib Thymoma/Thymic Ca CTEP Protocol #: 9174  
Version Date:  04/30/2020  
 
3 
  
Drug Sponsor:   CTEP # 9174 
 
NCI Supplied Agent:   Sunitinib malate  (NSC 736511,  IND # 74019) 
 Protocol Type:  Interventional / Version #19/ Version Date:   04/30/2020 
  Affiliated Institution  Indiana  University Simon Cancer Center  
    Federal Wide Assurance Number (FWA) # 00003544 
 Lead Site Investigator:  Patrick J. Loehrer, Sr., MD  
Director, Indiana University Simon Cancer Center 535 Barnhill Drive, Room 473 Indianapolis, IN 46202-5289 Telephone: 317-274-3539 Fax: 317-278-4190 E-mail: ploehrer@iupui.edu
  
 IRB/Research Contacts:  Jessica Sastre  
Regulatory Compliance Coordinator Clinical Trials Office  
535 Barnhill Drive, RT380 Indianapolis, IN 46202 Phone: 317.278.5615 Fax:  317.274.8022 
jsastre@iu.edu
 
 Pharmacy Contact:   Bonnie Klank, PharmD 
Investigational Drug Services IUSCC Room C2102 550 N. University Blvd.  Indianapolis, IN 46202 Direct Line: 317 -948-6881; 
IDS Main: 317-944-1900; Fax: 317-948-1697 Email: bklank@iuhealth.org
   
    IDS@iuhealth.org   
 
Research Nurse:  A. John Spittler RN, BSN 
GI Oncology and Thymoma Clinical Research Nurse 535 Barnhill Drive Indianapolis, IN 46202 Telephone: 317-274-0771 Fax: 317-274-8007 
    E- mail: ajspittl@iupui.edu
  
Abbreviated Title:  Ph2Sunitinib Thymoma/Thymic Ca CTEP Protocol #: 9174  
Version Date:  04/30/2020  
 
4 
 PRÉCIS   
 
Background:  
Platinum- based  chemotherapy is the standard of care for advanced unresectable thymoma and  
thymic carcinoma. However over 50% of these patients may fail initial therapy and therefore 
require second -line therapy. New therapeutic options are needed for patients who have disease 
progression on or after platinum- containing therapy. Results obtained from protocol 12-C- 0118 so 
far have shown impressive clinical activity of sunitinib in patients with recurrent thymic carcinoma with an objective response rate of 23% and disease control rate of 91% which is unprecedented for this histology. Treatment at a dose of 50 mg once daily for four weeks followed by 2 weeks off 
was poorly tolerated. Twenty five out of 41 patients needed  dose reductions due to development 
of intolerable adverse events.   Objectives:  
Primary objective:  
• To evaluate the objective response rate (PR+CR) for sunitinib in patients with relapsed or refract ory thymoma or thymic carcinoma 
 Main Eligibility:  
• Patients with histologically confirmed thymoma (Group 1 only) or thymic carcinoma who have previously been treated with  at least one platinum-containing chemotherapy regimen 
with progressive disease prior to study entry 
• Measurable disease by RECIST 1.1 criteria  
• Adequate renal, hepatic and hematopoietic function 
• No major surgery, radiotherapy, chemotherapy or biologic therapy within 28 days  of 
sunitinib  
 Design:  
• In the first group (Group 1), sunitinib will be administered orally using a continuous 
schedule at 50 mg per day for 4 weeks with 2 weeks off to constitute a 6- week cycle 
(Schedule 4/2) until disease progression or development of intolerable side- effects.  
• In the second group (Group 2), s unitinib will be administered orally using a continuous 
schedule at 50  mg per day for 2 weeks with 1 week off to constitute a 3- week cycle 
(Schedule 2/1) until disease progression or development of intolerable side- effects.  
• Toxicity will be assesse d every cycle by CTCAE Version 5.0  
• Tumor res ponse assessments by RECIST 1.1 criteria will be performed every  cycle for 
Group 1 and every other cycle for Group 2 (every 6 weeks) for patients receiving treatment 
for less than one year, and every two cycles  for Group 1 and every four cycles for Group 2 
(every 12 weeks) for patients who have been receiving treatment one year or longer. 
• Exploratory studies include evaluation of serum VEGFR2, PLGF, IL -4, IL -12, HGF, and 
b-FGF (Group 1 only) ; and circulating tumor cells, endothelial progenitors , and mature 
apoptotic endothelial cells  (both groups). In Group 2, regulatory T cells (Tregs), exhausted 
CD8 T cells, myeloid -derived suppressor cells (MDSCs), and Th1/Th2 T cell populations  
will also be evaluated . Where tumor samples are available, intra-tumoral immune infiltrate  
will be assessed  (both groups).  Exploratory studies apply to NCI only.  
Abbreviated Title:  Ph2Sunitinib Thymoma/Thymic Ca CTEP Protocol #: 9174  
Version Date:  04/30/2020  
 
5 
 TABLE OF CONTENTS  
SUMMARY OF PROTOCOL CHANGES  ................................... Error! Bookmark not defined.  
Précis  4 
TABLE OF CONTENTS  .................................................................................................................5  
1 OBJECTIVES  ......................................................................................................................8  
1.1 Primary Objectives ...................................................................................................8  
1.2 Secondary Objectives ...............................................................................................8  
1.3 Explor atory Objectives  ............................................................................................8  
2 BACKGROUND AND RATIONALE  ................................................................................8  
2.1 Thymoma and Thymic Carcinoma ..........................................................................8  
2.2 Sunitinib Malate  .....................................................................................................11  
2.3 Rationale  ................................................................................................................21  
2.4 Exploratory Studies Background ...........................................................................25  
3 PATIENT SELECTION  ....................................................................................................27  
3.1 Eligibility Criteria  ..................................................................................................27  
3.2 Exclusion Criteria  ..................................................................................................29  
3.3 Inclusion of Women and Minorities ......................................................................31  
4 REGISTRATION PROCEDURES  ...................................................................................32  
4.1 Coordinating Center ...............................................................................................32  
4.2 Participating Site  ....................................................................................................32  
4.3 Treatment Initiation Timeline  ................................................................................32  
5 TREATMENT PLAN  ........................................................................................................32  
5.1 Agent Administration .............................................................................................32  
5.2 General Concomitant Medication and Supportive Care Guidelines ......................34  
5.3 Duration of Therapy ...............................................................................................37  
5.4 Durati on of Follow Up ...........................................................................................37  
5.5 Criteria for Removal from Study  ...........................................................................37  
6 DOSING DELAYS/DOSE MODIFICATIONS  ...............................................................38  
6.1 General Guidance ...................................................................................................38  
6.2 Treatment delays and modifications for administrative needs  ..............................38  
6.3 Treatment delays and modifications for medical needs  .........................................39  
6.4 Sunitinib Monotherapy Dose Level Reductions (Groups 1 and 2) ........................39  
6.5 Management of Treatment -Emergent Hypertension .............................................39  
6.6 Dosage Modification Criteria for Other Hematologic and Non-
Hematologic Adverse Events  .................................................................................39  
6.7 Management of Other Clinically Significant Sunitinib -related AEs  .....................41  
7 NIH REPORTING REQUIREMENTS/DATA AND SAFETY MONITORING PLAN .................................................................................................................................42
 
Abbreviated Title:  Ph2Sunitinib Thymoma/Thymic Ca CTEP Protocol #: 9174  
Version Date:  04/30/2020  
 
6 
 7.1 Definitions ..............................................................................................................42  
7.2 OHSRP Office of Compliance and Training  / IRB Reporting  ............................42  
7.3 NCI Clinical Director Reporting  ............................................................................42  
7.4 IND Sponsor Reporting Criteria ............................................................................42  
7.5 Routine Adverse Event Reporting .........................................................................50  
7.6 NIH Required Data and Safety Monitoring Plan ...................................................51  
8 PHARMACEUTICAL INFORMATION  ..........................................................................51  
8.1 Sunitinib [Sunitinib Malate (NSC 736511)] ..........................................................51  
8.2 Agent Ordering and Agent Accountability ............................................................53  
9 BIOMARKER, CORRELATIVE, AND SPECIAL STUDIES  ........................................54  
9.1 Serum VEGFR2, PLGF, IL- 4, IL -12, HGF, b- FGF – Group 1 only .....................54  
9.2 Circulating tumor cells, circulating endothelial progenitors, mature 
apoptotic endothelial cells, regulatory T cells (Tregs)*, exhausted CD8 T cells*, myeloid -derived suppressor cells (MDSCs)*, and Th1/Th2 T cell 
populations* ...........................................................................................................54
 
9.3 Intra -tumoral immune infiltrate, where tumor samples are available  ....................54  
9.4 Sample Storage, Tracking and Disposition ............................................................55  
10 DATA COLLECTION AND EVALUATION  ..................................................................55  
10.1  Data Collection  ......................................................................................................55  
11 STUDY CALENDAR  .......................................................................................................56  
12 MEASUREMENT OF EFFECT ........................................................................................61  
12.1  Antitumor Effect – Solid Tumors ..........................................................................61  
13 DATA REPORTING / REGULATORY REQUIREMENTS  ...........................................66  
13.1  Data Reporting  .......................................................................................................66  
14 CTEP MULTICENTER GUIDELINES  ............................................................................67  
15 CCR MULTI -INSTITUTIONAL GUIDELINES  .............................................................67  
15.1  IRB Approvals .......................................................................................................67  
15.2  Amendments and Consents ....................................................................................67  
16 COLLABORATIVE AGREEMENTS  ..............................................................................67  
17 STA TISTICAL CONSIDERATIONS ...............................................................................69  
17.1  Study Design/Endpoints.........................................................................................69  
17.2  Sample Size/Accrual Rate ......................................................................................71  
17.3  Stratification Factors  ..............................................................................................71  
17.4  Analysis of Secondary Endpoints ..........................................................................71  
17.5  Reporting and Exclusions ......................................................................................72  
18 HUMAN SUBJECTS PROTECTIONS  ............................................................................72  
18.1  Rationale For Subject Selection  .............................................................................72  
Abbreviated Title:  Ph2Sunitinib Thymoma/Thymic Ca CTEP Protocol #: 9174  
Version Date:  04/30/2020  
 
7 
 18.2  Participation of Children  ........................................................................................73  
18.3  Participation of Subjects Unable to Give Consent .................................................73  
18.4  Evaluation of Benefits and Risks/Discomforts ......................................................74  
18.5  Risks/Benefits Analysis  .........................................................................................74  
18.6  Consent and Assent Process and Documentation ..................................................74  
19 REFERENCES  ..................................................................................................................75  
20 Appendix A: performance status criteria ...........................................................................84  
21 Appendix B: New York Heart Association Classification of Cardiac Disease .................85  
22 Appendix C: Drugs Known to be Metabolized by Selected CYP450 Isoenzymes  ...........86  
23 Appendix D: Patient’s medication diary ............................................................................88  
24 Appendix E: CTEP MULTICENTER GUIDELINES  ......................................................92  
25 Appendix F: Collection/Recording of Blood Pressure Information ..................................94  
26 Appendix G: Management of Sunitinib- Induced Hyperte nsion ........................................96  
27 Appendix H ......................................................................................................................100  
28 Appendix I: LIST OF PRESCRIPTION AND OVER THE COUNTER 
MEDICATIONS THAT MAY INTERACT WITH SUNITINIB (SUTENT®)  .............104  
Abbreviated Title:  Ph2Sunitinib Thymoma/Thymic Ca CTEP Protocol #: 9174  
Version Date:  04/30/2020  
 
 8 1 OBJECTIVES  
1.1 PRIMARY OBJECTIVES  
 
• To evaluate the objective response rate (PR+CR) for sunitinib in patients with relapsed or 
refractory thymoma (Group 1 only) or thymic carcinoma  
 
1.2 SECONDARY OBJECTIVES  
 
• To determine the progression-free survival (PFS) and overall survival (OS) for sunitinib 
in patients with relapsed or refractory thymoma (Group 1 only) or thymic carcinoma  
• To assess safety and tolerability of sunitinib 
• To assess the duration of response to sunitinib 
 
1.3 EXPLORATORY OBJECTIVES   
 
Periph eral blood will be collected to evaluate serum VEGFR2, PLGF, IL -4, IL -12, HGF, and b-
FGF (Group 1); and circulating tumor cells, endothelial progenitors, and mature apoptotic endothelial cel ls at various time points  (both groups). For Group 2, regulatory T cells (Tregs), 
exhausted CD8 T cells, myeloid-derived suppressor cells (MDSCs), and Th1/Th2 T cell populations will also be evaluated at  various time points . Where tumor samples are available, 
intra-tumoral immune infiltrate will be assessed  (both groups).  Exploratory studies apply to NCI 
only.  
2 BACKGROUND AND RATIONALE  
2.1 T
HYMOMA AND THYMIC CARCINOMA  
Thymoma is the most common tumor in the anterior mediastinum in adults with an incidence of 
0.15 cases per 100,000 person years based on National Cancer Institute Surveillance, Epidemiology, and End Results data.
1 Although thymomas are histologically benign, they can 
potentially invade through the capsule, infi ltrate surrounding organs and rarely metastasize to 
distant organs. Thymomas are primary tumors of thymic epithelial cells; but on histology, B and T lymphocytes, intradigitating reticulum cells, macrophages, and myoid cells are also seen.  
2,3   
 World Health Organization (WHO) pathologic classification which takes into account both histologic and morphologic features, is the most widely used classification system of thymomas (Table 1).
4 Proposed in 1999, it and has since then been validated as an indicator of invasiveness, 
immunologic function and prognosis .5-7 This system divides thymomas into two groups based on 
whether the neoplastic epithelial cells and their nuclei have a spindle and/or oval shape (type A) or whether these cells have a dendritic or plump (epithelioid) appearance (type B). Tumors that combine these two morphologies are designated type  AB. Type B tumors are further subdivided 
into B1, B2, and B3, respectively, on the basis of the proportional increase of the epithelial component and the emergence of atypia of the neoplastic cells. Thymic carcinomas are categorized 
Abbreviated Title:  Ph2Sunitinib Thymoma/Thymic Ca CTEP Protocol #: 9174  
Version Date:  04/30/2020  
 
 9 as type C .4 Thymic carcinomas are rare, constituting only 0.06% of all thymic neoplasms. They 
are typically invasive, have a greater propensity to capsular invasion, metastases and a higher risk 
of relapse and death . 8-10 
 
Table 1: WHO classification of epithelial thymic malignancies  
WHO type  Histologic description  
A Medullary thymoma  
AB Mixed thymoma  
B1 Predominantly cortical thymoma  
B2 Cortical thymoma  
B3 Well -differentiated thymomic carcinoma  
C Thymic carcinoma  
 
Since most patients do not have nodal disease or metastases, the tumor, node, metastasis staging system is not particularly useful for thymomas. The Masaoka staging which takes into account the extension and invasion of tumor into surrounding organs is the most widely used staging system 
for thymomas  (Table 2).
11 Proposed in 1981, it and has since then been found to correlate with 
overall survival of patients with thymoma and thymic carcinoma. 12,13  
 
Table 2: Masaoka staging of thymomas  
Masaoka 
Stage  Stage description  
Stage I  Macro and microscopically encapsulated (tumors invading into but  
not through the capsule)  
Stage II  A. Microscopic transcapsular invasion  
B. Macroscopic invasion into surrounding fatty tissue or grossly 
adherent to but not through mediastinal pleura or  pericardium  
Stage III  Macroscopic invasion into neighboring organs (i.e. pericardium,  great 
vessels, lung) 
A. without invasion of great vessels 
B. with invasion of great  vessels  
Stage IV  A. Pleural or pericardial dissemination  
B. Lymphogenous or hematogenous metastases  
 Thymomas are slow growing tumors and a large proportion of patients are asymptomatic at diagnosis, while the rest may present either with symptoms related to a mediastinal mass or with autoimmune paraneoplastic syndromes.
14 The latter may be found in up to 50- 60% of patients and 
includes a wide spectrum of disorders: immune mediated cy topenias, hypogammaglobulinemia, 
pemphigus, systemic lupus erythematosus and neurologic syndromes. Polymyositis, hepatitis, and 
myocarditis are less frequent autoimmune paraneoplastic syndromes associations of thymoma. 
However, myasthenia gravis (MG) is the most common paraneoplastic syndrome associated with thymoma, seen in approximately 30–45% of the patients. The etiology of autoimmune phenomenon associated with thymoma is not known. Thymomas tend to grow locally and do not 
often extend beyond the chest. Although unilateral metastatic pleural depositions  are not rare, 
distant metastases are very uncommon, except in very advanced stages of the disease.
14 
Abbreviated Title:  Ph2Sunitinib Thymoma/Thymic Ca CTEP Protocol #: 9174  
Version Date:  04/30/2020  
 
 10  
Table 3: Responses to combination chemotherapy and biologic agents in thymic 
malignancies  
Author  
(year of publication)  Number of patients  Drugs  ORR 
Chemotherapy  
Fornasiero (1991 )15 37 ADOC  91% 
Loehrer (1994 )16 29 PAC  50% 
Giaccone (1996)17 16 EP 56% 
Berruti (1999)18 16 ADOC  81% 
Loehrer (2001 )19 34 VIP 32% 
Loehrer (2006)20 27 Pemetrexed  17% 
Lemma (2011 )21 44 Carbo platin /Paclitaxel  32% 
Biologic agents   
Loehrer (2004 )22 38 Octreotide± prednisone  11% 
Giaccone (2009 )23 7 Imatinib  0 
Giaccone (2011 )24 41 Belinostat  8% 
Kurup (2005)25 26 Gefitinib  4% 
Gordon (19 95)26 14 Interleukin -2 0 
Abbr eviations: ADOC: Cisplatin, doxorubicin, cyclophosphamide  and vincristine ; PAC: 
cisplatin, doxorubicin, and cyclophosphamide; EP: Cisplatin, etoposide; VIP: Etoposide, 
ifosfamide , and cisplatin ; ORR Objective response rates  
 
Due to the rare nature of thymic malignancies , there are no definitive trials which guide the 
management of these patients. Based on retrospective case series, surgery has been established as 
the mainstay of treatment of non- metastat ic thymoma and thymic carcinoma. Given the relatively 
slow growth of well differentiated thymomas, surgery also has a role in locally advanced tumors that are not radically resectable and in those that have loco -regionally relapsed. Chemotherapy, 
before and/or after surgery, and radiation therapy (RT) may be useful in selected patients.
3  
 In patients with unresectable or metastatic disease, chemotherapy is the primary treatment modality.
2 In general, response rates are higher with combination chemotherapy (in the range of 
30-90%) compared with single- agent chemotherapy; 2  however, no randomized trials have been 
conducted to date. Over 50% of patients with locally advanced or metastatic thymoma or thymic carcinoma may fail initial therapy and therefore require second -line therapy.  Active agents 
include cisplatin,  vincristin e, doxorubicin, etoposide, cyclophosphamide and ifosfamide. Widely 
used first line chemotherapy combinations include cisplatin/etoposide (EP), cisplatin/etoposide/ifosfamide  (VIP), cisplatin/ doxorubicin/ cyclophosphamide (PAC) and 
Cisplatin/ doxorubicin/ cyclophosphamide/ vincristine (ADOC). Biological agents investigated thus far also have variable rates of response, ranging from 0 to 40%. Table 3 summarizes 
response rates to  combination chemotherapy and biologic agents in patients with recurrent or 
metastatic thymic malignancies  who failed prior chemotherapy.  
 
Abbreviated Title:  Ph2Sunitinib Thymoma/Thymic Ca CTEP Protocol #: 9174  
Version Date:  04/30/2020  
 
 11 As discussed  earlier, thymic c arcinomas are associated with poorer response rates, more 
aggressive clinical course and shorter survival. Results of systemic therapy in patients with 
recurrent thymic carcinoma have been discouraging with most studies showing minimal to no objective responses and median PFS ranging between 1.4 and 6 months ( Table 3B
). In contrast, 
treatment with sunitinib was associated with a response rate of 23%, a disease control rate of 91% and median PFS of 6.7 months in patients with thymic carcinoma. These results were comparable to those seen in a recently reported clinical trial of carboplatin and amrubicin. It should be noted that almost 60% of patients with thymic carcinoma on this study had received no previous chemotherapy. 
 
However, treatment was poorly tolerated at the prescribed dose of 50 mg per day using a 4 weeks on and 2 weeks off schedule. More than half of the patients treated needed a dose reduction to 37.5 mg per day or 25 mg per day. 
 
Table 3B. Systemic therapy in previously treated patients with Thymic Epithelial 
Tumors  
InterventionRef Number of Patients  Responses  PFS/TTP  OS 
Pemetrexed20 Thymoma = 16  
Thymic carcinoma = 11  NR 
NR 45.4 weeks  
5.1 weeks  NR 
Capecitabine + 
Gemcitabine27 Thymoma = 12  
Thymic carcinoma = 3  5 
1 11 months  
6 months  Not reached  
Octreotide + 
Prednisone22 Thymoma = 32  
Thymic Carcinoma = 6  12 
0 8.8 months  
4.5 months  Not reached  
23.4 months  
Erlotinib + 
Bevacizumab28 Thymoma = 11  
Thymic carcinoma = 7  0 
0 NR 
NR Not reached  
Belinostat24 Thymoma = 25  
Thymic carcinoma = 16  2 
0 11.4 months  
2.7 months  Not reached  
12.4 months  
Amrubicin + 
Carboplatin*29 Thymoma = 18  
Thymic carcinoma = 33  3 
10 7.6 months  
7.6 months  Not reached  
27.3 months  
Cixutumumab 
(unpublished)  Thymoma = 37  
Thymic carcinoma = 12  5 
0 9.5 months  
1.4 months  25 months  
8.3 months  
Sunitinib  
(unpublished)  Thymoma = 16  
Thymic carcinoma = 22  1 
5 7.6 months  
6.7 months  Not reached  
12.6 months  
* Only 3 of 18 patients with thymoma and 14 of 33 thymic carcinoma had received previous chemotherapy  
 
2.2 SUNITINIB MALATE  
 Sunitinib malate (sunitinib; SU11248; SU011248; Sutent®) is an oral, multi- targeted, small 
molecule inhibitor of the receptor tyrosine kinases (RTKs) involved in tumor proliferation and angiogenesis, including vascular endothelial growth factor receptor- 1 (VEGFR -1), - 2, and -3, 
platelet -derived growth factor receptor (PDGFR) - α and -β, stem cell factor receptor (KIT), the 
tyrosine kinase (TK) receptor encoded by the ret proto -oncogene (RET; rearranged during 
transfection), fm s-like tyrosine kinase 3 (Flt3), basic fibroblast growth factor (bFGF) and colony-
stimulating factor (CSF) -1R. 
30-34  Sunitinib selectively and potently inhibits the class III and 
Abbreviated Title:  Ph2Sunitinib Thymoma/Thymic Ca CTEP Protocol #: 9174  
Version Date:  04/30/2020  
 
 12 class V split -domain RTKs.30 
 
Sunitinib shows significant antitumor and anti-angiogenic activity in a number of human  tumor xenograft and angiogenesis models in mice as well as in phase 1 and 2 studies in  patients with a 
variety of tumor types.
31,32  As of Oc tober 2009, a total of 9914 subjects with solid malignant 
tumors have received sunitinib, including patients with renal cell carcinoma (RCC) and those with gastrointestinal stromal tumors (GIST) (Investigator’s  Brochure, 2011).  In phase 2 studies in cytokine-refractory metastatic RCC, sunitinib produced objective responses in 40% of patients with a median time -to-tumor- progression (TTP) of 8.7 months.
 33  In phase 3 studies of patients 
with imatinib -resistant GIST, sunitinib was highly superior to placebo (p<0.0001) with respect to 
median TTP (27.3 weeks vs. 6.4 weeks), progression-free survival (PFS), and overall survival (OS).
34 
 Sunitinib was granted regular approval on January 26, 2006 by Food and Drug Administration 
(FDA) for the treatment of gastrointestinal stromal tumor (GIST) after disease progression on or 
intolerant to imatinib mesylate and accelerated approval for advanced RCC, which was changed to regular approval on February 2, 2007.
35-37 
 
2.2.1 Mechanism of Action  
Tumor VEGF expression has been associated clinically with disease prognosis in many different types of malignancies.  VEGF expression is increased by diverse stimuli including proto-oncogene activation and hypoxia, with the hypoxic state frequently arising in solid tumors because of inadequate perfusion.  In addition to its angiogenic role, VEGF also profoundly increases the permeability of the vasculature thereby, potentially contributing to tumor progression.  A leaky tumor endothelium enhances nutrient and catabolite exchange and represents less of a barrier to tumor cell migration and intravasation during metastasis.  Two high- affinity receptors for VEGF with associated TK activity have b een identified on human 
vascular endothelium; VEGFR- 1/Flt-1 and VEGFR-2/kinase insert domain-containing receptor 
(KDR).  Although the relative contributions of KDR and Flt-1 signaling in mediating tumor progression have not been elucidated, a number of studies suggest that KDR performs a predominant role.  In addition to VEGF receptor signaling, increasing evidence implicates PDGFR signaling in tumor angiogenesis.  Recent nonclinical evidence suggests that inhibition of PDGFR signaling augments the antitumor and anti-angiogenic effects of VEGFR inhibitors.  In addition, PDGF signaling is implicated in the autocrine growth of tumor cells and in the recruitment and regulation of tumor fibroblasts.  Upon chronic oral dosing, sunitinib is expected to inhibit PDGF - and VEGF- driven angiogenesis 
and as a consequence, limit solid tumor growth.  Because angiogenesis is necessary for the growth and metastasis of solid tumors, and VEGF is believed to have a pivotal role in this process, sunitinib treatment may have broad -spectrum clinical utility.
31,38  Sunitinib also exerts 
direct antitumor activity on cells that express target RTKs associated with tumor cell proliferation, such as KIT, PDGFR, and RET.  The clinical activity of sunitinib in patients with advanced GIST is an example of this antitumor effect. 
Abbreviated Title:  Ph2Sunitinib Thymoma/Thymic Ca CTEP Protocol #: 9174  
Version Date:  04/30/2020  
 
 13  
2.2.2 Nonclinical Specificity and Efficacy Studies  
In vitro  studies have demonstrated the specificity of sunitinib for inhibition of the Class 3 and 
Class 5 RTKs, including receptors for VEGF (VEGFR), KIT, Flt-3, and PDGFR (Investigator’s 
Brochure, 2011).  Specifically, receptor phosphorylation inhibition studies have shown that sunitinib inhibits KIT -ligand -induced phosphotyrosine levels in a dose-dependent manner with 
IC
50 values of 0.001-0.01 mcM in vitro  and reduced PDGFR- β phosphotyrosine levels in vivo .39  
Sunitinib also selectively inhibited proliferation of human umbilical vein endothelial cells (HUVEC) stimulated with VEGF (IC
50=0.04 mcM) compared to FGF- stimulated prolif eration 
(IC 50=0.7 mcM).30 
 In animal efficacy studies, sunitinib showed broad antit umor activity in mouse  xenograft models 
against a variety of human tumor cell lines including colorectal cancer (HT-29, Colo205), non-small cell lung cancer (H460), breast cancer (MDA -MB-435), melanoma (A375), epidermoid 
cancer (A431), and glioma (SF763T).
30  Sunitinib has also demonstrated antitumor activity 
against other breast cancer  models (MMTV -v-Ha-ras transgenic mouse mammary carcinoma and 
dimethylbenzanthracene [DMBA] -induced rat mammary carcinomas).40  In an animal model of 
KIT-expressing small cell lung cancer (SCLC; NCI -H526), sunitinib administration resulted in 
greater tumor growth inhibition than did imatinib.39 
 Combination studies of sunitinib with docetaxel, 5- fluorouracil (5 -FU), or doxorubicin resulted 
in significantly enhanced growth inhibition of human MX- 1 breast cancer xenografts compared 
to levels of inhibition with either sunitinib or the cytotoxic agent alone.
40  Moreover, the 
combination therapies each led to a significantly increased survival compared to either single agent alone. 
40 Significantly delayed tumor growth has also been demonstrated in combination 
studies of sunitinib and cisplatin in NCI-H526 SCLC xenografts.39 
 
2.2.3 Nonclinical Toxicology Studies 
Single- and multiple -dose toxicology studies were conducted in mice, rats, rabbits, dogs, and 
monkeys (Investigator’s Brochure, 2011).  The acute oral maximally -tolerated dose (MTD) for 
mice, rats, and dogs was greater than the maximum dose of 500 mg/kg.  The MTD in monkeys was greater than the 1200 mg/kg maximum dose tested, but emesis occurred at doses ≥50 mg/kg.  Treatment -related effects in the lymphoid tissue, bone marrow, adrenal glands, and bone growth 
plate were seen in rat repeated -dose studies with gastrointestinal tract, reproductive organ, 
kidney, pancreas, and pituitary effects reported at the highest dose.  Death was obser ved at the 
highest dose level of 240 mg/kg/day.  Gastrointestinal disturbances (diarrhea, loss of appetite, emesis) as well as hematologic disturbances also occurred in an 8 -week study in female 
monkeys.  Other toxicities seen in monkeys included mild elevations in AST, ALT, and creatinine kinase (CK), adrenal gland cortex hemorrhage, acinar degranulation of the salivary glands, decreased erythropoiesis in the bone marrow, and lymphoid atrophy.  Possible impairment of immune function in the highest dose group was manifested as cytomegalovirus and bacterial infections.  There is an indication that repeated high doses of sunitinib may lead to cardiac function/contractility changes as confirmed by altered ECG and MUGA or echocardiographic parameters and increas ed cTnI and/or T in single animals that died or were 
euthanized early due to a moribund condition.  These changes appear to be primarily functional 
Abbreviated Title:  Ph2Sunitinib Thymoma/Thymic Ca CTEP Protocol #: 9174  
Version Date:  04/30/2020  
 
 14 and reversible.  Due to the poor clinical condition of these animals, it appears that the cardiac 
changes were not a direct result of sunitinib treatment, but rather resulted from an important, noncompensated volume loss and additional suppression of heart function due to chronotropic incompetence and possible myocardial involvement of uncertain etiology.  Data from this study indicate that functional cardiac changes were induced primarily at the highest dose of sunitinib.  Sunitinib was found to be negative for genotoxicity in vivo  and in vitro . Wound-healing studies 
showed a subtle transient delay in skin wound healing in mice treated continuously for up to 5 weeks with supratherapeutic doses of sunitinib at 80 mg/kg/day.  However, it was determined that this alteration in wound healing has minimal biologic significance.  
 
2.2.4 Nonclinical Pharmacokinetics  
Single-dose pharmacokinetics (PK) was evaluated in mice, rats, rabbits, dogs, and monkeys at oral doses of 20, 40, 80, and 160 mg/kg, respectively (Investigator’s Brochure, 2011).  At these 
doses, the respective T
max values in mice were 3, 3, 0.5, and 6 hours, while maximum plasma 
concentration (C max) values were 420, 708, 877, and 1670 ng/mL, respectively.  In monkeys, 
t1/2α, t1/2β, and t 1/2γ were 4, 14.9, and 252 hours, respectively.  Repeat-dose PK studies indicated 
that increases in exposure were not consistently proportional to dose.  Steady state plasma 
concentrations were reached after 28 days of dosing with little change in levels thereafter.  Sunitinib appeared to readily distribute into the CNS in mice and to a lesser extent in rats and monkeys.  Sunitinib me tabolism is predominantly mediated by CYP3A4 and produces an active metabolite, 
SU012662.  This metabolite and sunitinib were the only major drug-related compounds found in the systemic circulation in mice, rats, monkeys and humans.  Sunitinib and its major metabolite are highly (90-98%) protein bound in mouse, rat, monkey, and human plasma.  IC
50 values 
measured in vitro  are expected to be reached with the currently recommended 50 mg dose.  
Sunitinib and SU012662 are not potent inducers or inhibitors of major CYP450 enzymes.  Therefore, they are both predicted to have a low potential to cause clinically relevant drug -drug 
interactions mediated by CYP450 enzymes and efflux transporters.  However, concurrent treatment with CYP3A4 inducers and inhibitors may a ffect sunitinib metabolism.  
2.2.5 Clinical Experience  
 
As of October 2009, 10186 subjects had received at least one dose of sunitinib in 84 completed or ongoing clinical studies, (Investigator’s Brochure, 2011).  In phase 1 studies, sunitinib demonstrated single-agent activity in patients with RCC, GIST, non-GIST sarcomas, non- small 
cell lung cancer (NSCLC), colorectal cancer, neuroendocrine tumors (NET), melanoma, prostate cancer, and thyroid cancer.  Sunitinib has also been studied in the phase 1 setting in pat ients with 
acute myeloid leukemia (AML).  Sunitinib is approved for use in previously untreated patients with advanced RCC, imatinib-refractory gastrointestinal stromal tumors GIST and unresectable, locally advanced, or metastatic progressive well -differen tiated pancreatic neuroendocrine tumors 
(pNET).  
 
2.2.5.1  Phase 1 Experience 
In an early phase 1 study designed to investigate dosing regimen and scheduling (in human 
Abbreviated Title:  Ph2Sunitinib Thymoma/Thymic Ca CTEP Protocol #: 9174  
Version Date:  04/30/2020  
 
 15 subjects, the results of clinical pharmacology studies demonstrate that C max and area under the 
concentration -time curve (AUC) increased in a proportional manner after single doses of 50 to 
350 mg as well as after multiple doses of 25-100 mg), 41 patients with a variety of advanced 
solid tumors received sunitinib administered on a schedule of 2 weeks of treatment followed by 2 weeks off (2/2 schedule) or 4 weeks on with 2 weeks off (4/2 schedule).
41  Doses evaluated on 
the 2/2 schedule (n=23) included 50 mg every other day (n=3), 50 mg daily (n=15), or 75 mg daily (n=5); the 18 patients enrolled in the 4/2 schedule received 25 mg daily (n=3) or 50 mg daily (n=15).  The most frequent adverse events (AEs) were const itutional (fatigue/asthenia), 
gastrointestinal (nausea, vomiting, diarrhea) and hematologic (neutropenia, thrombocytopenia).  Most of the AEs were grade 1 or 2, although at 75 mg daily, grade 3 and 4 fatigue/asthenia were dose limiting but readily reversib le on discontinuation of treatment.  There were 4 partial 
responses (PRs) assessed by RECIST and 22 patients with stable disease (SD) among the 41 patients.  
 
A phase 1 dose-escalation study in 28 patients with advanced tumors evaluated sunitinib doses of 
30 mg/m
2 every other day, and doses of 30, 42, or 59 mg/m2 daily on the 4/2 schedule.42 Grade 3 
fatigue and hypertension were dose limiting at 59 mg/m2 as well as grade 2 bullous skin toxicity, 
and the MTD was defined as 42 mg/m2 daily.  Based on these and other reversible AEs in the 12 
patien ts treated at the MTD, the recommended phase 2 dose on the 4/2 schedule was determined 
to be 50 mg/day.  Responses determined by RECIST were seen in 6 of 23 evaluable patients: 3 in RCC, 1 in NET, 1 in GIST, and 1 in adenocarcinoma of unknown primary.  Tumor responses in patients treated at higher doses were often associated with reduced intratumoral vascularization and central tumor necrosis, leading to organ perforation in one patient and fistula in another.  These observations suggest the possible necess ity for careful tumor density monitoring to detect 
early evidence of necrosis.  
 Two phase 1 studies have been conducted in AML, the first with the primary endpoint of evaluation of the inhibition of FLT3 phosphorylation and the second designed as a conventional dose-escalation study.
43,44  O’Farrell and colleagues studied FLT3 phosphorylation in 29 AML 
patients who received a single dose of sunitinib at doses ranging from 50-350 mg.  Over 50% of patients showed strong inhibition of Flt3 phosphorylation at doses of 200 mg and higher.  As anticipated from nonclinical data, patients with FLT3 internal tandem duplication (ITD) mutations were more sensitive than those with wild -type Flt3 (FLT3-WT) as shown by 100% 
inhibition in FLT3-ITD compared to 50% in FLT3-WT.  This study also gave evidence of downstream signal inhibition (STAT5 and ERK pathways), with STAT5 levels reduced primarily in FLT3 -ITD patients while ERK inhibition occurred in the majority of patients 
independently of FLT3 inhibition.  The dose-escalation study enrolled 15 patients with refractory or resistant AML who were treated with sunitinib on either the 4/2 or 4/1 schedule at a starting dose of 50 mg/day.  Dose-limiting AEs (grade 4 fatigue and hypertension) occurred in both patients treated at 75 mg/day, and one of these patients (who had received prior mitoxantrone) developed cardiac failure.  The 75 mg dose level was therefore terminated and 50 mg/day was considered to be the MTD.  All four patients with FLT3 mutations had morphologic or partial responses compared to 2 of 10 evaluable patients with wild-type FLT3.  Responses, although longer in patients with mutated FLT3, were of short duration.  
Abbreviated Title:  Ph2Sunitinib Thymoma/Thymic Ca CTEP Protocol #: 9174  
Version Date:  04/30/2020  
 
 16 Preliminary results from phase 1 studies exploring the combination of sunitinib with 
chemotherapeutic agents like capecitabine,45 pemetrexed,46 docetaxel,47  gemcitabine,48 
carboplatin/paclitaxel,49 and metronomic cyclophosphamide/ methotrexate50  in patients with 
various solid tumors have been presented.  The MTD of sunitinib on the 4/2 schedule with docetaxel (60  mg/m
2) was 25 mg daily; with capecitabine (1000 mg/m2), it was 37.5 mg daily.  
The MTD of sunitinib on the 2/1 schedule with docetaxel (75 mg/m2) was 37.5 mg daily and 
with capecitabine (1000 mg/m2) was 50 mg daily. The MTD for sunitinib as continuous daily 
dosing (CDD) with capecitabine (1000 mg/m2) was 37.5 mg daily and for pemetrexed (500 
mg/m2) was 37.5 mg daily.  Reported DLTs included febrile neutropenia, fatigue, hand-foot 
syndrome, gastrointestinal hemorrhage, cerebral hemorrhage, and ischemic optic neuropathy.  Phase 1 trials evaluating the combination of sunitinib with other targeted agents like temsirolimus, 
51 bevacizumab52 and IFN- α53 have shown problems with increased toxicity in 
patients with RCC.54   
 
2.2.5.2  Phase 2 and 3 Experience 
Updated results have recently been published on 750 patients with MRC C treated on a phase 3 
study of sunitinib at a daily dose of 50 mg on the 4/2 schedule compared to interferon (IFN)- α 9 
MU subcutaneously thrice weekly.55  Median overall survival (OS) was greater in the sunitinib 
group than in the IFN- α group (26.4 vs. 21.8 months, respectively).  Sunitinib treatment was 
associated with a higher objective response rate (RR) than IFN- α (47% vs. 12%, respectively).  
Eleven patients in the sunitinib group and four patients in the IFN- α group achieved a complete 
response per investigator assessment.  Median progression-free survival (PFS) was 11 months for sunitinib compared with 5 months for IFN- α.  The most commonly r eported sunitinib- related 
grade 3 adverse events included hypertension (12%), fatigue (11%), diarrhea (9%), and hand-foot syndrome (9%).  An exploratory analysis, which censored 25 patients from the IFN- α group 
who had crossed over to receive sunitinib on study, showed a median OS time of 26.4 months for sunitinib compared with 20 months for the IFN- α group.  Results from a phase 1/2 dose -finding 
trial of sunitinib plus gefitinib, enrolling 42 patients, have been published.
56  In phase 1, patients 
received sunitinib 37.5 or 50 mg on the 4/2 schedule plus gefitinib 250 mg, both once daily. The MTD was determined to be 37.5 mg.  Two DLTs were observed with the 50 mg dose: grade 2 left ventricular ejection fraction decline and grade 3 fatigue.  In phase 2, patients received sunitinib at the MTD plus gefitinib.  Thirteen patients treated at the MTD achieved a partial response and 12 had stable disease.  Median PFS was 11 months.  The most commonly reported grade 3/4 adverse event was diarrhea.   
 The promising results in phase 1 trials and the involvement of KIT and PDGFR- α, two of the 
sunitinib target RTKs in GIST led investigators to undertake a phase 1/2 trial in patients with GIST refractory or intolerant to imatinib to determine an appropriate dose and regimen for phase 2 development of sunitinib in this disease.  Patients received up to 75 mg sunitinib daily on the 2/2, 4/2, or 2/1 schedule, with 50 mg daily on the 4/2 schedule being selected for continued study.  In all, 75 patients were treated on the trial.  Among 41 patients treated for at least 6 months, 6 had an objective response (OR; RECIST criteria) and an additional 16 had cessation of disease progression and minor responses for >6 months.  Overall, 54% of the 41 patients had evidence of clinical benefit (OR or PFS).  Determination of the GIST genotype in these 41 patients showed that clinical benefit had been achieved in several secondary mutational variants 
Abbreviated Title:  Ph2Sunitinib Thymoma/Thymic Ca CTEP Protocol #: 9174  
Version Date:  04/30/2020  
 
 17 that conferred imatinib resistance.57  Fifty -three of the GIST patients treated on this trial 
subsequently underwent serial 18FDG -PET imaging where qualitative responses were graded as 
good in 33/53 patients, mixed in 15/53, and poor in 5/53.58  Correlation with clinical response 
(Fisher’s exact p=0.03) showed that 22 of 33 patients graded as good by 18FDG -PET imaging 
had clinical benefit (OR or SD ≥ 6 months) after 6 months of therapy whi le 4 of 15 patients 
graded as mixed had benefit as did 2 of 5 patients graded as poor.  
 Data from a pivotal multinational, randomized (2:1), double-blind, placebo-controlled phase 3 trial in over 300 patients with imatinib -resistant GIST has shown signifi cant clinical effect with 
sunitinib compared with placebo.
59  Patients on the active treatment arm received sunitinib at a 
dose of 50 mg daily on the 4/2 schedule.  The median TTP for the treatment arm (n=207) was 27.3 weeks compared to a median of 6.4 weeks for placebo (n=105) (p<0.0001).  Therapy was reasonably well tolerated; the most common adverse events were fatigue, diarrhea, skin discoloration and nausea. 
 
In addition to patients with RCC and GIST, sunitinib has been evaluated in breast cancer,
60 
NSCLC,61transitional cell carcinoma (TCC),62 NET 63, thyroid carcinoma,64 certai n subtypes of 
sarcoma,65 gastro -eosophageal cancer,66 high-grade glioma ,67 squamous c ell carcinoma of the 
head and neck (SCCHN),68 hepatocellular carcinoma (HCC) (Zhu  et al. , 2008),69 colorectal 
carcinoma (CRC)70 and uveal melanoma .71   
 
2.2.5.3  Safety Profile  
Sunitinib is reasonably well tolerated, with asthenia, hypertension, dermatitis, and mild myelosuppression as the most common AEs.
72  Additionally, the inhibition of TK receptors by 
agents such as sunitinib can result in cutaneous AEs such as acral erythema, subungal splinter hemorrhages, modification of hair and skin pigmentation, mucositis, and ( occasionally) 
periocular edema.
73,74  Hand -foot skin reaction, a group of signs and symptoms that can affect, 
usually bilaterally, the hands and/or feet of patients, has occurred in patients receiving sunitinib.  A recent analysis of dermatological AEs in patients receiving sunitinib therapy has reported that all-grade hand -foot skin reactions occurred in 19% of patients (5% grades 3-4), skin 
discoloration in 28% (no grades 3-4), dry skin in 16% (1% grades 3-4), skin rash in 13% (1% grades 3 -4), dermatitis in 8% (2% grades 3-4), hair color changes in 10% (no grades 3- 4), 
alopecia in 6% (no grades 3-4), and phototoxicity in <0.1% (no grades 3-4) (Rosenbaum et al ., 
2008).  Cardiotoxicity, including congestive heart failure (3%-8%) and left ventricular dysfunction (12%-14%), has been reported in patients undergoing treatment with sunitinib.
75-78  More 
subjects treated with sunitinib experienced decline in left ventricular ejection fraction (LVEF) than subjects receiving either placebo or IFN- α (Investigator’s Brochure, 20 11).  In a phase 3 
GIST study in subjects with imatinib -resistant or -intolerant GIST, 22 of 209 (11%) subjects on 
sunitinib and 3 of 102 (3%) subjects on placebo had treatment- emergent LVEF values below the 
lower limit of normal (LLN).  In a phase 3 study t reatment -naive RCC patients, 27% and 15% of 
subjects on sunitinib and IFN- α, respectively, had an LVEF value below the LLN.  Among 461 
patients enrolled in CDUS-monitored trials with sunitinib alone, 2% of patients experienced left ventricular systolic dysfunction (CDUS data).  It is unknown whether patients with concurrent 
Abbreviated Title:  Ph2Sunitinib Thymoma/Thymic Ca CTEP Protocol #: 9174  
Version Date:  04/30/2020  
 
 18 cardiac conditions may be at a higher risk for developing drug- related LVEF.  Baseline and 
periodic evaluations of LVEF should be considered while these patients are on sunitinib 
treatme nt.  In patients without cardiac risk factors, a baseline evaluation of LVEF should be 
considered.  Sunitinib has been shown to prolong the QT interval in a dose-dependent manner, which may lead to an increased risk for ventricular arrhythmias,  including Torsade de Pointes.  This 
condition has been reported in <0.1% of sunitinib-exposed patients.  The DCTD, NCI, issued an IND AE Action Letter to all investigators using sunitinib describing the occurrence of QTc prolongation and Torsade de pointes (ventricul ar tachycardia) in patients on clinical trials 
utilizing sunitinib.  As a result of this Action Letter, DCTD, NCI -sponsored sunitinib protocols 
were amended to include the requirement for a baseline EKG prior to study treatment, exclude patients with histo ries of serious ventricular arrhythmias or prolonged QTc, and exclude patients 
with certain cardiac conditions.  
 Among 8832 solid tumor subjects treated with single-agent sunitinib, Grade 3 hypertension was reported in 6.8% of patients and was one of the most commonly reported Grade 3 AEs.  Of subjects receiving sunitinib for treatment-naive MRCC, 34% receiving sunitinib experienced hypertension, compared with 4% on IFN- α.  Grade 3 hypertension was reported in 13% of 
treatment -naive metastatic RCC subjects on sunitinib compared to <1% on IFN- α.  Severe 
hypertension occurred in 4% GIST subjects on sunitinib, 1% GIST subjects on placebo, 9% RCC subjects on sunitinib and 1% RCC subjects on IFN- α (Investigator’s Brochure, 2011).  Among 
516 patients enrolled in C DUS -monitored trials with sunitinib alone, 33.9% experienced 
hypertension (CDUS data).  In subjects receiving sunitinib for treatment-naive MRCC, 37% had bleeding events  compared 
with 8% receiving IFN- α (Investigator’s Brochure, 2011).  Bleeding events occurred in 18% of 
patients receiving sunitinib in the double-blind treatment phase of the GIST phase 3 study, compared with 17% receiving placebo.  Among 516 patients enrolled in CDUS -monitored trials 
with sunitinib alone or in combination with other agents, there were 123 reported bleeding events (CDUS data).  Epistaxis was the most common hemorrhagic AE reported.  Tumor- related 
hemorrhage can occur with sunitinib and in the case of pulmonary tumors, may present as severe and life-threatening hemoptysis or pulmonary hemorrhage.  Hypothyroidism  has been reported in 71% patients with RCC and in 36% of those with GIST 
treated with sunitinib.
79  Among 8832 subjects with solid tumors treated with single- agent 
sunitinib as of October 2009, 978 (11.1%) experienced treatment-emergent hypothyroidism.  Among subjects treated with single-agent sunitinib, hyperthyroidism was reported in 0.7% and thyroiditis in 0.1% (Investigator’s Brochure, 2011).  Baseline measurement of thyroid function is recommended, and patients with thyroid dysfunction should be treated appropriately prior to starting sunitinib therapy.  Nonclinical  evidence of adrenal toxicity following sunitinib exposure led the company to 
perform specialized safety assessments in clinical studies, including computed tomography or MRI in 336 subjects to specifically identify any change in adrenal gland structure or the presence 
Abbreviated Title:  Ph2Sunitinib Thymoma/Thymic Ca CTEP Protocol #: 9174  
Version Date:  04/30/2020  
 
 19 of adrenal gland hemorrhage (Investigator’s Brochure, 2011).  Neither event was observed.  
Adrenocorticotropic hormone (ACTH) stimulation testing was done in 400 patients across multiple sunitinib trials.  One subject developed consistently a bnormal test results during 
treatment that were unexplained and may be related to sunitinib treatment.  Eleven additional subjects had abnormalities in the final test, with low peak cortisol levels.  None of these patients had clinical evidence of adrenal insufficiency.  However, based on the nonclinical findings, patients receiving sunitinib should be clinically followed for signs and symptoms of adrenal insufficiency, especially in (1) patients with comorbidities associated with adrenal dysfunction, (2) p atients with preexisting adrenal insufficiency (primary or secondary), and (3) patients with 
concomitant stress (e.g., fever, infection, bleeding, serious accident, surgery) that may precipitate overt adrenal insufficiency in the presence of subclinical sunitinib -induced adrenal toxicity. 
 Diarrhea, nausea, abdominal pain, vomiting, constipation and dyspepsia are some of the most frequent AEs reported with sunitinib (Investigator’s Brochure, 2011).  Serum chemistries 
including phosphate should be performed at the beginning of each treatment cycle.  Supportive 
care may include anti -emetic premedication, supportive oral care products, and analgesics.  
Serious complications due to degeneration or shrinkage of tumors, including gastrointestinal perforation and tracheoesophageal fistula, have occurred rarely in patients with abdominal, head and neck, thyroid, and other malignancies treated with sunitinib, believed to be the result of the antitumor effect of sunitinib.  Other serious effects include thromboembolic events, rare reversible posterior leukoencephalopathy syndrome (RPLS), proteinuria with rare nephrotic syndrome, and rare microangiopathic hemolytic anemia.   Alternative dosing schedules  
Due to the toxicity associated with the standard dosing (50 mg per day for 4 weeks followed by a 2-week break) alternative dosing schedules have been explored. Superior tolerability has been demonstrated with a 2-weeks on and 1- week off schedule in patients with metastatic renal 
carcinoma. 
80,81 
 
2.2.5.4  Clinical Pharmacokinetics  
Orally -administered sunitinib is well absorbed in humans, with linear pharmacokinetics (PK) at 
doses of 50-150 mg/day.  Metabolism of sunitinib occurs primarily through the cytochrome P450 3A4 (CYP3A4) to N-deethyl sunitinib to form the metabolite SU012662. SU012662 undergoes further metabolism to an inactive metabolite SU014335.  SU012662 is also catalyzed primarily by CYP3A4, but at a much slower rate than the N-deethylation of sunitinib in human liver microsomes (Investigator’s Brochure, 2011 ).  There are no studies done to date that directly 
evaluate the effect of dexamethasone, a weak CYP3A4 inducer, on sunitinib.  Studies done by Pfizer on the effects of coadministration of rifampin, a potent CYP3A4 inducer, resulted in a 23% and 46% reduction in C
max and AUC 0-∞ values, respectively  (Investigator’s Brochure, 
2011).  Metabolism of sunitinib administration with food does not significantly affect the bioavailability of sunitinib.  The PK of sunitinib was studied in a variety of company-sponsored studies in both healthy volunteers (n=135) and in patients with solid tumors (n=266), including GIST and metastatic RCC; the PK was similar in the volunteers and in those with solid tumors.  Terminal half -lives 
Abbreviated Title:  Ph2Sunitinib Thymoma/Thymic Ca CTEP Protocol #: 9174  
Version Date:  04/30/2020  
 
 20 (t1/2) of sunitinib and SU012662 are 40-60 hours and 80-110 hours, respectively, with a time to 
maximum concentration (T max) of 6 -12 hours for sunitinib and its primary active metabolite, 
followed by a biexponential decline in concentrations.  The PK of sunitinib and SU012662 were 
measured in a phase 1 dose-escalation study in patients with advanced solid malignancies.82  
Twenty -eight patients received doses ranging from 15 mg/m2 to 59 mg/m2 (ranging from 50 mg 
every other day to 150 mg/day), on a 4 weeks on, 2 weeks off (4/2) schedule.  Concentration-versus-time data were analyzed using a noncompartmental analytic technique.  Overall, sunitinib displayed a long half- life and a large volume of distribution with moderate interpatient 
variability.  Trough plasma concentrations of sunitinib and SU012662 increased with increasing doses.  However, AUC values increased less than proportionally with dose.  Accumulation ratios of sunitinib were >1, with detectable trough drug levels, suggesting drug accumulation over time.  At the  recommended dose, C
max occurred approximately 5 hours after administration and t 1/2 
ranged from 41-86 hours.  Doses of 50 mg daily led to plasma concentrations ranging from 50-100 ng/mL.  Most patients with DLTs had combined (sunitinib plus SU012662) trough plasma 
concentrations ≥100 ng/mL.
82 
 
PK values determined from body surface area (BSA)- based doses were adjusted to reflect fixed 
doses of 50, 75-100, and 100-150 mg doses to determine if there was a need for BSA- based 
dosing to be employed.  AUC sum values obtained using BSA-normalized and fixed dosing were found to be comparable, suggesting that normalizing the dose based on BSA would not improve variability.  Therefore, fixed dosing on a milligram basis was considered appropriate for phase 2 studies.
82 
 To determine the effect of food on the PK of sunitinib and its active metabolite SU012662, 16 healthy subjects received a single dose of sunitinib 50 mg under fasting conditions and 14 subjects received a single dose of sunitinib 50 mg under fed conditions.
83  Subjects were 
randomized to one of two treatment sequences each comprising two treatment periods (fasted and fed ).  In Sequence 1, the fasted treatment period was followed by the fed treatment period, 
and for Sequence 2, the fasted period followed the fed period.  For the fasted period, a single oral (PO) dose of sunitinib 50 mg was administered after a 10- hour fast .  For the fed period, a single 
PO dose of sunitinib 50 mg was administered within 30 minutes of a high-fat, high- calorie meal.  
A washout period of at least 4 weeks separated sunitinib dosing between the two treatment periods.  Two subjects in Sequence 1 discontinued prematurely due to grade 1 and 2 rash, but PK information was collected and included in the analysis.  Only a negligible difference in T
max of 
sunitinib was observed between fed and fasted treatment periods; SU012662 T max was prolonged 
by 2 hours (median difference) in the fed compared with the fasted state.  The 90% confidence intervals (CIs) for C
max and AUC were within the 80-125% bioequivalence range, indicating the 
absence of food effect.  Sunitinib exposure increased slightly in the fed compared with the fasted state (ratios of fed/fasted geometric least square means: C
max 104%, AUC 0-last and AUC 0-∞ both 
112%).  There was a delay in the formation/absorption of the active metabolite SU012662 in the fed state (mean C
max decreased 23%), but exposure remained unaffected (90% CIs for AUC 0-last 
and AUC 0-∞ were within 80-125%).  Sunitinib and SU012662 half- lives, and oral clearance of 
sunitinib, were not affected by food.83 
 A study of sunitinib PK in patients with AML indicated that a plasma concentration of 50-100 
Abbreviated Title:  Ph2Sunitinib Thymoma/Thymic Ca CTEP Protocol #: 9174  
Version Date:  04/30/2020  
 
 21 ng/mL of combined sunitinib and SU012662 could be achieved on the first cycle of a 50 mg/day 
4/2 regimen, similar to that achieved in studies with patients having other tumor types.43 
 In a phase 1 trial of sunitinib given on the 4/2 schedule in pediatric patients with relapsed or refractory solid tumors, the median day 21 steady-state trough sunitinib plasma concentration was 24.6 ng/mL (range, 6.0-37.7 ng/mL) at the 15 mg/m
2 dose and 37.4 (range, 24.2-62.9 
ng/mL) at the 20 mg/m2 dose.84 
 Population PK methods indicated that the covariates of weight, gender, race, ethnicity, ECOG score, and tumor type had no clinically significant effects on drug exposure, and that adjustments of starting doses based on these covariates were not required (Investigator’s Brochure, 2011).  
 Concurrent administration of a single dose of sunitinib with ketoconazole (a CYP3A4 inhibitor) in healthy volunteers resulted in 49% and 51% increases in the combined (sunitinib + 
SU012662) C
max and AUC 0-∞ values, respectively, compared with sunitinib alone.85  Concurrent 
administration of sunitinib and rifampin (a potent CYP3A4 inducer) in healthy subjects resulted 
in 23% and 46% reduction in combined C max and AUC 0-∞, respectively, compared with sunitinib 
alone (Bello et al ., 2005).86  Thus, dose adjustments for sunitinib should be considered when 
coadministered with CYP3A4 inhibitors and inducers. 
 
2.3 RATIONALE  
 Molecular pathways and potential therapeutic targets in thymic malignancies are not well 
understood largely due to the rarity of the tumor, controversies about histopathologic classification, and the lack of established cell lines and  animal models. Based on existing body of 
knowledge, some of the main targets of sunitinib including VEGFR -1, -2, and -3, KIT  and 
PDGFR play key roles in the pathogenesis of thymic malignancies. Moreover, inhibition of these targets has led to clinical responses in anecdotal reports and case series.  
 
2.3.1 Angiogenesis in thymic malignancies  
Neovascularization is crucial for tumor growth beyond 1–2 mm
3 and for the switch from local 
vascular supply to novel microcapillary formation enabling progression and metastasis of cancer. It is also a crucial pro gnostic factor in many cancers, frequently correlating with tumour 
progression, disease severity and potential for metastasis.
87,88 
 
2.3.1.1  The role of VEGF/VEGFR family  
The VEGF receptor family includes VEGFR1 (Flt-1), VEGFR2 (Flk-1/KDR, Fetal liver kinase-1/kinase domain-containing receptor), and VEGFR3 (Flt- 4). VEGF, a mitogen specific for 
vascular endothelial cells, is one of the most potent pro-angiogenic molecules . VEGF -related 
angiogenic signal is mediated by intracellular tyrosine kinases and leads to angiogenesis, cell migration, proliferation, and survival.   Angiogenesis plays an important role in the pathogenesis of thymic malignancies. M icrovessel 
density and VEGF expression correlate with tumor invasion and clinical stage thymic epithelial 
Abbreviated Title:  Ph2Sunitinib Thymoma/Thymic Ca CTEP Protocol #: 9174  
Version Date:  04/30/2020  
 
 22 tumors. Higher expression of angiogenesis markers is  seen in invasive thymomas and thymic 
carcinomas as compared to non-invasive thymomas.89 Elevated serum VEGF and b -FGF levels 
are also seen  in patients with thymic carcinoma.90 
 
2.3.1.2  The role of PDGF/PDGFR family  
The PDGF/PDGFR family plays a supporting role in angiogenesis.91 The PDGFR family 
includes the colony stimulating factor -1 receptor (CSF -1R), Flt- 3 (Fms -like tyrosyl kinase-3), 
Kit (the stem cell factor receptor), and the platelet -derived growth factor re ceptors (PDFGR -α 
and PDFGR -β). PDGF  through PDGFR tyrosine kinases functions as a potent mitogen in 
mesenchymal and glial cells. During carcinogenesis, PDGF receptor is frequently activated 
through over-expression of the ligand and its receptor. KIT  is a transmembrane receptor with 
tyrosine kinase activity encoded by the proto-oncogene c- KIT, which plays a major role in the 
development and maintenance of GISTs. KIT expression does not predict the presence and/or type of the c- KIT mutation, but its expression in GISTs has been associated with c- KIT activating 
mutations that mainly occur in exons 9 (extracellular domain), 11 (juxtamembrane domain), 13 (first kinase do main), and 17 (activation loop). These mutations lead to the constitutive 
activation of the KIT kinase.   Imatinib mesylate, an oral KIT tyrosine kinase inhibitor, leads to rapid, substantial, and durable tumor responses in GIST , mainly in the form of stable disease or a partial response. Furthermore, 
the presence of the exon 11 c- KIT mutation seems to be the strongest predictor of a response in 
patients with GISTs. Imatinib resistance, which may result from secondary KIT mutations, may 
be overcome with sunitinib, which is approved for use in disease progression  on imatinib.  
 In thymic malignancies, KIT overexpression, as determined by immunohistochemistry has been 
reported in 23% of cases, with a higher frequency in thymic carcinomas (79%) especially of the squamous cell subtype (75-100%).
92,93  However, KIT  mutations are found only in 5% to 10% of 
thymic malignancies and have been found exclusively in thymic carcinoma.94-96 The known KIT  
mutations in thymic carcinoma are listed in Table 4.  The published mutations are located in 
exon 11, exon 14, and exon17.93 V560del and H697Y mutations were associated in vitro  with 
imatinib sensitivity with H697Y mutant cells exhibiting greater sensitivity to sunitinib than imatinib.
94 However, presence of KIT  mutations may not be essential for sunitinib activity as 
demonstrated by responses of tumors with wild -type KIT .97 PDGF and PDGFR -α were also 
overexpressed in epithelial cells of thymoma, with increased intensity of staining in WHO types B2 and B3.
98  
 
Table 4: Known Kit mutations in thymic carcinoma  
Location  Mutations  
Exon 11  V560, L576P, P577 -D579del , Y533N  
Exon 14  H697Y  
Exon 17  D820E  
 
2.3.2 Clinical studies  
Strobel and colleagues have described a series of 4 patients with refractory thymic carcinoma who were treated with variable schedules of sunitinib.
97 Three patients achieved a partial 
Abbreviated Title:  Ph2Sunitinib Thymoma/Thymic Ca CTEP Protocol #: 9174  
Version Date:  04/30/2020  
 
 23 response and one achieved disease stabilization. On phosphoprotein arrays, these tumors showed 
simultaneous activation of several receptor tyrosine kinases, including the EGFR, TYRO3, insulin receptor, and insulin-like growth factor-1 receptor (IGF1R). All three patients who responded had the squamous cell subtype of thymic carcinoma and none of them had c- KIT 
mutations.
97  
 SU14813 is a multi- kinase inhibitor with a profile very similar to sunitinib  (blocks VEGFR 1, 2, 
and 3, PDGFR- A and -B, KIT and FLT3 at nanomolar concentrations).
99 In a phase I, open- label, 
dose-escalation study, SU14813 was evaluated in 77 patients who received it either in a 4/1 (4 weeks of treatment followed by 1 week off) or continuous schedule. Two patients out of the 4 with malignant thymoma had partial resp onses (PFS 15.3 and 9.0 months).
99 Unfortunately the 
development of this agent has been discontinued by the sponsor. Sunitinib and SU14813 differ in their pharmacokinetic properties: Sunitinib is more slowly absorbed, and eliminated, hence achieves steady state concentrations in 2 weeks while SU14813 attains steady state after 8 days 
of administration.
99   
 
As of Amendment E  (version date 05/12/14):   Group 1 results obtained from protocol 12-C-0118 
so far in patients with recurrent thymic carcinoma have shown an objective response rate of 23% 
and disease control rate of 91% with sunitinib which is unprecedented for this histology. However, treatment at a dose of 50 mg once daily for four weeks followed by 2 weeks off was poorly tolerated. Twenty five out of 41 patients need dose reductions due to development of intolerable adverse events. Of the five partial responses seen in patients with thymic carcinoma ( Table 5, 
Thomas et al), two were seen at dose level one (50 mg daily) and three were seen despite dose reductions (37.5 mg and 25 mg daily for 4 weeks followed by two weeks off). Due to these promising results, we will  evaluate the role of sunitinib further in patients with thymic carcinoma 
at an initial dose of 5 0 mg daily for 2 weeks followed by 1 week off to confirm the response rate 
and determine if the reduced dose of sunitinib is tolerated better  (Group 2) .
  Additionally, Group 
1 results obtained from protocol 12-C- 0118 have shown that among patients with thymoma only 
1 partial response was observed in 16 treated patients (Table 5.) This is lower than the pre -specified 
statistical endpoint of  2 or more responses among the first 16 patients with thymoma. Hence, 
accrual for this cohort was stopped after the completion of the first stage and enrollment did not proceed to the accrual goal of 25 for the second stage in the thymoma cohort. In view of this lack of activity in patients with thymoma, we do not propose to evaluate further the activity of sunitini b 
for this histology. Hence, a thymoma cohort is not included in Group 2 of Amendment E.  Table 5 summarizes the reports of clinical activity of anti-angiogenic agents in thymic malignancies.
97,100-108  As noted by Girard N, despite the large tumor burden of thymic tumors 
and the frequent abutment of mediastinal vascular structur es, no hemorrhagic side effects have 
been reported with the use of anti-angiogenic drugs in thymic malignancies.109  
  
Table 5:  Reports of clinical activity of anti -angiogenic agents in thymic malignancies  
Drug  Author  
(year of 
publication)  Number 
of 
patients  Dose/ 
Schedule  Hist
olog
y Prior systemic 
treatment  Response  Comments  
 Azad A et al 1 75 mg BID/  THY  PAC  28% tumor PFS 12 months  
Abbreviated Title:  Ph2Sunitinib Thymoma/Thymic Ca CTEP Protocol #: 9174  
Version Date:  04/30/2020  
 
 24 Motesanib  
 (2009)  2 weeks on 
and 1week 
off ChlVPP  
 shrinkage after 
17 cycles  
Rosen LS et 
al (2007)  
 
 1 NR THY NR SD for 8 
months   
Bevacizumab 
+ Erlotinib  Bedano PM 
et al 
(2008) 
[Abstract]  18 15 mg/kg IV 
q 3 weeks+ 
150 mg q 
day THY 
(11) 
TC 
(7) NR 11 patients had 
SD  
Aflibercept+ 
docetaxel  Isambert N et 
al 
(2008) 
[Abstract]  1 NR THY NR PR  
Dasatinib   
 
 
Chuah C et al 
(2006)  1 140 mg 
daily  THY 
B2 None  PR Patient also had 
CML and was in 
lymphoid blast 
crisis. Tumor c -Kit 
staining negative  
  
Sunitinib   
 
 
Ströbel P et al 
(2010)  4 50 mg daily  
continuous  TC chemotherapy  SD OS 40 months  
50 mg  4/2; 
later 4/4,4/6 
and 4/8 
schedule  TC chemotherapy  PR PFS 18 months  
37.5 mg 
daily  TC No 
chemotherapy  PR PFS 14 months  
50 mg daily  
4/2 schedule  TC chemotherapy  PR OS 4 months  
Thomas A et al  
(2013)  
[Abstract]  38 50 mg daily 
4/2 schedule  THY  
(16) Chemotherapy 
(median prior 
chemo = 2)  PR=1: SD=12  
 PFS 7.6 mo; OS not 
reached 
TC 
(22) Chemotherapy 
(median prior 
chemo = 2)  PR=5; SD=15  PFS 6.7 mo; OS 12.6 
mo 
SU14813  W. Fiedler et 
al (2010)  2 4/1 schedule  THY NR  PR  PFS 15.3 and 9.0 
months  
Imatinib   
 
Buti S et al  
(2011)  1 400 mg 
daily  TC ADOC  SD PFS 9 months  
c-KIT exon 11 
mutation ( Y553N ) 
Sorafenib  
  
Bisagni G et 
al (2009)  1 200 mg BID  TC Surgery  
PEI 
IA 
octreotide  PR after 8 
weeks; 
maintained 
after 15 months  c-kit exon 17 
(D820E) mutation  
 
 
Li X et al 
(2008)  1 Sorafenib  TC CDC  
CEIO  
CEP 
Paclitaxel  SD PFS 9 months ; 
Tumor c -Kit and 
VEGF staining 
positive  
 
 
Diel U et al 
(2011)  1 Sorafenib  TC  ADOC  PR PFS 6 months  
c-KIT exon 9 
deletion present  
Abbreviations used: PAC: cisplatin, doxorubicin, cyclophosphamide; ChlVPP: chlorambucil, vinblastine, procarbazine and predni solone; THY: Thymoma; 
Abbreviated Title:  Ph2Sunitinib Thymoma/Thymic Ca CTEP Protocol #: 9174  
Version Date:  04/30/2020  
 
 25  
2.4 EXPLORATORY STUDIES BACKGROUND  
 
Cell-surface receptors and several pro - and anti -angiogenic factors mediate the complex process 
of angiogenesis, which results in the formation of new vasculature.110 As discussed earlier, there 
is considerable evidence associating angiogenesis with tumor growth and metastasis. However, 
the clinical development of antiangiogenic agents in many other malignancies has been hampered by the lack of objective measures of pharm acological response to these drugs. For 
example, in NSCLC, although several potential angiogenic biomarkers (e.g. microvessel density, vascular endothelial growth factor, vascular endothelial growth factor receptors) have been extensively studied, and seve ral more are under investigation, no clinically validated predictive 
marker of antiangiogenic therapy has been  identified to date.
111   
 Translational research associated with clinical studies of sunitinib has led to the identification of three main types of potentially promising biomarkers: circulating proteins related to angiogenesis, circulating endothelial cells and/or their stem-cell progenitors, and vascular imaging.
112 In this study we propose to evaluate in an exploratory fashion the first two: 
angiogenesis- associated circulating proteins on pre- dose plasma samples on days 1 and 28 of 
cycles 1 and 2 as well as at p rogression; circulating endothelial cells (CEC)/ circulating 
endothelial progenitor cells (CEP) on days 1 and 14 of cycle 1. Where tumor samples are 
available, intra -tumoral immune infiltrate  and tumor molecular profiling will be performed prior 
to study entry and at disease progression.   
 
2.4.1 Serum VEGFR2, PlGF, IL- 4, IL -12, HGF, b- FGF (Group 1 only) 
Utility of cytokine and angiogenic factors has been assessed for several different VEGF pathway inhibitors in various malignancies. A consistent pharmacodynamic effect for VEGF, placental growth factor (PlGF), soluble VEGFR 3 (sVEGFR3 ) and soluble VEGFR2 (sVEGFR2) was 
observed in patients with RCC, refractory breast cancer, or unresectable GIST or (neuroendocrine tumors) NET. Significant increases in mean plasma levels of VEGF and PlGF, 
as well as dose- dependent decreases in sVEGFR2 and sVEGFR3  levels  were observed during 
sunitinib treatment compared with baseline. These changes returned to baseline levels off drug, and greater magnitudes of changes were observed in patients showing an objective response to sunitinib .
113-115 The effects of sunitinib on soluble forms of target receptors, including sVEGFR2 
may be a result of a direct decrease in the number of receptor- secreting cancer and endothelial 
cells associated with tumor -growth inhibition and/or indirect transcriptional inhibiting effects on 
components of VEGFR-associated signaling pathways. By contrast, the slight elevation of VEGF observed in several patients may result from an autocrine survival feedback loop trying to compensate for the reduced receptor availability.
115 However, baseline levels of these soluble 
factors have not been shown to correlate with outcome, limiting the predictive ability of these markers to affect clinical practice. Further, prospective work on a larger number of patients is 
needed to delineate whether these factors represent only a marker of pharmacodynamic drug 
effect or have predictive potential.
114 TC: Thymic carcinoma; NR: not reported; SD: stable disease; PR: partial respo nse; EPI: cisplatin, etoposide, ifosfamide IA: ifosfamide, doxorubicin; CDC: 
cisplatin, doxorubicin, and cyclophosphamide; CEIO: cisplatin, ifosfamide, endostar, oxaliplatin; CEP: cisplatin, etoposide, pirarubicin; CML: chronic 
myeloid leukemia; ADOC: Cisp latin (CDDP), doxorubicin, vincristine, cyclophosphamide  
Abbreviated Title:  Ph2Sunitinib Thymoma/Thymic Ca CTEP Protocol #: 9174  
Version Date:  04/30/2020  
 
 26  
A potential mechanism for sunitinib resistance is the upregulation of alternative proteins and/or pathways that could drive tumor angiogenesis and/or growth independent of VEGF. Preclinical studies, involving RCC and non-RCC models, have identified a variety of candidate proteins that may be involved in resistance to VEGF therapy. Among these proteins which stimulate angiogenesis directly or indirectly are fibroblast growth factor (FGF), HGF (hepatocyte growth factor) and PlGF.
114 For example, HGF promotes angiogenesis through upregulation of VEGF 
and also via downregulating thrombospondin-1 expression. HGF/c- Met activation has been 
suggested as a potential alternate mechanism of angiogenesis in sunitinib resistant tumors.116  
 Angiogenesis-associated circulating proteins have not been systematically studied previously in thymic malignancies. Whether the changes found in other tumors would be applicable to thymic malignancies is not known. We propose to explore the potential utility of these proteins as biomarkers of pharmacological and clinical activity of antiangiogenic agents in thymic 
malignancies. These assays will be performed using sandwich ELISA or an 
electrochemiluminescent multiplexed sandwich immunoassay (Meso- Scale Discovery), in the 
Trepel laboratory, DTB , NCI.  
 
2.4.2 Regulatory T cells (Tregs), exhausted CD8 T cells, myeloid-derived suppressor cells 
(MDSCs), and Th1/Th2 T cell populations (Group 2 only) 
The immune system plays a critical role not only during oncogenesis, but also during tumor progression and as established neoplastic lesions respond to therapy. Sunitinib has been shown to decrease the frequency of regulatory T cells (Tregs) and myeloid -derived suppressor cells 
(MDSCs) in metastatic renal cell carcinoma patients
117,118. It has been shown that development of 
sunitinib resistance is partly mediated by the survival of MDSCs, thereby providing sustained immune  suppression and angiogenesis 
119. Sunitinib ha s also been shown to shift T -helper cells 
toward a T helper 1 (Th1) -polarized response and decrease the Th1 cell/ T helper 2 (Th2) cell ratio. 
A sig nificant decrease in the Th1/Th2 ratio was seen after sunitinib treatment in the PFS -short 
group in mRCC 117,120. Exhausted CD8+ T cells, which express inhibitory receptors PD -1 and Tim -
3, were found in cancer patients117,121. Recent clinical trials have validated that blockade of PD -
L1/PD -1 signaling is a meaningful immune therapeutic regimen 122,123. In a phase I/II trial of 
belinostat in combination with cisplatin, doxorubicin and cyclophosphamide in the first -line 
treatment of advanced or recurrent thymic epithelial tumors ([STUDY_ID_REMOVED]), decline in Tim -3+ 
CD8+T cells with treatment was larger in patients who responded to treatment compared with those who did not (p=0.049) (manuscript in preparation), suggesting that exhausted CD8+ T cells may play an important role in the prognosis of patients with thymic carcinoma.  Therefore, monitoring immune subsets in thymic carcinoma pre - and post -sunitinib therapy will contribute to 
understanding of the mechanism of sunitinib activity in thymic carcinoma and the potential survival advantage of improved immune response, and inform future studies of combination regimens with immune modulatory agents. 
 
2.4.3 Circulating Endothelial Cells and Endothelial Progenitor Cells  (both groups) 
CECs have emerged as a potentially useful marker to assess anti-angiogenic therapy. At least two distinct populations of CECs have been identified, bone marrow- derived  CEP cells and 
mature CECs. CEP cells bear  antigens that identify them as endothelial cells, such as VEGFR-2 
Abbreviated Title:  Ph2Sunitinib Thymoma/Thymic Ca CTEP Protocol #: 9174  
Version Date:  04/30/2020  
 
 27 (Flk-1) and CD31 (platelet/endothelial c ell adhesion molecule-1), as well as antigens for stem 
cells, such  as CD117 (c-kit ligand receptor), CD133, and CD34. Upon appropriate stimulation, 
bone marrow- derived endothelial progenitor cells migrate to the circulation, where they  are 
referred to as C EP cells. CEP cells have been shown to infiltrate human tumors and give rise to 
tumor neovasculature.124,125 Mature CECs derive from mature vasculature. They are thought to 
enter circulation as a result of vascular injury. Though the exact role that CECs play in tumor 
neovascularization is heavily debated, some evidence supports the observations discussed below. Firstly, levels of CECs are  increased in patients with cancers and are correlated with disease 
progression.
126,127 Secondly, VEGF and expression of VEGFR-2 mobilize CECs in human 
models.128-130 Thirdly, treatment with VEGF pathway inhibitors can have different effects on 
mature  CECs and CEP cells. Inhibitors inhibit bone marrow- derived CEP cells  mobilized by 
VEGF and trigger an increase in mature CECs, reflecting an increase in sloughing of fragile mature endothelium from tumor vasculature.
131-133  
 
Limited data is available on CEP/CEC in RCC patients treated with sunitinib. Available data 
thus far have yielded conflicting results with regard to baseline CEP/CEC numbers or change in 
these parameters and clinical outcome.134,135 To explore the effects of sunitinib on CECs and 
CEP cells  in patients with thymic malignancies , these will be assayed on pre-dose peripheral 
blood samples on days 1 and 14 of cycle 1. Two lavender top tubes of whole blood will be collected for CEC/CEP analysis, which will be  performed by multi-parameter flow cytometry, in 
the Trepel laboratory, DTB , NCI. Cells will be analyzed for forward and side scatter, and a dump 
channel will  be created to exclude cells expressing hematopoietic markers, such as CD45. 
Endothelial cells will be identified using co -expression markers, such as CD31, and CD146 for 
mature endothelial cells and CD133 for CEP c ells. The cell populations will also be analyzed for 
viability using scatter profiles and a vital stain (e.g., Hoechst 33258). Multi- parameter flow 
analysis will be performed with a flow cytometer equipped with FlowJo software, using a minimum of 500,000 events per analysis.
136-139  
 
2.4.4 Intra -tumoral immune infiltrate  
Sunitinib has been shown in preclinic al models and in patients to favorably alter the immune cell 
environment through promotion of a T-helper 1 phenotype, reduction in T-regulatory cells and 
reduction in myeloid derived suppressor cells.117,118,140,141 The contribution of these observations 
to the antitumor mechanism of sunitinib is unclear at present. Where fresh tissue is available, we propose to analyze immune subsets including but not limited to CD8, CD4, CD56, CD68 by multiparameric flow cytometry in the Trepel laboratory, DT B, NCI.  
 
3 PATIENT SELECTION  
3.1 
 ELIGIBILITY CRITERIA  
 
3.1.1 Histological confirmation of thymoma (Group 1 only) or thymic carcinoma  by the 
pathology department/CCR/NCI or the pathology department of participating institutions.  
 
3.1.2 At least one prior line of platinum- based ch emotherapy or patient must have r efused 
Abbreviated Title:  Ph2Sunitinib Thymoma/Thymic Ca CTEP Protocol #: 9174  
Version Date:  04/30/2020  
 
 28 cytotoxic chemotherapy. Progressive disease must be documented prior to study entry. 
 
3.1.3 Patients must not have received chemotherapy, radiation therapy, or undergone major 
surgery within 4 weeks prior to enrollment.  
 
3.1.4 Patients must have measurable disease, per RECIST 1.1. See Section 12 for the 
evaluation of measurable disease.  
 
3.1.5 Age ≥ 18 years   
 3.1.6 ECOG performance status ≤ 2 (Karnofsky >50%, see Appendix A ). 
 3.1.7 Life expectancy of greater than 3 months 
 
3.1.8 Patients must have normal organ and marrow function as defined below: 
− hemoglobin   >9 g/dL 
− leukocytes      >3,000/mcL 
− absolute neutrophil count   >1,200/mcL  
− platelets       >100,000/mcL 
− total bilirubin      within normal institutional limits  
− serum calcium        <12.0 mg/dL 
− AST(SGOT)/ALT(SGPT)   <2.5 × institutional upper limit of normal* 
− creatinine       within normal institutional limits  
 OR 
− creatinine clearance     >60 mL/min/1.73 m2 for patients with 
creatinine levels above institutional normal.  
− * If subjects have liver metastases, both ALT and AST must be <5 × 
ULN.  
− Patients must have QTc < 500 msec  
 
3.1.9 PT or INR, and APTT ≤ 1.5 x upper limit of  normal (ULN), unless the abnormality can 
be explained by the presence of lupus anticoagulant or if these values are in the 
therapeutic range for a patient on low molecular  weight heparin.   
 
3.1.10 The following groups of patients are eligible provided they have New York Heart 
Association Class II (NYHA; see Appendix B ) cardiac function on baseline 
ECHO/MUGA:  
• those with a history of Class II heart failure who are asymptomatic on 
treatment  
• those with prior anthracycline exposure 
those who have received central thoracic radiation that included the heart in the radiotherapy port. 
3.1.11  Patients must have blood pressure (BP) no greater than 140 mmHg (systolic) and 90 
Abbreviated Title:  Ph2Sunitinib Thymoma/Thymic Ca CTEP Protocol #: 9174  
Version Date:  04/30/2020  
 
 29 mmHg (diastolic) for eligibility.  Initiation or adjustment of BP medication is permitted 
prior to study entry provided that the average of three BP readings at a visit prior to enrollment is less than 140/90 mmHg.  
 
3.1.12 Absence of brain metastases as confirmed by imaging of the brain by MRI or CT brain 
with contrast performed at baseline screen ing.   
 
3.1.13 The effects of sunitinib on the developing human fetus at the recommended therapeutic 
dose are unknown.  For this reason and because anti-angiogenic agents are known to be teratogenic, women of childbearing potential and men must agree to use adequate contraception (hormonal or barrier method of birth control; abstinence) prior to study entry and for the duration of study participation.  All women of childbearing potential must have a negative pregnancy test prior to receiving sunitinib.  Should a woman become pregnant or suspect she is pregnant while participating in this study, she should 
inform her treating physician immediately.   Men treated or enrolled on this protocol must 
also agree to use adequate contraception prior to the study, for the duration of study 
participation, and 4 months after completion of sunitinib  administration.  
 
3.1.14 Ability to understand and willingness to sign a written informed consent document. 
 
3.2 E
XCLUSION CRITERIA  
3.2.1 Patients with tumor amenable to potentially curative therapy.   
 
3.2.2 Prior treatment within the past 6 months with sunitinib, sorafenib, bevacizumab or other 
multikinase  inhibitors targeting any of the following: vascular endothelial growth factors 
1–3 (VEGF1 –3), FMS -like tyrosine kinase 3 (FLT3), stem cell growth factor (c -KIT), 
platelet -derived growth factors- α and - β (PDGF -α,-β), colony- stimulating factor 1 
(CSF1), and the ‘RET’ receptor for glial-derived neurotrophic factors. 
 
3.2.3 Patients with symptomatic brain metastases will be excluded from trial secondary to poor 
prognosis.  However, patients who have had treatment for their brain metastasis and whose brain disease has remained stable for  3 months without steroid therapy may be 
enrolled.   
  
3.2.4 Patients with evidence of severe or uncontrolled systemic disease, or any concurrent 
condition, which could compromise participation in the study, including, but not limited to, active or uncontrolled infection, immune deficiencies, uncontrolled HBV and/or HCV 
infection unless sustained virologic response to HCV therapy, uncontroll ed diabetes,   
serious non-healing ulcer, wound or bone fracture, history of intra- abdominal abscess, 
abdominal fistula or gastrointestinal perforation within 28 days of treatment, history of pulmonary embolism in the past 12 months, uncontrolled hypertension, myocardial infarction, cardiac arrhythmia, stable/unstable angina, symptomatic congestive heart failure, or coronary/peripheral artery bypass graft or stenting within 12 months prior to 
Abbreviated Title:  Ph2Sunitinib Thymoma/Thymic Ca CTEP Protocol #: 9174  
Version Date:  04/30/2020  
 
 30 study entry, Class III or IV heart failure as defined by the NYHA functional classification  
system (see Appendix B ),stroke/cerebrovascular accident or transient ischemic attack 
within the past 12 months or psychiatric illness/social situations which would jeopardize 
compliance with the protocol.   
 
3.2.5 Histor y of a previous invasive malignancy within the last 5 years, except adequately 
treated non- melanoma skin cancer, papillary carcinoma  of the thyroid or car cinoma in 
situ of the uterine cervix.   
 3.2.6 Patients who have had chemotherapy or radiotherapy within 4 weeks (6 weeks for 
nitrosoureas or mitomycin C) prior to entering the study or those who have not recovered from adverse events due to agents administered more than 4 weeks earlier.  
  
3.2.7 Patients who are receiving any other investigational agents.  
 3.2.8 History of allergic reactions attributed to compounds of similar chemical or biologic 
composition to sunitinib.  
 
Patients receiving any medications or substances that are strong inhibitors or inducers of CYP3A4 are ineligible.  (A list of potent CYP3A4 inducers or inhibitors can be found in 
Section 5.2)  An exception will be made for patients who are on ritonavir-based highly active antiretroviral therapy, in which case t he starting dose of sunitinib will be modified 
as indicated in Sections 5.2.11.  Every effort should be made to switch patients taking such agents or substances to other medications.  A comprehensive list of medications and substances known or with the potential to alter the pharmacokinetics of sunitinib through CYP3A4 is provided in Appendix C .   
 
3.2.9 Pregnant women are excluded from this study because sunitinib angiogenesis inhibitor 
with the potential for teratogenic or abortifacient effects.  Because there is an unknown but potential risk for adverse events in nursing infants secondary to treatment of the mother with sunitinib breastfeeding should be discontinued if the mother is treated with sunitinib .   
 
3.2.10 Patients who require therapeutic doses of Coumadin derivative anticoagulants s uch as 
warfarin are excluded. Low molecular weight heparin is permitted, provided the patient’s 
PT/INR is ≤ 1.5. Coumadin doses of up to 2 mg daily are permitted for prophylaxis of thrombosis. 
 
3.2.11 Patients with a pre -existing thyroid abnormality who are unable to maintain thyroid 
function in the normal range with medication are ineligible. 
 3.2.12 Patients with any condition ( e.g., gastrointestinal tract disease resulting in an inability to 
take oral medication or a requirement for IV alimentation, prior surgical pro cedures 
affecting absorption, or active peptic ulcer disease) that impairs their ability to swallow 
Abbreviated Title:  Ph2Sunitinib Thymoma/Thymic Ca CTEP Protocol #: 9174  
Version Date:  04/30/2020  
 
 31 and retain sunitinib tablets are excluded. 
 
3.2.13 Patients with QTc prolongation (defined as a QTc interval equal to or greater than 500 
msec) or other significan t ECG abnormalities are excluded.  
 
3.2.14 Patients with poorly controlled hypertension (systolic blood pressure of 140 mmHg or higher or diastolic blood pressure of 91 mmHg or higher) are ineligible.   
 
3.2.15 Patients who require use of therapeutic doses of coumar in-derivative anticoagulants such 
as warfarin are excluded, although doses of up to 2 mg daily are permitted for 
prophylaxis of thrombosis.  Note : Low molecular weight heparin is permitted provided 
the patient’s PT INR is ≤ 1.5. 
 
3.2.16 Patients with HIV infection  are eligible provided their CD4 count is greater than or equal 
to the institutional LLN ( ≥ 334 cells/uL). 
 
3.3 I
NCLUSION OF WOMEN AND MINORITIES  
Both men and women of all races and ethnic groups are eligible for this trial.   
Accrual Targets  
Ethnic Category  Sex/Gender  
Females   Males   Total  
Hispanic or Latino  3 + 3 = 6 
Not Hispanic or Latino  26 + 26 = 52 
Ethnic Category:  
Total of all subjects  29    (A1)  + 29 (B1) = 58 (C1) 
Racial Category   
American Indian or Alaskan 
Native  2 + 2 = 4 
Asian  5 + 5 = 10 
Black or African American  4 + 4 = 8 
Native Hawaiian or other 
Pacific Islander  1 + 1 = 2 
White  17 + 17 = 34 
Racial Category:  
Total of all subjects  29 (A2)  + 29 (B2) = 58 (C2) 
 (A1 = A2)   (B1 = B2)   (C1 = C2)  
 
Accrual Rate:  3 patients/month     Total Expected Accrual :  41 Min   58 Max  
Abbreviated Title:  Ph2Sunitinib Thymoma/Thymic Ca CTEP Protocol #: 9174  
Version Date:  04/30/2020  
 
 32  
4 REGISTRATION PROCEDURES  
4.1 COORDINATING CENTER  
Authorized staff must register an eligible candidate with NCI Central Registration Office (CRO) 
within 24 hours of signing consent.  A registration Eligibility Checklist from the web site (http://home.ccr.cancer.gov/intra/eligibility/welcome.htm
) must be completed and sent via 
encrypted email to:  NCI Central Registr ation Office ncicentralregistration -l@mail.nih.gov .  
After confirmation of eligibility at Central Registration Office, CRO staff will call pharmacy to advise them of the acceptance of the patient on the protocol prior to the release of any investigational agents.  Verification of Registration will be forwarded electronically via e -mail to 
the research team. A recorder is available during non-working hours.  
 
4.2 PARTICIPATING SITE 
All patients must be registered through the NCI Central Registration Office (CRO). The CRO is 
open from 8:30am to 5:30pm EST Monday through Friday, excluding federal holidays.  A 
protocol registration form will be supplied by the CCR study coordinator and updates will be provided as needed. Subject eligibility and demographic information is required for registration. To initially register a subject  after the participant has signe d consent, complete the top portion of 
the form and send to CCR study coordinator.  Once eligibility is confirmed, complete the remainder of the form which is the eligibility checklist and send to CCR study coordinator. In addition, source documents supporting the eligibility criteria must be sent to the CCR study coordinator. The CCR study coordinator will notify you either by e- mail or fax that the protocol 
registration form has been received which will include the unique patient/subject ID number.  Questions about eligibility should be directed to the CCR study coordinator or PI.  Questions related to registration should be directed to the CCR study coordinator.  
 
Technical questions about the form should be directed to the Central Registration: Office (301-402-1732). 
 
4.3 T
REATMENT INITIATION TIMELINE  
Following registration, patients should begin protocol treatment within 5 days. Issues that would cause treatment delays should be discussed with the Principal Investigator.  If a patient does not receive protocol therapy within 5 days following registration, the patient may have to be 
removed from study.  The Lead Associate Investigator  should be notified of treatment initiation 
delays  as soon as possible. 
 
5 TREATMENT PLAN 
5.1 A
GENT ADMINISTRATION  
Sunitinib  will be administered on an outpatient basis.  Reported  adverse events and potential 
risks are described in Section 7.  Appropriate dose modifications are described in Section 6.  No 
investigational or commercial agents or therapies other than sunitinib  may be administered with 
Abbreviated Title:  Ph2Sunitinib Thymoma/Thymic Ca CTEP Protocol #: 9174  
Version Date:  04/30/2020  
 
 33 the intent to treat the patient's malignancy.  
 
5.1.1 For Group 1, sunitinib will be administered orally at a dose of 50 mg daily  for 4 
consecutive weeks followed by 2 weeks of rest with no sunitinib, every 6 weeks (4/2 
schedule).  For Group 2, sunitinib will be administered orally at a dose of 50 mg daily for 
2 consecutive weeks followed by 1 week of rest with no sunitinib, every 3 weeks (2/1 schedule).  Patients should be instructed to store sunitinib at room temperature.  Patients will take sunitinib once daily, with or without food, as desired.  Patients should be advised 
to drink plenty of water or take rehydration fluids to avoid dehydration if diarrhea occurs.  
 
5.1.2 Because hypertensi on is a known and potentially serious but rare adverse event 
associated with sunitinib maleate treatment, patients will have their blood pressure 
monitored and recorded at baseline and weekly during treatment including the weeks off 
the investigational drug either at  the doctor’s office or using any calibrated electronic 
device (such as those found at a local drug store or pharmacy). Appendix D  and 
Appendix F  detail the collection and recording of blood pressure related information.  
 
5.1.3 Baseline assessment of cardiac function (ECHO/MUGA) is required for all patients. 
Routine monitoring for cardiac function (ECHO/MUGA) should be performed at baseline and then every other cycle of treatment in the following groups of patients: (1) those entering the trial with NYHA Class II cardiac dysfunction (see Appendix B ), (2) those 
with a history of Class II heart failure who are asymptomatic on treatment, and (3) in those previously exposed to anthracyclines or thoracic irradiation if the heart was included in the radiotherapy port.  
 
5.1.4 Although adrenal gland insufficiency is rarely seen with sunitinib treatment, patients 
should be clinically followed for the signs and symptoms of this complication, especially (1) patients with co -morbidities associated with adrenal  dysfunction, (2) patients with 
pre-existing adrenal insufficiency (primary or secondary), and (3) patients with 
concomitant stress (e.g., fever,  infection, bleeding, serious accident, surgery) that may 
precipitate overt adrenal insufficiency in the presence of subclinical sunitinib-induced adrenal toxicity.  If clinically indicated, objective testing for adrenal gland function should be conducted.  
 
5.1.5 Patients with bulky solid tumors should be monitored closely for pneumothorax, 
intestinal fistulae, or intestinal perforation in the event of rapid tumor destruction. 
 
5.1.6 Patients should be alerted to the possibility that sunitinib capsules can cause a  yellow 
discoloration of the skin on direct contact. If this happens, the patient  should wash immediately with soap and water.  
 
5.1.7 Patient s will be requested to maintain a med ication diary of each dose of medication.  
The medication diary will be returned to clinic staff at the end of  each course.  
 
Abbreviated Title:  Ph2Sunitinib Thymoma/Thymic Ca CTEP Protocol #: 9174  
Version Date:  04/30/2020  
 
 34 5.1.8 Thyroid function (free T4 and TSH) will be monitored at baseline and subsequently every 
6 weeks ( 2 cycles ). 
 
5.2  GENERAL CONCOMITANT MEDICATION AND SUPPORTIVE CARE GUIDELINES  
5.2.1 Concomitant medications  
 A concomitant medication is any medication a patient entering the trial is  using and is 
 expected  to continue using for some portion of the trial as well as any medication the 
 patient uses during the course of the trial. Study drugs are not considered concomitant 
 medication.  
 
5.2.2 All concomitant medications recorded at trial entr y must have a related, ongoing 
concomitant illness listed under the medical history at the time of  patient entry into the 
trial unless the medication is used for prophylaxis. Patients may continue to use any ongoing medications not prohibited by the protocol.  
 
5.2.3 All prescription and over-the- counter medications at trial entry as well as any new 
medications started during the trial must be documented. The documentation should 
continue until 30 days from the end of the last study drug treatment.  
 
5.2.4 No other anti-cancer therapy including chemotherapy, radiation therapy, hormonal cancer therapy and immunotherapy, or experimental medications are permitted while the patient is on this trial.  
 
5.2.5 Any disease progression that requires other specific anti-tumor therapy w ill be cause for 
discontinuation from study medication.  
 5.2.6 Steroid use is not recommended during sunitinib treatment unless absolutely necessary 
(e.g., for treatment of adverse events or protocol-required premedication) because many steroids (e .g., prednisone, prednisolone, dexamethasone, etc.) effectively lo wer sunitinib 
exposure through CYP3A4 interactions. Also steroid s are known to have anti-tumor 
activity in thymic malignancies.  
  
5.2.7 The case report form  (CRF) must capture the concurrent use of all other drugs, over-the-
counter medications, or alternative therapies.  
 5.2.8 The Principal Investigator should be alerted if the patient is taking any agent known to 
affect or with the potential to affect selected CYP450 isoenzymes. A comprehensive list of CYP3A4 inhibitors, inducers, and substrates is provided (see Appendix C ). 
 
5.2.9 In addition, patients and their caregivers should be provided the patient information sheet 
(see Appendix H ) describing potential interactions of the study agents with other drugs, 
remedies, and  medications.  
 
Abbreviated Title:  Ph2Sunitinib Thymoma/Thymic Ca CTEP Protocol #: 9174  
Version Date:  04/30/2020  
 
 35 5.2.10 Use of agents with proarrhythmic potential (terfenadine, quinidine, procainamide, 
disopyramide, sotalol, probucol, bepridil, haloperidol, risperidone, indapamide, and flecainide) is not permitted during treatment with sunitinib . A comprehensive list of 
agents with proarrhythmic potential can be found at http://torsade.org. 
 
5.2.11 Cytochrome P450- 3A4 (CYP3A4) inhibitors and/or inducers :  Patients must not have 
received potent inhibitors within 7  days and potent inducers within 12 days prior to drug 
administration.  
 
Sunitinib is primarily metabolized by liver enzymes, in particular CYP3A4. There was a mean 1.8-fold increase in exposure of SU011248 when co-administered with ketoconazole, a strong inhibitor of CYP3A4 and a mean 4-fold decreased in exposure of SU011248 when co-administered with rifampin, a strong inducer of CYP3A4.    
Therefore, co -administration with strong inhibitors (grapefruit/grapefruit juice, ketoconazole, 
itraconazole, clarithromycin, indinavir, saquinavir, ritonavir, atazanavir, nelfinavir, nefazodone, voriconazole, telithromycin) and strong inducers (dexamethasone, rifampin, rifabutin, rifapentin, 
carbamazepine, phenobarbital, phenytoin, St. John’s wort) of CYP3A4 may result in significant increases/decreases in exposure of SU011248 and may alter the safety/efficacy of the drug. However for patients who are on ritonavir, sunitinib may be administered at a starting dose of 37.5 mg q day.
142  
 Strong CYP3A4 inhibitors and inducers are not permitted 7 and 12 days before dosing, 
respectively. During the study, strong CYP3A4 inhibitors and inducers are not recommended.  Alternative therapies should be used when available.  If usage of a strong CYP3A4 inhibitor or inducer is necessary, this must be in agreement with the Sponsor.  The following drugs should not be used before or during the study: 
 
Inhibitors  – prohibited 7 days  before dosing and during study.  
azole antifungals (ketoconazole, 
itraconazole)  diltiazem  
clarithromycin  verapamil  
erythromycin   
 
Inducers  – prohibited 12 days  before dosing and during study.  
rifampin  phenobarbital   
rifabutin  phenytoin   
carbamazepine  St. John’s wort   
 
Aprepitant, fluconazole and voriconazole are clinically relevant moderate CYP3A4 inhibitors that should be avoided, if possible, or used with great caution. 
Abbreviated Title:  Ph2Sunitinib Thymoma/Thymic Ca CTEP Protocol #: 9174  
Version Date:  04/30/2020  
 
 36  
Additional inducers or inhibitors of CYP3A4 can be found at http://medicine.iupui.edu/clinpharm/ddis
. Interacting drugs with sunitinib should be avoided or 
used with great caution. 
 A comprehensive list of CYP3A4 inhibitors, inducers, and substrates is provided in Appendix C .  
In addition, patients and their caregivers should be provided the patient information sheet (see Appendix E ) describing potential interactions of sunitinib with other drugs, remedies, and 
medications.  
 
5.2.12 The use of coumarin -derivative anticoagulants such as warfarin (Coumadin®) is not 
recommended, although doses of up to 2 mg daily are permitted for prophylaxis of 
thrombosis. 
 
5.2.13 Supportive care guidelines  
• Nausea/vomiting – Patients with treatment-related nausea should be treated 
initially with a phenothiazine (prochlorperazine – 10 mg every 8 hours orally 
as needed or promethazine – 12.5-25 mg IV every 6 hours as needed).  If this is inadequate, a benzodiazepine should be added until acute nausea is controlled or toxicity is limiting.  Should this prove inadequate acutely, a steroid may be added ( e.g., dexamethasone 4 mg every 6 hours as needed).  
 
After acute nausea has resolved, consideration should be given to initiation of prophylactic anti- emetic therapy.  If nausea recurs despite reasonable medical 
intervention (as outlined above), dose reduction will be needed as described in Section 6. 
 
• Diarrhea  should be managed with loperamide:  4 mg at first onset, then 2 mg 
every 2 -4 hours until diarrhea is controlled (maximum = 16 mg loperamide 
per day).  
 
• Hand-foot syndrome may be tr eated with topical emollients (such as 
Aquaphor), topical/systemic steroids, and/or antihistamine agents.  Vitamin 
B6 (pyridoxine; 50-150 mg orally each day) may also be used.  Avoid exposure to heat, hot water, pressure, or friction. Use of soft, well- fitting 
shoes may help, as may use of acetaminophen if needed for analgesia.  
 
• Patients with neutropenic fever or infection should be evaluated promptly 
and treated with IV antibiotic therapy or therapeutic colony- stimulating 
factors as appropriate following the ASCO guidelines [ J Clin Oncol 
18(20):3558-85, 2000].  Packed red blood cell and platelet transfusion should be administered as clinically indicated.  Erythropoietic agents may be used at the discretion of the treating physician. 
 
Abbreviated Title:  Ph2Sunitinib Thymoma/Thymic Ca CTEP Protocol #: 9174  
Version Date:  04/30/2020  
 
 37 5.3 DURATION OF THERAPY  
In the absence of treatment delays due to adverse event (s), treatment may continue until one of 
the following criteria (off treatment criteria) applies: 
• Disease progression,  
 
• Intercurrent illness that prevents further administration of treatment,  
 
• Unacceptable adverse event(s),  
 
• Delay of treatment of ≥  3 weeks,  
 
• Positive pregnancy test 
 
• Patient decides to withdraw from the study, or 
 
• General or specific changes in the patient's condition render the patient unacceptable for 
further treatment in the judgment of the investigator.  
 
5.4 DURATION OF FOLLOW UP 
Prior to documenting removal from the study, effort must be made to have all subjects complete 
a safety visit approximately 30 days following the last dose of study therapy; then patients will be followed either with clinic visits or phone interviews yearly  until death .  Patients removed 
from treatment  for unacceptable adverse event (s) will be followed  clinical ly until resolution or 
stabilization of the adverse event, and then via clinic visits or phone interviews yearly  until 
death . 
 The following information will be collected:  
• Date of follow up 
• Is patient dead or alive?  
• If dead, document exact date of death.  
• Further treatment(s) , if any 
• Document date of disease progression 
 
5.5 C
RITERIA FOR REMOVAL FROM STUDY  
5.5.1 Once a patient has been removed from study, no further data can be collected; therefore, 
with completion of the duration of follow-up described in Section 5.4, the criteria for removal from study are: 
• Lost to follow-up 
• Death , or 
• The pat ient decides to withdraw from the study. 
 
The reason for study removal and the date the patient was removed must be documented in the database. 
Abbreviated Title:  Ph2Sunitinib Thymoma/Thymic Ca CTEP Protocol #: 9174  
Version Date:  04/30/2020  
 
 38  
5.5.2 Off Protocol Therapy and Off Study Procedure 
Authorized staff  must notify the NCI C entral Registration O ffice (CRO) when a patient is taken 
off protocol therapy and when a subject is taken off study. The CRO is open from 8:30am to 
5:30pm EST Monday through Friday, excluding federal holidays. A Participant Status Update Form  from the web site  (http://home.ccr.cancer.gov/intra/eligibility/welcome.htm
) main page 
must be completed and sent via encrypted email to:  NCI Central Registration Office 
ncicentralregistration -l@mail.nih.gov . The Participant Status Update Form will be supplied by 
the CCR study coordinator. Send the completed form to the CCR study coordinator. 
 
6 DOSING DELAYS/DOSE MODIFICATIONS  
6.1 GENERAL  GUIDANCE  
6.1.1 Patients may continu e to receive therapy provided  the following criteria are met on day 1 
of each cycle:  
• ANC ≥ 1,000/mcL  
• Platelets ≥  75,000/mcL 
• Non-hematologic toxicity recovered to < grade 2 (or tolerable grade 2 or baseline)  
• No evidence of progressive disease  
6.1.2 In the event of an adverse event at least possibly related to the agent, the doses of  such agent  should be adjusted according to the guidelines shown in the Dose Delays / Dose 
Modifications tables shown below. If a patient  experiences several adverse events and 
there are conflicting recommendations, the investigator should use the recommended dose adjustment that reduces the dose to the lowest level. If an adverse event is not covered in such tables, doses may be reduced or held at the discretion of the investigator for the subject’s safety. Subjects with adverse events that are manageable with supportive therapy may not require dose  reductions (e.g., nausea/vomiting may be treated with antiemetics, diarrhea may  be treated with loperamide, and electrolyte abnormalities may 
be corrected with supplements rather than by dose reduction). 
 
6.1.3 Subjects will be withdrawn from the study if they fail to recover to CTC Grade 0-1 or 
tolerable grade 2 (or within 1 grade of starting values for pre -existing laboratory 
abnormalities)  from a treatment -related adverse event within 21 days OR they experience 
agent related adverse events requiring dose modification despite two previous dose reductions (i.e. would require a 3rd dose reduction) unless the investigator and CTEP monitor agree that the subject should remain in  the study arm because of evidence that 
the patient is/may continue deriving benefit from continuing study treatment (i.e. patient has PR, CR, SD > 3 months). The appropriate reduced  dose will be determined after 
discussion between the principal investigator and CTEP monitor.  
6.2 T
REATMENT DELAYS AND MODIFICATIONS FOR ADMINISTRATIVE NEEDS  
Brief interruptions and delays may occasionally be required due to travel delays, airport closure, 
Abbreviated Title:  Ph2Sunitinib Thymoma/Thymic Ca CTEP Protocol #: 9174  
Version Date:  04/30/2020  
 
 39 inclement weather, family responsibilities, security alerts, and government holidays, etc. Delays 
of up to 1 week will not be considered protocol deviations and will not be separately reported. If 
a patient takes 75% or more of scheduled doses during a cycle, missed doses will not be reported as deviations. If the study team instructs a patient to hold the investigational drug, it will not be considered a protocol deviation.  A patient that interrupts therapy for more than 3 weeks  will be 
taken off treatment.  
 
6.3 T
REATMENT DELAYS AND MODIFICATIONS FOR MEDICAL NEEDS  
Patients experiencing complications of their disease or other medical illness not attributable to disease progression, or protocol therapy may also require brief interruptions and delays that will not be considered protocol deviations, and will not be separately reported. A patient that interrupts therapy for more than 21 days will be taken off treatment.  
6.4 
 SUNITINIB MONOTHERAPY DOSE LEVEL REDUCTIONS  (GROUPS 1 AND 2) 
 
Dose Level  Sunitinib  Dose  
Starting Dose  50 mg once a day  
First Dose Reduction  37.5 mg once a day  
Second Dose Reduction  25 mg once a day  
          
 
6.5  MANAGEMENT OF TREATMENT -EMERGENT HYPERTENSION  
Increases in blood pressure (BP) and cases of hypertension have been associated with many 
drugs acting on the VEGF pathway.  The proposed mechanism for this increase is through inhibition of VEGF-induced peripheral vasodilation.  Hypertension following sunitinib treatment has rarely been seen in animal studies or clinical trials.  Specific guidelines for management of this adverse event and a table of various antihypertensive medications are provided in Appendix G.  In addition, guidance on the collection and recording of BP information is provided in 
Appendix F . 
 
6.6 D
OSAGE MODIFICATION CRITERIA FOR OTHER HEMATOLOGIC AND NON-
HEMATOLOGIC ADVERSE EVENTS   
  
Event  AE Grade 
or 
Observation  Dose modification  
Neutropenia  Grades 1 and 
Grade 2 ≥ 
1200  Maintain dose  
Abbreviated Title:  Ph2Sunitinib Thymoma/Thymic Ca CTEP Protocol #: 9174  
Version Date:  04/30/2020  
 
 40 Event  AE Grade 
or 
Observation  Dose modification  
Grade 2 < 
1200 and 
Grade 3*  Hold sunitinib until  ANC > 1000 , then 
reduce 1 dose level and resume treatment  
Grade 4  Hold sunitinib until ANC  > 1000 , then 
reduce 1 dose level and resume treatment  
Thrombocytopenia Grade 1  Maintain dose  
Grade s 2 and 
3* Hold sunitinib until platelets > 75, 000 , 
then reduce 1 dose level and resume 
treatment  
Grade 4  Hold sunitinib until platelets > 75, 000 , 
then reduce 1 dose level and resume 
treatment  
Fever or flu -like 
symptoms  Grades 1 -4 Maintain dose  
Fatigue (lethargy, 
malaise, asthenia) Grades 1 and 
2 Maintain dose  
Grade 3* and 
severe grade 2, at investigator 
discretion  Hold sunitinib until ≤ grade 2, then 
reduce 1 dose level and resume treatment  
 
      
QTc prolongation 
Do not use CTCAE 
v5 grades  >450 but 
 < 550 msec Review patient’s concomitant 
medications for QT interval-prolonging agents.  Correct any electrolyte abnormalities.  
Continue sunitinib at current dose level.  
> 550 msec  Stop sunitinib and any other QT -interval 
prolonging agents immediately.  Correct any electrolyte abnormalities, then : 
If there is a plausible explanation for AE other than sunitinib treatment, resume sunitinib at current dose level. If sunitinib may have contributed  to the 
AE: 
Reduce 2 dose levels and restart sunitinib. If QTc remains <500 msec after 14 days at reduced dose, increase one dose level and continue sunitinib. 
If QTc remains <500 msec after 14 days, original dose of sunitinib may be 
resumed.  
Abbreviated Title:  Ph2Sunitinib Thymoma/Thymic Ca CTEP Protocol #: 9174  
Version Date:  04/30/2020  
 
 41 Event  AE Grade 
or 
Observation  Dose modification  
Hand-foot syndrome Grades 1 and 
2 Maintain dose  
Grade 3*  Hold sunitinib until ≤ grade 1, then 
resume treatment at same dose or reduce 
1 dose level  
AST and/or ALT 
elevation 
(SGOT, SGPT)  
 Grades 1 and 
2 Maintain dose  
Grades 3 and 
4 Sunitinib should be dose delayed if 
elevation of ALT is >5 × ULN, AST is 
>5 × ULN, and/or bilirubin is >3 × ULN.  Sunitinib may be re-administered when levels of ALT and AST are ≤5 × ULN and bilirubin is ≤3 × ULN.  Sunitinib should NOT be re- administered if 
subjects develop ≥ grade 3 hepatic failure (CTCAE  v5 definition).  
 
Patients must have LFTs checked at baseline and during each treatment cycle.  LFTs should be obtained at any time 
when they are clinically indicated.  
  
6.7 M
ANAGEMENT OF OTHER CLINICALLY SIGNIFICANT SUNITINIB -RELATED AES 
(not specifically addressed above) 
 
Observation  
 Action  
 
AE resolves promptly with supportive care  
 Maintain dose level  
1. Grade 3 or higher (non -hematologic or grade 4  
(hematologic) AE related to sunitinib and lasting >5  
days that does not resolve to grade 2 or below despite  
maximum supportive care for < 48 hours.  Reduce one dose level  
AE does not resolve to grade 2 or below after treating  
patient at the lowest (i.e., 25* mg or 12.5* daily)  
reduced dose level.  In general, remove patient from study**  
* 25 mg if the patients start dosing at 50 mg on a 4/2 schedule (solid tumors) or 12.5 mg if  
patients start dosing at 37.5 mg 
** After consultation with study sponsor (DCTD, NCI), a dose of 25 mg daily may be  
considered for patients on study > 3 months who are ben efiting from the agent.  
Abbreviated Title:  Ph2Sunitinib Thymoma/Thymic Ca CTEP Protocol #: 9174  
Version Date:  04/30/2020  
 
 42 7 NIH REPORTING REQUIREMENTS/DATA AND SAFETY MONITORING PLAN 
7.1 DEFINITIONS  
Please refer to definitions provided in Policy 801: Reporting Research Events found here . 
7.2 OHSRP  OFFICE OF COMPLIANCE AND TRAINING  / IRB  REPORTING  
7.2.1 Expedited Reporting 
Please refer to the reporting requirements in Policy 801: Reporting Research Events and Policy 
802 Non-Compliance Human Subjects Research found here . Note: Only IND Safety Reports that 
meet the definition of an unanticipated problem will need to be reported per the se policies . 
 
7.2.2 NIH Intramural  IRB Requirements for PI Reporting at Continuing Review 
Please refer to the reporting requirements in Policy 801: Reporting Research Events found her e.  
 7.2.3 NCI Guidance for Reporting Expedited Adverse Events for Multi- Center Trials  
Report events to the Reviewing IRB as per its policy. Please also notify the coordinating center 
PI and study coordinator of your submission at the time you make it. 
7.3 NCI
 CLINICAL DIRECTOR REPORTING  
Problems expeditiously reported to the OHSRP in iRIS will also be reported to the NCI Clinical 
Director.  A separate submission is not necessary as reports in iRIS will be available to the Clinical Director.  
In addition to those reports, all deaths that occur within 30 days  after  receiving a research 
intervention s hould be reported via email to the Clinical Director unless they are due to 
progressive disease.   
To report these deaths, please send an email describing the circumstances of the death to Dr. 
Dahut at NCICCRQA@mail.nih.gov
 within one business day of learning of the death.  
7.4 IND  SPONSOR  REPORTING CRITERIA  
7.4.1 Adverse Events:  List and Reporting Requirements  
Adverse event (AE) monitoring and reporting is a routine part of every clinical trial.  The following list of AEs (Section  7.3.1.1) and the characteristics of an observed AE (Section 
7.3.1.2) will determine whether  the event requires expedited  reporting (via CTEP -AERS ) in 
addition  to routine reporting.   
 
7.4.1.1  Comprehensive Adverse Events and Potential Risks list (CAEPR)  For Sunitinib Malate 
(SU011248 L- malate, NSC 736511) 
 
Comprehensive Adverse Events and Potential Risks list (CAEPR)  
for 
Sunitinib malate (SU011248 L-malate, NSC 736511) 
 
The Comprehensive Adverse Events and Potential Risks list (CAEPR) provides a single list of 
reported and/or potential adverse events (AE) associated with an agent using a uniform 
Abbreviated Title:  Ph2Sunitinib Thymoma/Thymic Ca CTEP Protocol #: 9174  
Version Date:  04/30/2020  
 
 43 presentation of events by body system. In addition to the comprehensive list, a subset, the 
Specific Protocol Exceptions to Expedited Reporting (SPEER), appears in a separate column and is identified with bold and italicized text. This subset of AEs (SPEER) is a list of events that are protocol specific exceptions to expedited reporting to NCI (except as noted below).  Refer to the 'CTEP, NCI Guidelines: Adverse Event Reporting Requirements' http://ctep.cancer.gov/protocolDevelopment/electronic_applications/docs/aeguidelines.pdf
  for 
further clarification. Frequency is provided based on 7115 patients. Below is the CAEPR for Sunitinib malate (SU011248 L- malate).  
NOTE : Report AEs on the SPEER ONLY IF  they exceed the grade noted in parentheses 
next to the AE in the SPEER.  If this CAEPR is part of a combination protocol using multiple investigational agents and has an AE listed on different SPEERs, use the lower of the grades to determ ine if expedited reporting is required. 
 
   Version 2.14, February 15, 20191 
 
 Adverse Events with Possible  
 Relationship to Sunitinib malate (SU011248 L- malate)  
 (CTCAE 5.0 Term)  
[n= 7115]   
 
 Specific Protocol Exceptions to 
Expedited Reporting (SPEER)  
Likely (>20%)  Less Likely (<=20%)  Rare but Serious (<3%)    
BLOOD AND LYMPHATIC SYSTEM DISORDERS    
 Anemia    Anemia (Gr 3)  
  Hemolytic uremic syndrome    
  Thrombotic thrombocytopenic 
purpura    
CARDIAC DISORDERS    
  Cardiac disorders - Other 
(cardiomyopathy)    
  Heart failure    
  Left ventricular systolic 
dysfunction    
  Myocardial infarction    
ENDOCRINE DISORDERS    
  Endocrine disorders - Other 
(thyroiditis)    
  Hyperthyroidism    
 Hypothyroidism    Hypothyroidism (Gr 2)  
EYE DISORDERS    
  Eye disorders - Other (macular 
edema)   Eye disorders - Other (macular edema) (Gr 
2) 
  Papilledema     Papilledema (Gr 2)  
   Vision decreased   Vision decreased (Gr 2)  
GASTROINTESTINAL DISORDERS    
 Abdominal distension    Abdominal distension (Gr 2)  
Abdominal pain     Abdominal pain (Gr 3)  
Anal mucositis     Anal mucositis (Gr 2)  
Constipation     Constipation (Gr 2)  
Diarrhea     Diarrhea (Gr 3)  
Abbreviated Title:  Ph2Sunitinib Thymoma/Thymic Ca CTEP Protocol #: 9174  
Version Date:  04/30/2020  
 
 44  
 Adverse Events with Possible  
 Relationship to Sunitinib malate (SU011248 L- malate)  
 (CTCAE 5.0 Term)  
[n= 7115]   
 
 Specific Protocol Exceptions to 
Expedited Reporting (SPEER)  
Likely (>20%)  Less Likely (<=20%)  Rare but Serious (<3%)    
 Dry mouth    Dry mouth (Gr 2)  
Dyspepsia     Dyspepsia (Gr 2)  
  Esophagitis    
 Flatulence    Flatulence (Gr 2)  
  Gastritis    Gastritis (Gr 2)  
  Gastroesophageal reflux disease      
   Gastrointestinal perforation143   
Mucositis oral     Mucositis oral (Gr 3)  
Nausea     Nausea (Gr 3)  
 Oral pain    Oral pain (Gr 2)  
  Pancreatitis    
Rectal mucositis     Rectal mucositis (Gr 2)  
Small intestinal mucositis     Small intestinal mucositis (Gr 2)  
Vomiting     Vomiting (Gr 3)  
GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS    
 Chills    Chills (Gr 2)  
 Edema limbs    Edema limbs (Gr 2)  
Fatigue     Fatigue (Gr 3)  
 Fever    Fever (Gr 2)  
 Flu like symptoms     
 Non-cardiac chest pain    Non-cardiac chest pain (Gr 2)  
HEPATOBILIARY DISORDERS    
  Cholecystitis    
  Hepatic failure    
IMMUNE SYSTEM DISORDERS    
  Allergic reaction144   
INFECTIONS AND INFESTATIONS    
  Infections and infestations - 
Other (necrotizing fasciitis)    
INJURY, POISONING AND PROCEDURAL COMPLICATIONS    
  Wound complication    
INVESTIGATIONS    
 Alanine aminotransferase increased    Alanine aminotransferase increased (Gr 3)  
 Alkaline phosphatase increased    Alkaline phosphatase increased (Gr 2)  
 Aspartate aminotransferase increased    Aspartate aminotransferase increased (Gr 
3) 
 Blood bilirubin increased    Blood bilirubin increased (Gr 2)  
 CPK increased     
 Creatinine increased    Creatinine increased (Gr 3)  
  Electrocardiogram QT 
corrected interval prolonged    
 Lipase increased    Lipase increased (Gr 4)  
 Lymphocyte count decreased    Lymphocyte count decreased (Gr 2)  
Abbreviated Title:  Ph2Sunitinib Thymoma/Thymic Ca CTEP Protocol #: 9174  
Version Date:  04/30/2020  
 
 45  
 Adverse Events with Possible  
 Relationship to Sunitinib malate (SU011248 L- malate)  
 (CTCAE 5.0 Term)  
[n= 7115]   
 
 Specific Protocol Exceptions to 
Expedited Reporting (SPEER)  
Likely (>20%)  Less Likely (<=20%)  Rare but Serious (<3%)    
 Neutrophil count decreased    Neutrophil count decreased (Gr 4)  
 Platelet count decreased    Platelet count decreased (Gr 4)  
 Serum amylase increased    Serum amylase increased (Gr 2)  
 Weight loss    Weight loss (Gr 2)  
 White blood cell decreased    White blood cell decreased (Gr 3)  
METABOLISM AND NUTRITION DISORDERS    
Anorexia     Anorexia (Gr 3)  
 Dehydration    Dehydration (Gr 3)  
 Hyperuricemia    Hyperuricemia (Gr 2)  
 Hypoalbuminemia    Hypoalbuminemia (Gr 2)  
 Hypocalcemia     
  Hypoglycemia    
 Hypophosphatemia    Hypophosphatemia (Gr 2)  
  Tumor lysis syndrome    
MUSCULOSKELETAL AND CONNECTIVE TISSUE DISORDERS    
 Arthralgia    Arthralgia (Gr 2)  
 Back pain    Back pain (Gr 2)  
  Musculoskeletal and 
connective tissue disorder - 
Other (fistula formation)    
 Myalgia    Myalgia (Gr 2)  
  Osteonecrosis of jaw    
 Pain in extremity    Pain in extremity (Gr 2)  
  Rhabdomyolysis    
NEOPLASMS BENIGN, MALIGNANT AND UNSPECIFIED (INCL CYSTS AND 
POLYPS)    
  Leukemia secondary to 
oncology chemotherapy    
  Myelodysplastic syndrome    
NERVOUS SYSTEM DISORDERS    
 Dizziness     
Dysgeusia     Dysgeusia (Gr 2)  
 Headache    Headache (Gr 3)  
  Leukoencephalopathy    
  Nervous system disorders - 
Other (cerebral infarction)    
 Paresthesia     
  Reversible posterior 
leukoencephalopathy syndrome    
  Transient ischemic attacks    
PSYCHIATRIC DISORDERS    
 Depression     
 Insomnia    Insomnia (Gr 2)  
RENAL AND URINARY DISORDERS    
Abbreviated Title:  Ph2Sunitinib Thymoma/Thymic Ca CTEP Protocol #: 9174  
Version Date:  04/30/2020  
 
 46  
 Adverse Events with Possible  
 Relationship to Sunitinib malate (SU011248 L- malate)  
 (CTCAE 5.0 Term)  
[n= 7115]   
 
 Specific Protocol Exceptions to 
Expedited Reporting (SPEER)  
Likely (>20%)  Less Likely (<=20%)  Rare but Serious (<3%)    
  Acute kidney injury    
  Nephrotic syndrome    
  Proteinuria    
RESPIRATORY, THORACIC AND MEDIASTINAL DISORDERS    
 Cough    Cough (Gr 2)  
 Dyspnea    Dyspnea (Gr 3)  
 Epistaxis    Epistaxis (Gr 2)  
Laryngeal mucositis     Laryngeal mucositis (Gr 2)  
Pharyngeal mucositis     Pharyngeal mucositis (Gr 2)  
Tracheal mucositis     Tracheal mucositis (Gr 2)  
SKIN AND SUBCUTANEOUS TISSUE DISORDERS    
 Alopecia    Alopecia (Gr 2)  
 Dry skin    Dry skin (Gr 2)  
  Erythema multiforme    
  Hair color changes    Hair color changes (Gr 2)  
Palmar -plantar 
erythrodysesthesia syndrome     Palmar -plantar erythrodysesthesia 
syndrome (Gr 3)  
 Pruritus     
 Rash maculo -papular    Rash maculo -papular (Gr 3)  
  Skin and subcutaneous tissue 
disorders - Other (pyoderma 
gangrenosum)    
 Skin hypopigmentation    Skin hypopigmentation (Gr 2)  
  Stevens -Johnson syndrome    
  Toxic epidermal necrolysis    
VASCULAR DISORDERS    
 Hypertension    Hypertension (Gr 3)  
  Thromboembolic event    
 Vascular disorders - Other 
(hemorrhage)5    
1This table will be updated as the toxicity profile of the agent is revised.  Updates will be distributed to all Principal 
Investigators at the time of revision.  The current version can be obtained by contacting PIO@CTEP.NCI.NIH.GOV .  
Your name, the name of the investigator, the protocol and the agent should be included in the e -mail.  
 
2Gastrointestinal perforation includes Colonic perforation, Duodenal perforation, Esophageal perforation, Gastric 
perforation, Ile al perforation, Jejunal perforation, Rectal perforation, and Small intestinal perforation under the 
GASTROINTESTINAL DISORDERS SOC.  
 
3Allergic reactions observed include anaphylaxis and angioedema.  
 
4The majority of hemorrhage events were mild.  Major even ts, defined as symptomatic bleeding in a critical area or organ 
(e.g., eye, GI tract, GU system, respiratory tract, nervous system [including fatal intracranial hemorrhage, and 
cerebrovascular accident], and tumor site) have been reported.  
 
 
Abbreviated Title:  Ph2Sunitinib Thymoma/Thymic Ca CTEP Protocol #: 9174  
Version Date:  04/30/2020  
 
 47 Adverse events reported on Sunitinib malate (SU011248 L -malate) trials, but for which there is insufficient evidence 
to suggest that there was a reasonable possibility that Sunitinib malate (SU011248 L -malate) caused the adverse 
event : 
 
BLOOD AND LYMPHATIC SYSTEM DISORDERS  - Febrile neutropenia  
CARDIAC DISORDERS  - Atrial fibrillation; Cardiac arrest; Pericardial effusion  
GASTROINTESTINAL DISORDERS - Ascites; Dysphagia; Gastrointestinal disorders - Other (enteritis); Hemorrhoids; 
Ileus; Small intestinal obstruction  
GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS  - Pain 
INVESTIGATIONS  - GGT increased; INR increased  
METABOLISM AND NUTRITION DISORDERS  - Hypercalcemia; Hyperglycemia; Hyperkalemia; Hypokalemia; 
Hyponatremia  
MUSCULOSKELETAL AND CONNECTIVE TISSUE DISORDERS  - Bone pain 
NERVOUS SYSTEM DISORDERS  - Cognitive disturbance; Peripheral sensory neuropathy; Seizure; Spinal cord 
compression; Syncope  
PSYCHIATRIC DISORDERS  - Anxiety; Confusion  
RENAL AND URINARY DISORDERS  - Hematuria; Urinary retention  
REPRODUCTIVE SYSTEM AND BREAST DISORDERS - Hematosalpinx  
RESPIRATORY, THORACIC AND MEDIASTINAL DISORDERS  - Pharyngolaryngeal pain; Pleural effusion; 
Pneumothorax  
VASCULAR DISORDERS  - Flushing; Hypotension  
 Note : Sunitinib malate (SU011248 L -malate) in combinatio n with other agents could cause an exacerbation of any adverse 
event currently known to be caused by the other agent, or the combination may result in events never previously associated with either agent.  
 
7.4.1.2  Adverse Event Characteristics  
• CTCAE term (AE desc ription) and grade:  The descriptions and grading scales 
found in the revised NCI Common Terminology Criteria for Adverse Events 
(CTCAE) version 4.0 will be utilized until March 31, 2018 for AE reporting. CTCAE version 5.0 will be utilized for AE reporting beginning April 1, 2018. All appropriate treatment areas should have access to  a copy of the CTCAE version 
5.0.  A copy of the CTCAE version 5.0 can be downloaded from the CTEP web site http://ctep.cancer.gov/protocolDevelopment/electronic_applications/ctc.htm
.   
 
• For expedited reporting purposes only:   
o AEs for the agent  that are bold and italicized  in the CAEPR ( i.e., those listed 
in the SPEER column, Section 7.3.1.1) should be reported through CTEP -
AERS  only if the grade is above the grade provided in the SPEER. 
o Other AEs for the protocol that do not require expedited reporting are outlined 
in section 7.3.2.4. 
 
• Attribution  of the AE: 
- Definite – The AE is clearly related  to the study treatment.  
- Probable – The AE is likely related to the study treatment.  
- Possible – The AE may be related  to the study treatment.  
- Unlikely – The AE is doubtfully related to the study treatment.  
- Unrelated – The AE is clearly NOT related  to the study treatment.  
 
Abbreviated Title:  Ph2Sunitinib Thymoma/Thymic Ca CTEP Protocol #: 9174  
Version Date:  04/30/2020  
 
 48 7.4.2 Expedited Adverse Event Reporting 
Expedited AE reporting for this study must use CTEP -AERS  (CTEP Adverse Event Reporting 
System), accessed via the CTEP Web site ( http://ctep.cancer.gov ).  The reporting procedures to 
be followed are presented in the “ NCI G uidelines for Investigators: A dverse Event Reporting 
Requir ements  for DCTD (CTEP and CIP) and DCP INDs and IDEs ” which can be downloaded 
from the CTEP Web site ( http://ctep.cancer.gov ).  These requirements are briefly outlined in the 
table s below (Sectio ns 7.3.2.3 and 7.3.2.4).  
 
In the rare occurrence when Internet connectivity is lost, a 24-hour notification is to be made to 
CTEP by telephone at 301-897-7497.  Once Internet connectivity is restored, the 24-hour 
notification phoned in must be entered electronically into CTEP -AERS  by the original submitter 
at the site.  
 
7.4.2.1  CTEP- AERS  is programmed for automatic electronic distribution of reports to the following 
individuals:  Study Coordinator of the Lead Organization, Principal Investigator, and the local 
treating physician.  CTEP- AERS  provides a copy feature for other e- mail recipients.  
 
7.4.2.2   Expedited Reporting Guidelines  
Use the NCI protocol number and the protocol- specific patient ID assigned during trial 
registration on all reports. 
 
Note:  A death on study requires both  routine and expedited reporting , regardless of 
causality.  Attribution to treatment or other cause must be provided.  
 Death due to progressive disease should be reported as Grade 5 “Disease progression” in the system organ class (SOC) “General disorders and administration site conditions.”  Evidence that the death  was a manifestation of underlying disease ( e.g., radiological changes suggesting tumor 
growth or progression: clinical deterioration associated with a disease process) should be submitted.  
 
7.4.2.3  Late Phase 2 and Phase 3 Studies: Expedited Reporting Requiremen ts for Adverse Events that 
Occur on Studies under an IND/IDE within 30 Days of the Last Administration of the 
Investigational Agent/Intervention1, 2  
 
FDA REPORTING REQUIREMENTS FOR SERIOUS ADVERSE EVENTS (21 CFR Part 312)  
NOTE:   Investigators MUST  immediately report to the sponsor (NCI) ANY Serious Adverse Events, whether or not 
they are considered related to the investigational agent(s)/intervention (21 CFR 312.64)  
 An adverse event is considered serious if it results in ANY  of the following outcomes:   
1) Death  
2) A life -threatening adverse event  
3) An adverse event that results in inpatient hospitalization or prolongation of existing hospitalization for ≥ 24 
hours  
4) A persistent or significant incapacity or substantial disruption of the ability to conduct normal life functions  
5) A congenital anomaly/birth defect.  
6) Important Medical Events (IME) that may not result in death, be life threatening, or require hospitalization may be considered serious when, based upon medical judgment, they m ay jeopardize the patient or 
subject and may require medical or surgical intervention to prevent one of the outcomes listed in this definition. (FDA, 21 CFR 312.32; ICH E2A and ICH E6).  
 
Abbreviated Title:  Ph2Sunitinib Thymoma/Thymic Ca CTEP Protocol #: 9174  
Version Date:  04/30/2020  
 
 49 ALL SERIOUS  adverse events that meet the above criteria MUST  be immediately reported to the NCI via CTEP -
AERS within the timeframes detailed in the table below.  
Hospitalization Grade 1 
Timeframes  Grade 2 
Timeframes  Grade 3 Timeframes  Grade 4 & 5 
Timeframes  
Resulting in 
Hospitalization  
≥ 24 hrs 10 Calendar Days  
24-Hour 5 
Calendar Days  Not resulting in  
Hospitalization  
≥ 24 hrs Not required  10 Calendar Days  
NOTE:  Protocol specific exceptions to expedited reporting of serious adverse events are found in the Specific 
Protocol Exceptions to Expedited Reporting (SPEER) portion of the CAEPR  
Expedited AE reporting timelines are defined as:  
o “24-Hour; 5 Calendar Days” - The AE must initially be reported via CTEP -AERS within 24 hours of 
learning of the AE, followed by a complete expedited report within 5 calendar days of the initial 24-
hour report.  
o “10 Calendar Days” - A complete expedited report on the AE must be submitted within 10 calendar 
days of learning of the AE.  
1Serious adverse events that occur more than 30 days after the last administration of investigational 
agent/intervention and have an attribution of possible, probable, or definite require reporting as follows:  
Expedited 24 -hour notification followed by complete report within 5 calendar days for:  
• All Grade 4, and Grade 5 AEs  
Expedited 10 calendar day reports for:  
• Grade 2 adverse events resulting in hospitalization or prolongation of hospitalization  
• Grade 3 adverse events  
2 For studies using PET or SPECT IND agents, the AE reporting period is  limited to 10 radioactive half -lives, 
rounded UP to the nearest whole day, after the agent/intervention was last administered.  Footnote “1” above 
applies after this reporting period.  
Effective Date:  May 5, 2011  
 
 
7.4.2.4  Additional Protocol-Specific Expedited Adverse Event Reporting Exclusions 
For this protocol only, the AEs/grades  listed below  do not require expedited reporting via CTEP -
AERS .  However, they still must be reported through the routine reporting mechanism ( Section  
7.4): 
 
CTCAE SOC  Adverse Event  Grade  Hospitalization/ 
Prolongation of 
Hospitalization  Attribution  Comments  
GI disorders  Nausea  2 to 3  
    
Diarrhea  2 to 3     
Constipation  2 to 3     
Vomiting  2 to 3     
Metabolism 
and Electrolyte  
abnormalities  2 to 4     
Abbreviated Title:  Ph2Sunitinib Thymoma/Thymic Ca CTEP Protocol #: 9174  
Version Date:  04/30/2020  
 
 50 nutrition 
disorders  
Nervous 
system  
disorders 
  
Disguesia  
 2    
Dermatology/
Skin Rash  
Acne/Acneifo
rm 2 to 3     
 Events that are clearly consequences of the “main” event (e.g., hypokalemia associated with  
diarrhea or the arrhythmias, hypotension, hypoxia, etc. that are known to occur concurrently with sepsis) may be noted in the Description of Event in the CTEP -AERS  report and do not require 
separate CTEP -AERS  reports.  
 The possibility of the contribution of comorbid conditions to the event should be considered when reporting adverse events. Examples include hyperglycemia in patients with diabetes or headaches and seizures in patients with brain tumors. 
  
7.5 R
OUTINE ADVERSE EVENT REPORTING  
All Adverse Events must be reported in routine study data submissions.  AEs reported through CTEP -AERS  must also  be reported in routine study data submissions. 
 
7.5.1 Secondary Malignancy 
A secondary malignancy is a cancer caused by treatment for a previous malignancy ( e.g., 
treatment with investigational agent/intervention, radiation or chemotherapy). A secondary 
malignancy is not considered a metastasis of the initial neoplasm.  CTEP requires all secondary malignancies that occur following treatment with an agent under an NCI IND/IDE be reported via CTEP -AERS . Three options are available to describe the event:  
• Leukemia secondary to oncology chemotherapy ( e.g., a cute m yelocytic 
leukemia [AML])  
• Myelodysplastic syndrome (MDS)  
• Treatment -related secondary malignancy  
 Any malignancy possibly related to cancer treatment (including AML/MDS) should also be reported via the routine reporting mechanisms outlined in each protocol.  
 
7.5.2 Second Malignancy 
A second malignancy is one unrelated to the treatment of a prior malignancy (and is NOT a metastasis from the initial malignancy).   Second malignancies require ONLY routine reporting 
via CDUS  unless otherwise specified .  
 
Abbreviated Title:  Ph2Sunitinib Thymoma/Thymic Ca CTEP Protocol #: 9174  
Version Date:  04/30/2020  
 
 51 7.6 NIH  REQUIRED DATA AND SAFETY MONITORING PLAN 
All clinical research requires monitoring to ensure the quality data and human subjects protection 
(HSP).  The following plan will be used for this study.     
7.6.1 Principal Investigator/Research Team  
The clinical research team will meet on a regular basis (at  least weekly) when patients are being 
actively treated on the trial to discuss each patient.  All data will be collected in a timely manner 
and reviewed by the principal investigator or the lead associate investigator. Events meeting 
requirements for exped ited reporting as described in section 7.2.1 will be submitted within the 
appropriate timelines .  
 The principal investigator will review adverse event and response data on each patient to ensure safety and data accuracy. The principal i nvestigator will personally conduct or supervise the 
investigation and provide appropriate delegation of responsibilities to other members of the 
research staff.  
 
8 PHARMACEUTICAL  INFORMATION 
A list of the adverse events and potential risks associated with the investigational agent 
administered in this s tudy can be found in Section 7.3. 
 
8.1 S
UNITINIB  [SUNITINIB MALATE (NSC  736511)] 
  Chemical Name  
N-[2-(Diethylamino)ethyl] -5-[(Z)-(5-fluoro -1,2-dihydro-2-oxo-3H -indol-3-
ylidene)methyl]-2,4-dimethyl-1H -pyrrole-3-carboxamide, compound with (S)-2-
hydroxybutanedioic acid  
   Other Names  
   SU011248 L-m alate; Sutent  
   Classification  
  Multi -kinase inhibitor  
   Molecular Formula :  C
22H27FN 4O2•C4H6O5  M.W.:  532.57 Daltons 
   Description :  Sunitinib malate is the L -malate salt of SU011248 free base. 
   CAS Registry Number  
  341031-54-7    Aqueous Solubility  
Solvent  Solubility (mg/mL)  
0.1 M HCl  59.1 
Abbreviated Title:  Ph2Sunitinib Thymoma/Thymic Ca CTEP Protocol #: 9174  
Version Date:  04/30/2020  
 
 52  
    
    
 Solubility in Various Solvents  
 
Mode of Action :  Sunitinib is a 
small molecule that inhibits multiple receptor tyrosine kinases (RTKs), some of which 
are implicated in tumor growth, 
pathologic angiogenesis, and metastatic progression of cancer. Sunitinib is  an inhibitor 
of platelet -derived growth 
factor receptors (PDGFRα and PDGFRβ), vascular endothelial growth factor receptors 
(VEGFR1, VEGFR2 and VEGFR3), stem cell factor receptor (KIT), Fms -like 
tyrosine kinase-3 (FLT3), colony stimulating factor receptor Type 1 (CSF- 1R), 
and the glial cell -line derived neurotrophic factor receptor (RET). 
 
How Supplied: Sunitinib malate capsules are supplied by Pfizer, Inc. and 
distributed by the Pharmaceutical Management Branch, CTEP/DCTD/NCI.  Capsules are packaged in 28 -count bottles with mannitol, croscarmellose sodium, 
povidone (K -25) and magnesium stearate as inactive ingredients in the following 
strengths:
 
• 12.5 mg hard gelatin capsule (size 4) with orange cap and orange body, printed with white ink "Pfizer" on the cap and "STN 12.5 mg" on the body.  
• 25 mg hard gelatin capsule (size 3) with caramel cap and orange body, 
printed with white ink "Pfizer" on the cap and "STN 25 mg" on the body.  
• 50 mg hard gelatin capsule (size 2) with caramel top and caramel body, 
printed with white ink "Pfizer" on the cap and "STN 50 mg" on the body.  
Orange gelatin capsule shells contain titanium dioxide, and red iron oxide.  Caramel 
gelatin capsule shells cont ain titanium dioxide, red iron oxide, yellow iron oxide 
and black iron oxide.  W hite printing ink contains shellac, propylene glycol, sodium 
hydroxide, povidone and titanium dioxide. 
 
Storage :  Store at 25°C (77°F); excursions permitted to 15–30°C (59 –86°F).
 
 pH 4.5 buffer  25.4 
pH 6.8 buffer  37.8 
pH 7.5 buffer  0.05 
in water  1.6 
Solvent  Solubility (mg/mL)  
Acetonitrile  0.1 
Dimethyl sulfoxide  92.9 
Tetrahydrofuran  0.2 
Methanol  1.5 
Ethanol  0.3 
1-Butanol  0.1 
1-Butano:Water (80/20 
v/v)  6.2 
N,N-Dimethylacetamide  37 
N,N-
Dimethylformamide  18.4 
Abbreviated Title:  Ph2Sunitinib Thymoma/Thymic Ca CTEP Protocol #: 9174  
Version Date:  04/30/2020  
 
 53 Stability :  Refer to the package label for expiration.  
 
Route of Administration:  Oral administration, take with or without food.  
 Potential Drug Interaction  
Sunitinib is metabolized primarily by CYP3A4.  Avoid co- administration of 
strong CYP3A4 inducers/inhibitors.  Patient Care Implications:  
A yellow discoloration of the skin area may result following direct contact with the capsules. Wash the exposed area with soap and water immediately.  
 Availability:  
Sunitinib is an investigational agent supplied to investigators by the Division of 
Cancer Treatment and Diagnosis (DCTD), NCI.  Sunitinib  is provided to the NCI 
under a Collaborative Agreement between the Pharmaceutical Collaborator and 
the DCTD, NCI (see Section 16).  
 
8.2 A
GENT ORDERING  AND AGENT ACCOUNTABILITY  
8.2.1 NCI-supplied agents may be requested by the Principal Investigator (or their authorized 
designee) at each participating institution.   Pharmaceutical Management Branch (PMB) 
policy requires that agent be shipped directly to the institution wher e the patient is to be 
treated.   PMB does not permit the transfer of agents between institutions (unless prior 
approval from PMB is obtained).  The CTEP -assigned protocol number must be used for 
ordering all CTEP-supplied investigational agents.  The responsible investigat or at each 
participating institution must be registered with CTEP, DCTD through an annual 
submission of FDA Form 1572 (Statement of Investigator), Curriculum Vitae, Supplemental Investigator Data Form (IDF), and F inancial Disclosure Form (FDF).   If 
there a re several participating investigators at one institution, CTEP -supplied 
investigational agents for the study should be ordered under the name of one lead investigator at that institution.  
 
8.2.2 Active CTEP -registered investigators and investigator-designated shipping designees and 
ordering designees can submit agent requests through the PMB Online Agent Order 
Processing (OAOP) application ( https://eapps -ctep.nci.nih.gov/OAOP/pages/login.jspx
).  
Access to OAOP requires the establishment of a CTEP Identity and A ccess Management 
(IAM) account ( https://eapps -ctep.nci.nih.gov/iam/ ) and the maintenance of an “active” 
account status and a “current” p assword.   For questions about drug orders, transfers, 
returns, or accountability, call 240-276-6575 Monday through Friday between 8:30 am and 4:30 pm (ET) or email 
PMBAfterHours@mail.nih.gov  anytime.  
 
8.2.3 Agent Inventory Records – The investigator, or a responsible party designated by the 
investigator, must maintain a careful record of the inventory and disposition of all agents 
received from DCTD using the NCI Drug Accountability Record Form (DARF).  (See 
Abbreviated Title:  Ph2Sunitinib Thymoma/Thymic Ca CTEP Protocol #: 9174  
Version Date:  04/30/2020  
 
 54 the N CI Investigator’s Handbook for Procedures for Drug Accountability and Storage.) 
 
 
9 BIOMARKER, CORRELATIVE, AND SPECIAL STUDIES  
As soon as possible after the patient is scheduled please send an email n otification to the Trepel 
lab (trepel@helix.nih.gov), Sunmin Lee (leesun@pop.nci.nih.gov), and Min-Jung Lee 
(leemin@mail.nih.gov) that the  sample is scheduled. After the sample is drawn please call the 
Trepel lab at 240-760-6330 to  communicate that the sample is ready. Keep the sample o n the 
unit at room temperature and the sample will be picked up by the lab. Correlative studies will be 
performed on all patients who enroll in the protocol (including those with HIV infection).   
9.1 S
ERUM VEGFR2,  PLGF,  IL-4, IL-12,  HGF,  B-FGF  – GROUP 1 ONLY  
a. Collection of Specimen(s): one 10-cc redtop serum tube 
b. Handling of Specimens(s): keep at room temp.  The sample will be picked  up by the 
Trepel lab.  
c. Shipping of Specimen(s):  There is no shipping; these studies apply to NCI only. 
d. Methods; Isolate serum from redtop serum tube, freeze, thaw, run sandwich ELISA 
or an electrochemiluminescent multiplexed sandwich immunoassay (Meso- Scale 
Discovery). 
e. Site(s) Performing Correlative Study : Trepel Lab, DTB , Building 10, Room 12N218. 
 
9.2 CIRCULATING TUMOR CEL LS, CIRCULATING ENDOTHE LIAL PROGENITORS , MATURE 
APOPTOTIC ENDOTHELIA L CELLS , REGULATORY T CELLS (TREGS )*, EXHAUSTED CD8  T 
CELLS *, MYELOID -DERIVED SUPPRESSOR CELLS (MDSC S)*, AND TH1/TH2 T CELL 
POPULATIONS *   
a. Collection of Specimen(s): four 10- ml lavender top t ubes 
b. Handling of Specimens(s): Keep at room temp.  The sample will be picked up by the Trepel lab.  
c. Shipping of Specimen(s): There is no shipping; these studies apply to NCI only. 
d. Methods :  Cell -based analyses will be performed by m ultiparametic flow cytometry.  
e. Site( s) Performing Correlative Study: Trepel Lab, DTB,  Building 10, Room 12N218. 
 Note:  Subsets  marked with an asterisk (*) will be applicable to Group 2 only. 
 
9.3 I
NTRA -TUMORAL IMMUNE INFIL TRATE , WHE RE TUMOR SAMPLES ARE  AVAILABLE  
a. Collection of Specimen(s): Tissue will be placed in media provided by the lab.  The Trepel lab will go to the OR or IR to be present at the time of the procedure. 
b. Handling of Specimens(s): On ice.  Tumor will be immediately dissociated into single viable cells and viably frozen until thawing for multiparameter flow cytometric analysis.  
c. Shipping of Specimen(s): No shipping. 
d. Methods: Thaw and stain for immune subsets including but not limited to CD8, 
Abbreviated Title:  Ph2Sunitinib Thymoma/Thymic Ca CTEP Protocol #: 9174  
Version Date:  04/30/2020  
 
 55 CD4, CD56, CD68 and analyze by multiparameric flow cytometry. 
e. Site(s) Performing Correlative Study; Trepel Lab, DTB,  Building 10, Room 12N218. 
 
9.4 SAMPLE STORAGE , TRACKING AND DISPOSITION  
Samples will be ordered  in CRIS  and tracked through a Clinical Trial Data Management system .  
Should a CRIS screen not be available, the CRIS downtime procedures will be followed.  
Samples will not be sent outside NIH without appropriate approvals and/or agreements, if required .  
 Any specimens that are remaining at t he completion of the protocol will be stored in the 
conditions described below. The study will remain open so long as sample or data analysis continues.  Samples from consenting subjects will be stored until they are no longer of scientific value or if a subject withdraws consent for their continued use, at which time they will be destroyed.  
 
If the patient withdraws consent the participant ’s data will be excluded from future distributions, 
but data that have already been distributed for approved research use will not be able to be retrieved.  
 The PI will record any loss or unanticipated destruction of samples as a deviat ion. Reporting will 
be per the requirements of section 7.2.  
10 DATA COLLECTION AND EVALUATION  
10.1 D
ATA COLLECTION  
The PI will be responsible for overseeing entry of data into C3D, an in -house password protected 
electronic system ; and ensuring data accuracy, consistency and timeliness. The principal 
investigator, associate investigators/research nurses and/or a contrac ted data manager will assist 
with the data management efforts.  All data obtained during the conduct of the protocol will be 
kept in secure network drives or in approved alternative sites that comply with NIH security standards. Primary and final analyzed data will have identifiers so that research data can be attributed to an individual human subject participant.  
All adverse events, including clinically significant abnormal findings on laboratory evaluations, regardless of severity, will be followed until return to baseline or stabilization of event. Patients will be followed for adverse events for a minimum of 30 days after removal from study treatment 
or until off-study, whichever comes first. 
 An abnormal laboratory value will be recorded in the databas e as an AE only if the laboratory 
abnormality is characterized by any of the following: 
• Results in discontinuation from the study 
• Is associated with clinical signs or symptoms  
• Requires treatment or any other therapeutic intervention  
• Is associated with death or another serious adverse event, including hospitalization.  
Abbreviated Title:  Ph2Sunitinib Thymoma/Thymic Ca CTEP Protocol #: 9174  
Version Date:  04/30/2020  
 
 56 • Is judged by the Investigator to be of significant clinical impact 
• If any abnormal laboratory result is considered clinically significant, the investigator will 
provide details about the action taken with respect to the test drug and about the patient’s outcome. 
 End of study procedures: Data will be stored according to HHS, FDA regulations, and NIH Intramural Records Retention Schedule as applicable.   Loss or destructio n of data: Should we become aware that a major breach  in our plan to protect 
subject confidentiality and trial data has occurred, this will be reported expeditiously per requirements in section 7.3.2.   
11 STUDY CALENDAR  
Baseline evaluations are to be conducted within 1 week prior to start of protocol therapy.  Scans 
and x-rays must be done <4 weeks prior to the start of therapy.  In the event that the pat ient’s 
condition is deteriorating, laboratory evaluations should be repeated within 48 hours prior to 
initiation of the next cycle of therapy. 
  
Abbreviated Title:  Ph2Sunitinib Thymoma/Thymic Ca CTEP Protocol #: 9174  
Version Date:  04/30/2020  
 
 57 Group 1  Pre- 
Study  Wk 
1 Wk 
2 Wk 
3j Wk 
4 Wk 
5 Wk 
6 Wk 
7 Wk 
8 Wk 
9 Wk 
10 Wk 
11 Wk 
12 Wk 
13m Off- Treatment  Follow -up 
Evaluationsi 
Sunitinib   A A A A   A A A A      
Informed consent  X                
Demographics  X                
Medical history  X                
Concurrent meds  X X--------------------------------------------------------------------------------------------- X    
Physical exam  X X  X    X       X  
Vital signs  X X  X    X       X  
Blood Pressure h X X X X X X X X X X X X X    
Height  X                
Weight  X X  X    X       X  
Performance status  X X  X    X       X X 
CBC w/diff, pltsl X X  X    X       X  
Serum chemistrya X X  X    X       X  
Urinalysis  X                
PT/PTT  X                
EKG  X                
Echocardiogram /MUGA 
scan k X X               
Adverse event evaluation   X--------------------------------------------------------------------------------------------- X  X  
Tumor measurements  
X Tumor measurements are repeated every 6 weeks for  patients on treatment < 1 year; every 
12 weeks  for patients on treatment ≥ 1 year .  Documentation (radiologic) must be provided 
for patients removed from study for progressive disease.   
X  
Radiologic evaluation X Radiologic measurements should be performed every 6 weeks for patients on treatment < 1 
year; every 12 weeks  for patients on treatment ≥ 1 year .  X  
Abbreviated Title:  Ph2Sunitinib Thymoma/Thymic Ca CTEP Protocol #: 9174  
Version Date:  04/30/2020  
 
 58 Group 1  Pre- 
Study  Wk 
1 Wk 
2 Wk 
3j Wk 
4 Wk 
5 Wk 
6 Wk 
7 Wk 
8 Wk 
9 Wk 
10 Wk 
11 Wk 
12 Wk 
13m Off- Treatment  Follow -up 
Evaluationsi 
B-HCG  Xb                
TSH and Free T4  X       X         
Circulating angiogenic 
proteins d  X       X      X   
CEP/CEC/CTC e X       X      X   
Tumor molecular profiling f 
and intra -tumoral immune 
infiltrate g X              
X  
Follow -up Evaluations per 
Section  5.4                X 
 A: Sunitinib:  Dose as assigned; administration schedule  
a: Albumin, alkaline phosphatase, total bilirubin, bicarbonate, BUN, calcium, chloride, creatinine, glucose, LDH, phosphorus, po tassium, total protein, 
SGOT [AST], SGPT [ALT], sodium; at baseline; on week s 1 and 3 for Cycle 1;  and then on Weeks 1 and 7 only for subsequent cycles, unless 
clinically indicated.  
b: Serum pregnancy test (women of childbearing potential).  
c: Off-study evaluation.   
d:      Serum VEGFR2, PlGF, IL -4, IL -12, HGF, b-FGF will be collected at baseline; on Week 7 (= Cycle 2, Week 1), and Week 13 (= Cycle 3, Week 1) 
at NCI only  
e:    Circulating endothelial cells, circulating endothelial progenitor cells, and circulating tumor cells will be collected at baseline; on Week 7 (= Cycle 2, 
Week 1), and Week 13 (= Cycle 3, Week 1)  at NCI only  
f:      only in patients who also enroll in pilot study 11-C- 0096  
g:     only in patients who donate fresh tissue  
h:     BP wi ll be measured at baseline, and then weekly thereafter; i.e., at every clinic visit, and at home on weeks when there i s no clinic visit.  See Appendix 
F. 
i:    Follow -up evaluations will be conducted by clinic visits or phone interviews yearly until death, in accordance with Section 5.4 . Patients removed from 
treatment for unacceptable adverse event(s) will be followed clinically until resolution or stabilization of the adverse even t, and then via clinic visits 
or phone interviews yearly until death.  
j:      Cycle 1 only  
k:      Echo will be done at baseline, on Cycle 1 Week 1, and then every other cycle; i.e., Cycles 3, 5, 7, etc., according to Section 5.1.3   
l:     CBC w/diff, plts: at baseline; on week s 1 and 3  for Cycle 1;  and then on Weeks 1 and 7 only for subsequent cycles, unless clinically indicated.  
m:   Week 13 refers to Cycle 3 Week 1 only   
 
Abbreviated Title:  Ph2Sunitinib Thymoma/Thymic Ca CTEP Protocol #: 9174  
Version Date:  04/30/2020  
 
 59 Group 2  Pre- 
Study  Wk 
1 Wk 
2 Wk 
3 Wk 
4 Wk 
5 Wk 
6 Wk 
7 Wk 
8 Wk 
9 Wk 
10 Wk 
11 Wk 
12 Wk 
13 Off- Treatment  Follow -up 
Evaluationsh 
Sunitinib   A A  A A  A A  A A     
Informed consent  X                
Demographics  X                
Medical history  X                
Concurrent meds  X X--------------------------------------------------------------------------------------------- X    
Physical exam  X X   X   X       X  
Vital signs  X X   X   X       X  
Blood Pressure g X X X X X X X X X X X X X    
Height  X                
Weight  X X   X   X   X    X  
Performance status  X X   X   X   X    X X 
CBC w/diff, plts  X X   X   X   X    X  
Serum chemistrya X X   X   X   X    X  
Urinalysis  X                
PT/PTT  X                
EKG  X                
Brain  imaging (MRI or CT 
w/contrast ) X                
Echocardiogram /MUGA 
scan i X X      X         
Adverse event evaluation   X--------------------------------------------------------------------------------------------- X  X  
Tumor measurements  
X Tumor measurements are repeated every 6 weeks for patients on treatment < 1 year; every 
12 weeks  for patients on treatment ≥ 1 year .  Documentation (radiologic) must be provided 
for patients removed from study for progressive disease.   
X  
Abbreviated Title:  Ph2Sunitinib Thymoma/Thymic Ca CTEP Protocol #: 9174  
Version Date:  04/30/2020  
 
 60 Group 2  Pre- 
Study  Wk 
1 Wk 
2 Wk 
3 Wk 
4 Wk 
5 Wk 
6 Wk 
7 Wk 
8 Wk 
9 Wk 
10 Wk 
11 Wk 
12 Wk 
13 Off- Treatment  Follow -up 
Evaluationsh 
Radiologic evaluation X Radiologic measurements should be performed every 6 weeks for patients on treatment < 1 
year; every 12 weeks  for patients on treatment ≥ 1 year .  X  
B-HCG  Xb                
TSH and Free T4  X       X         
Immune subsets  d  X X   X   X      X   
CEP/CEC/CTC e X X   X   X      X   
intra-tumoral immune 
infiltrate f X              X  
Follow -up Evaluations per 
Section  5.4                X 
 A: Sunitinib:  Dose as assigned; administration schedule  
a: Albumin, alkaline phosphatase, total bilirubin, bicarbonate, BUN, calcium, chloride, creatinine, glucose, LDH, phosphorus, po tassium, total protein, 
SGOT [AST], SGPT [ALT], sodium; at baseline, and every 3 weeks, unless clinically indicated.  
b: Serum pregn ancy test (women of childbearing potential).  
c: Off-study evaluation.   
d:      Samples for Tregs, MDSCs, Th1/Th2, and exhausted T cell analysis  will be collected at baseline; on Week 4 and 7 (= Cycle 2, Week 1  and Cycle 3, 
Week 1), and Week 13 (= Cycle 5 , Week 1) at NCI only  
e:    Circulating endothelial cells, circulating endothelial progenitor cells, and circulating tumor cells will be collected at baseline; on Week 7 (= Cycle 2, 
Week 1), and Week 13 (= Cycle  3, Week 1)  at NCI only  
 
f:     only in patients who donate fresh tissue  
g:     BP will be measured at baseline, and then weekly thereafter; i.e., at every clinic visit, and at home on weeks when there i s no clinic visit.  See Appendix 
F. 
h:    Follow -up evaluations will be conducted by clinic visits or phone interviews yearly until death, in accordance with Section 5.4 . Patients removed from 
treatment for unacceptable adverse event(s) will be followed clinically until resolution or stabilization of the adverse event, and then via clinic visits 
or phone interviews yearly until death.  
i:      Echo will be done at baseline, on Cycle 1 Week 1, and then every other cycle; i.e., Cycles 3, 5, 7, etc., according to Section 5.1.3  for patients on 
treatment < 1 year; then every 12 weeks for patients on treatment ≥ 1 year .  
Abbreviated Title:  Ph2Sunitinib Thymoma/Thymic Ca CTEP Protocol #: 9174  
Version Date:  04/30/2020  
 
 61 12 MEASUREMENT OF EFFEC T 
12.1 ANTITUMOR EFFECT – SOLID TUMORS  
 
For the purposes of this study, patients should be re- evaluated for response every 6 weeks for 
patients on treatment < 1 year; every 12 weeks for patients on treatment ≥ 1 year .  In addition to 
a baseline scan, confirmatory scans should also be obtained 4 weeks following initial documentation of objective response.  Response and progression will be evaluated in this study using the new international criteria proposed by the revised Response Evaluation Criteria in Solid Tumors (RECIST) guideline (version 1.1) 
145.Changes in the largest diameter (unidimensional measurement) of the tumor 
lesions and the shortest diameter in the case of malignant lymph nodes are used in the RECIST criteria.  
 
12.1.1 Definitions  
Evaluable for toxicity:  All patients will be evaluable for toxicity from the time of their first 
treatment with sunitinib .  
 
Evaluable for objective response:  Only those patients who have received at least one cycle of 
therapy, and have had their disease re- evaluated will be considered evaluable for response.  
These patients will have their response classified according to the definitions stated below.  (Note:  Patients who exhibit objective disease progression prior to the end of cycle 1 will also be considered evaluable.)  
 
12.1.2 Disease Parameters  
Measurable disease:  Measurable lesions are defined as those that can be accurately measured in at least one dimension (longest diameter to be recorded) as: 
• By chest x -ray: ≥ 20 mm; 
• By CT scan:  
o Scan slice thickness 5mm or under: as ≥ 10 mm 
o Scan slice thickness >5 mm: double the slice thickness   
o With calipers on clinical exam ≥ 10 mm  
 
All tumor measurements must be recorded in millimeters  (or decimal fractions of centimeters).  
 Note:  Tumor lesions that are situated in a previously irradiated area might or might not be considered measurable.    
Malignant lymph nodes:  To be considered pathologically enlarged and measurable, a lymph 
node must be ≥ 15 mm in short axis when assessed by CT scan (CT scan slice thickness 
recommended to be no greater than 5 mm).  At baseline and in follow-up, only the short axis will be measu red and followed. 
 
Abbreviated Title:  Ph2Sunitinib Thymoma/Thymic Ca CTEP Protocol #: 9174  
Version Date:  04/30/2020  
 
 62 Non-measurable disease:  All other lesions (or sites of disease), including small lesions (longest 
diameter <10 mm or pathological lymph nodes with ≥ 10 to <15 mm short axis), are considered 
non-measurable disease.  Bone lesions, leptomeningeal disease, ascites, pleural/pericardial 
effusions, lymphangitis cutis/pulmonitis, inflammatory breast disease, and abdominal masses 
(not followed by CT or MRI), are considered as non- measurable.  
 Note:  Cystic lesions that meet the criteria for radiog raphically defined simple cysts should not 
be considered as malignant lesions (neither measurable nor non-measurable) since they are, by definition, simple cysts.  
 ‘Cystic lesions’ thought to represent cystic metastases can be considered as measurable lesi ons, 
if they meet the definition of measurability described above. However, if non- cystic lesions are 
present in the same patient, these are preferred for selection as target lesions.  
 
Target lesions :  All measurable lesions up to a maximum of 2 lesions per organ and 5 lesions in 
total, representative of all involved organs, should be identified as target lesions  and recorded 
and measured at baseline.  Target lesions should be selected on the basis of their size (lesions with the longest diameter), be representative of all involved organs, but in addition should be those that lend themselves to reproducible repeated measurements.  It may be the case that, on occasion, the largest lesion does not lend itself to reproducible measurement in which circumstance t he next largest lesion which can be measured reproducibly should be selected.  A 
sum of the diameters (longest for non-nodal lesions, short axis for nodal lesions) for all target lesions will be calculated and reported as the baseline sum diameters.  If ly mph nodes are to be 
included in the sum, then only the short axis is added into the sum.  The baseline sum diameters will be used as reference to further characterize any objective tumor regression in the measurable dimension of the disease. 
 
Non-target le sions:  All other lesions (or sites of disease) including any measurable lesions over 
and above the 5 target lesions should be identified as non- target lesions and should also be 
recorded at baseline.  Measurements of these lesions are not required, but the presence, absence, or in rare cases unequivocal progression of each should be noted throughout follow-up.  
 
12.1.3 Methods for Evaluation of Measurable Disease 
All measurements should be taken and recorded in metric notation using a ruler or calipers.  All 
baseline evaluations should be performed as closely as possible to the beginning of treatment and never more than 4 weeks before the beginning of the treatment.  The same method of assessment and the same technique should be used to characterize each identifie d and reported lesion at baseline and during follow- up. Imaging-based evaluation is 
preferred to evaluation by clinical examination unless the lesion(s) being followed cannot be imaged but are assessable by clinical exam.  
 
Clinical lesions :  Clinical lesio ns will only be considered measurable when they are superficial 
(e.g., skin nodules and palpable lymph nodes) and ≥10 mm diameter as assessed using calipers 
(e.g., skin nodules).  In the case of skin lesions, documentation by color photography, including a 
Abbreviated Title:  Ph2Sunitinib Thymoma/Thymic Ca CTEP Protocol #: 9174  
Version Date:  04/30/2020  
 
 63 ruler to estimate the size of the lesion, is recommended.  
 
Chest x -ray:  Lesions on chest x- ray are acceptable as measurable lesions when they are clearly 
defined and surrounded by aerated lung.  However, CT is preferable.  
 
Conventional CT and MRI:  Thi s guideline has defined measurability of lesions on CT scan 
based on the assumption that CT slice thickness is 5 mm or less.  If CT scans have slice thickness greater than 5 mm, the minimum size for a measurable lesion should be twice the slice thickness.  MRI is also acceptable in certain situations ( e.g. for body scans).   
 Use of MRI remains a complex issue.  MRI has excellent contrast, spatial, and temporal resolution; however, there are many image acquisition variables involved in MRI, which greatly impact image quality, lesion conspicuity, and measurement.  Furthermore, the availability of MRI is variable globally.  As with CT, if an MRI is performed, the technical specifications of the 
scanning sequences used should be optimized for the evaluation of the type and site of disease.  
Furthermore, as with CT, the modality used at follow-up should be the same as was used at baseline and the lesions should be measured/assessed on the same pulse sequence.  It is beyond the scope of the RECIST guidelines to pr escribe specific MRI pulse sequence parameters for all 
scanners, body parts, and diseases.  Ideally, the same type of scanner should be used and the image acquisition protocol should be followed as closely as possible to prior scans.  Body scans should be performed with breath-hold scanning techniques, if possible.  
Ultrasound: Ultrasound is  not useful in assessment of lesion size and should not be used as a 
method of measurement.  Ultrasound examinations cannot be reproduced in their entirety for independent review at a later date and, because they are operator dependent, it cannot be guaranteed that the same technique and measurements will be taken from one assessment to the next.  If new lesions are identified by ultrasound in the course of the study, confirmation by CT or MRI is advised.  If there is concern about radiation exposure at CT, MRI may be used instead of CT in selected instances.  
 
Endoscopy, Laparoscopy:  The utilization of these techniques for objective tumor evaluation is 
not advised.  However, such techniques may be useful to confirm complete pathological response when biopsies are obtained or to determine relapse in trials where recurrence following complete response (CR) or surgical resection is an endpoint. 
 
Cytology, Histology:  These techniques can be used to differentiate between partial responses 
(PR) and complete responses (CR) in rare cases ( e.g., residual lesions in tumor types, such as 
germ cell tumors, where known residual benign tumors can remain). 
 The cytological confirmation of the neoplastic origin of any effusion that appears or worsens during treatment when the measurable tumor has met criteria for response or stable disease is mandato ry to differentiate between response or stable disease (an effusion may be a side effect of 
the treatment) and progressive disease.  
 
Abbreviated Title:  Ph2Sunitinib Thymoma/Thymic Ca CTEP Protocol #: 9174  
Version Date:  04/30/2020  
 
 64 12.1.4 Response Criteria  
12.1.4.1  Evaluation of Target Lesions 
 
Complete Response (CR): Disappearance of all target lesions.  Any pathologi cal 
lymph nodes (whether target or non-target) must have 
reduction in short axis to <10 mm. 
 
Partial Response (PR) :  At least a 30% decrease in the sum of the diameters of 
target lesions, taking as reference the baseline sum diameters.  
 
Progressive Disease (PD) : At least a 20% increase in the sum of the diameters of 
target lesions, taking as reference the smallest sum on study (this includes the baseline sum if that is the smallest on study).  In addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of at least 5 mm.  (Note:  the appearance of one or more new lesions is also considered progressions). 
 
Stable Disease (SD) :   Neither sufficient shrinkage to qualify for PR nor 
sufficient increase to qualify for PD, taking as reference the smallest sum diameters while on study.  
 
12.1.4.2  Evaluation of Non- Target Lesions  
Complete Response (CR): Disappearance of all non -target lesions and 
normalization of tumor marker level.  All lymph nodes must be non-pathologi cal in size (<10 mm short axis).  
 
Note:  If tumor markers are initially above the upper normal limit, they must normalize for a patient to be considered in complete clinical response.  
 
Non-CR/Non -PD:    Persistence of one or more non- target lesion(s) and/or 
maintenance of tumor marker level above the normal limits.  
 
Progressive Disease (PD) : Appearance of one or more new lesions and/or 
unequivocal progression of existing non-target lesions.  Unequivocal progression  should not normally trump 
target lesion status.  It must be representative of overall 
disease status change, not a single lesion increase.     
 
Although a clear progression of “non-target” lesions only is exceptional, the opinion of the treating physician should prevail in such circumstances, and the progression 
Abbreviated Title:  Ph2Sunitinib Thymoma/Thymic Ca CTEP Protocol #: 9174  
Version Date:  04/30/2020  
 
 65 status should be confirmed at a later time by the review panel (or Principal 
Investiga tor). 
 
12.1.4.3  Evaluation of Best Overall Response 
The best overall response is the best response recorded from the start of the treatment until disease progression/recurrence (taking as reference for progressive disease the smallest measurements recorded since th e treatment started).  The patient's best response assignment will 
depend on the achievement of both measurement and confirmation criteria. 
    For Patients with Measurable Disease ( i.e., Target Disease) 
 
Target 
Lesions  Non-
Target 
Lesions  New 
Lesions  Overall 
Response  Best Overall 
Response when 
Confirmation is 
Required*  
CR CR No CR >4 wks. 
Confirmation**  
CR Non-
CR/Non -
PD No PR 
>4 wks. 
Confirmation** CR Not 
evaluated  No PR 
PR Non-
CR/Non -
PD/not 
evaluated  No PR 
SD Non-
CR/Non -
PD/not 
evaluated  No SD Documented at least 
once >4 wks. from 
baseline**  
PD Any Yes or 
No PD 
no prior SD, PR or 
CR Any PD***  Yes or 
No PD 
Any Any Yes PD 
* See RECIST 1.1 manuscript for further details on what is 
evidence of a new lesion. 
** Only for non-randomized trials with response as primary 
endpoint. 
*** In exceptional circumstances, unequivocal progression in non-
target lesions may be accepted as disease progression.  
 
Note : Patients with a global deterioration of health status requiring 
discontinuation of treatment without objective evidence of 
disease progression at that time should be reported as 
Abbreviated Title:  Ph2Sunitinib Thymoma/Thymic Ca CTEP Protocol #: 9174  
Version Date:  04/30/2020  
 
 66 “symptomatic deterioration.”   Every effort should be made to 
document the objective progression even after discontinuation 
of treatment.  
 
For Patients with Non -Measurable Disease ( i.e., Non- Target Disease)  
 
Non-Target Lesions  New Lesions  Overall Response  
CR No CR 
Non-CR/non -PD No Non-CR/non -PD* 
Not all evaluated  No not evaluated  
Unequivocal PD  Yes or No  PD 
Any Yes PD 
* ‘Non -CR/non -PD’ is preferred over ‘stable disease’ for non -target disease 
since SD is increasingly used as an endpoint for assessment of efficacy in 
some trials so to assign this category when no lesions can be measured is not 
advised  
 
12.1.5 Duration of Response  
Duration of overall response:  The duration of overall response is measured from the time 
measurement criteria are met for CR or PR (whichever is first recorded) until the first date that 
recurrent or progressive disease is objectively documented (taking as reference for progressive disease the smallest measurements recorded since the treatment started).  
 The duration of overall CR is measured from the time measurement criteria are first me t for CR 
until the first date that progressive disease is objectively documented.   
 
Duration of stable disease :  Stable disease is measured from the start of the treatment until the 
criteria for progression are met, taking as reference the smallest measurements recorded since the treatment started, including the baseline measurements.  
 
12.1.6 Progression-Free Survival  
PFS is defined as the duration of time from start of treatment to time of progression or death, 
whichever occurs first.  
 
13 DATA REPORTING / REGULATORY REQUIREMENTS  
Adverse event lists, guidelines, and instructions for AE reporting can be found in Section 7 (Adverse Events: List and Reporting Requirements).  
13.1 D
ATA REPORTING  
13.1.1 Method 
This study will be monitored by the Clinical Data Update System (CDUS) Version 3.0.  
Cumulative protocol- and patient -specific CDUS data will be submitted  electronically  to CTEP  
on a quarterly  basis , either by FTP burst of data or via the CDS web application.  Reports are due 
Abbreviated Title:  Ph2Sunitinib Thymoma/Thymic Ca CTEP Protocol #: 9174  
Version Date:  04/30/2020  
 
 67 January 31, April 30, July 31, and October 31.  Instructions for submitting data using the CDUS 
can be found on the CTEP Web  site: (http://ctep.cancer.gov/reporting/cdus.html ).  
 
13.1.2 Responsibility for Data Submission 
Participating sites will enter data into C3D. The coordinating center is responsible for quarterly CDUS submissions for all sites.  
 
14 CTEP MULTICENTER  GUIDELINES  
This protocol will adhere to the policies and requirements of the CTEP Multicenter Guidelines.  The specific responsibilities of the Principal Investigator and the Coordinating Center (Study Coordinator) and the procedures for auditing are presented in Appendix E . 
 
• The Principal Investigator/Coordinating Center is responsible for distributing all IND Action Letters or Safety Reports received from CTEP to all participating institutions for submission to their individual IRBs for action as required. 
 
• Except in very unusual circumstances, each participating institution will order DCTD-supplied agents directly from CTEP.  Agents may be ordered by a participating site only after the initial IRB approval for the site has been forwarded by the Coordinating Center to the CTEP PIO ( PIO@ctep.nci.nih.gov
) 
except for Group studies. 
 
15 CCR MULTI -INSTITUTIONAL GUIDELINES  
15.1 IRB  APPROVALS  
The PI will provide the NIH Intramural IRB  with a copy of the participating institution’s 
approved yearly continuing r eview.  Registration will be halted at any participating institution in 
which a current continuing approval is not on file at the NIH Intramural IRB . 
 15.2 A
MENDMENTS AND CONSENTS  
The CCR PI will provide the NIH Intramural IRB  with copies of all amendments, consents and 
approvals from each participating institution. 
 
16 COLLABORATIVE  AGREEMENTS   
The agent(s) supplied by CTEP, DCTD, NCI used in this protocol is/are provided to the NCI 
under a Collaborative Agreement (CRADA, CTA, CSA) between the Pharmaceutical Company(ies) (hereinafter referred to as “Collaborator(s)”) and the NCI Division of Cancer 
Treatment and Diagnosis.  Therefore, the following obligations/guidelines, in addition to the provisions in the “Intellectual Property Option to Collaborator ” 
(http://ctep.cancer.gov/industryCollaborations2/intellectual_property.htm
) contained within the 
terms of award, apply to the use of the Agent(s) in this study: 
 
Abbreviated Title:  Ph2Sunitinib Thymoma/Thymic Ca CTEP Protocol #: 9174  
Version Date:  04/30/2020  
 
 68 1.   Agent(s) may not be used for any purpose outside the scope of this protocol, nor 
can Agent(s) be transferred or licensed to any party not participating in the 
clinical study.  Collaborator(s) data for Agent(s) are confidential and proprietary to Collaborator(s) and shall be maintained as such by the investigators.  The protocol documents for studies utilizing Agents contain confidential information and should not be shared or distributed without the permission of the NCI.  If a copy of this protocol is requested by a patient or patient’s family member participating on the study, the individual should sign a confidentiality agreement.  A suitable model agreement can be downloaded from: http://ctep.cancer.gov
. 
 
2.   For a clinical protocol where there is an investigational Agent used in 
combination with (an)other Agent(s), each the subject of different Collaborative Agreements, the access to and use of data by each Collaborator shall be as follows (data pertaining to such combination use shall hereinafter be referred to as "Multi-
Party Data” ): 
 
a.  NCI will provide all Collaborators with prior written notice regarding the 
existence and nature of any agreements governing their collaboration with NCI, the design of the proposed combination protocol, and the existence of 
any obligations that would tend to restrict NCI's participation in the proposed combination protocol. 
 
b.  Each Collaborator shall agree to permit use of the Multi- Party Data from the 
clinical trial by any other Collaborator solely to the extent necessary to allow said other Collaborator to develop, obtain regulatory approval or commercialize its own Agent.  
 
c.  Any Collaborator having the right to use the Multi- Party Data from these trials 
must agree in writing prior to the commencement of the trials that it will use the Multi-Party Data solely for development, regulatory approval, and commercialization of its own Agent.  
 
3.   Clinical Trial Data and Results and Raw Data developed under a Collaborative 
Agreement will be made available to Collaborator(s), the NCI, and the FDA, as appropriate and unless additional disclosure is required by law or court order as described in  the IP Option to Collaborator 
(http://ctep.cancer.gov/industryCollaborations2/intellectual_property.htm
).  
Additionally, all Clinical Data and Results and Raw Data will be collected , used 
and disclosed consistent with all applicable federal statutes and regulations for the protection of human subjects, including, if applicable, the Standards for Privacy of Individually Identifiable Health Information set forth in 45 C.F.R. Part 164. 
 4.   When a Collaborator wishes to initiate a data request, the request should first be 
sent to the NCI, who will then notify the appropriate investigators (Group Chair for Cooperative Group studies, or PI for other studies) of Collaborator's wish to 
Abbreviated Title:  Ph2Sunitinib Thymoma/Thymic Ca CTEP Protocol #: 9174  
Version Date:  04/30/2020  
 
 69 contact them.  
 
5.   Any data provided to Collaborator(s) for Phase 3 studies must be in accordance 
with the guidelines and policies of the responsible Data Monitoring Committee 
(DMC), if there is a DMC for this clinical trial.  
 
6.   Any manuscripts reporting the results of this clinical trial must be provided to 
CTEP by the Group office for Cooperative Group studies or by the principal investigator for non-Cooperative Group studies for immediate delivery to Collaborator(s) for advisory review and comment prior to submission for publication.  Collaborator(s) will have 30 days from the date of receipt for review.  Collaborator shall have the right to request that publication be delayed for up to an additional 30 days in order to ensure that Collaborator’s confidential and proprietary data, in addition to Collaborator(s)’s intellectual p roperty rights, are 
protected.  Copies of abstracts must be provided to CTEP for forwarding to Collaborator(s) for courtesy review as soon as possible and preferably at least three (3) days prior to submission, but in any case, prior to presentation at the meeting or publication in the proceedings.  Press releases and other media presentations must also be forwarded to CTEP prior to release.  Copies of any manuscript, abstract and/or press release/ media presentation should be sent to: 
 
Email:  ncicteppubs@mail.nih.gov
  
 
The Regulatory Affairs Branch will then distribute them to Collaborator(s).  No publication, manuscript or other form of public disclosure shall contain any of Collaborator’ s confidential/ proprietary information.  
 
17 STATISTICAL CONSIDERATIONS  
17.1  S
TUDY DESIGN /ENDPOINTS  
 
The primary endpoint of the study is objective response rate (CR+PR) according to RECIST 1.1 criteria for sunitinib monotherapy in patients with advanced thymic malignancies.  The cohorts will separately be evaluated  in this regard as the primary endpoint for each. All sample size 
estimates are based on the objective response rate.   Group 1 Based on available results of systemic treatments of thymic carcinoma in the literature it is concluded that an objective response rate consistent with 25% and greater than 5% could be 
considered better, or at least similar, to what has been shown for chemotherapy in this setting. For thymomas, a target of 30% is being proposed. For each cohort, this study will use a Simon 2-stage design, optimal for thymic carcinomas and MinMax for thymomas, and set the probability for accepting a poor drug to 10% (alpha=0.10) and the probability of rejecting a good drug at 10% (beta=0.10).  
 
Abbreviated Title:  Ph2Sunitinib Thymoma/Thymic Ca CTEP Protocol #: 9174  
Version Date:  04/30/2020  
 
 70 For thymic carcinomas, the study will try to rule out a 5% objective response rate (p0=0.05) and 
target a modest response rate of 25% (p1=0.25). The study will initially enroll 9 evaluable 
patients with thymic carcinoma; if 0 of the 9 patients demonstrate a partial response then no further patients will be accrued. If 1 or more of the first 9 patients have a response, then accrual would continue until a total of 24 evaluable patients have been treated. A temporary pause in the accrual to the trial may be necessary to ensure that enrollment to the second stage is warranted. If there are 1 to 2 patients with a response in the total of 24 evaluable patients, then this would be an uninterestingly low rate, while if there were 3or more patients of the 24 who have a response, this would be sufficiently interesting to warrant further study of this agent in later trials. Under the null hypothesis (5% response rate), the probability of early termination in this cohort is 63%.  For thymomas, the study will try to rule out a 10% objective response rate (p0=0.10) and target a modest response rate of 30% (p1=0.30).  The study will initially enroll 16 evaluable patients with thymoma; if 0 to 1 of the 16 patients demonstrate a partial response then no further patients will be accrued. If 2 or more of the first 16 patients have a response, then accrual would continue 
until a total of 25 evaluable patients have been treated. A temporary pause in the accrual to the 
trial may be necessary to ensure that enrollment to the second stage is warranted. If there are 2 to 4 patients with a response in the total of 25 evaluable patients, then this would be an uninterestingly low rate, while if there were 5 or more patients of the 25 who have a response, this would be sufficiently interesting to warrant further study of this agent in la ter trials. Under 
the null hypothesis (10% response rate), the probability of early termination in this cohort is 51%.   Group 2 To gain further information about the use of this agent in this specific disease, we would like to treat 15 additional subjects with thymic carcinoma.  Effective with Amendment E (version date 05/12/14), up to 15 patients will be enrolled as a small, pilot cohort to obtain preliminary data on efficacy as well as on a small number of exploratory parameters. The prior overall response rate using the original dose and schedule was approximately 26%. This portion of the study would aim to demonstrate if the response rate were similar to that rate in a limited number of patients treated using a modified dosing schedule (50 mg per day for 2 weeks with 1 week off) in order to determine if further, more definitive study would be warranted. With 15 patients, the two- tailed 
90% confidence interval about 26% extends approximately +/- 18.6% and the two-tailed 80% confidence interval about 26% extends approximately +/- 14.5%. Thus, the response rate obtained would be able to only approximately estimate the true response rate, but would be sufficient to be used as a basis for determining if a more definitive study is warranted, and to estimate par ameters to consider for the subsequent study.  Similarly, with 15 patients, only an 
approximate estimate of the PFS probabilities can be obtained, but these results could be informally compared to those resulting from the original dose and schedule. A cohort of 15 subject s would also provide adequate patients for exploratory analyses of a variety of 
pharmacodynamic studies and to study the effect of sunitinib therapy on regulatory T cells (Tregs), exhausted CD8 T cells, myeloid-derived suppressor cells (MDSCs), and Th1/Th2 T cell populations, as well as the exploratory studies of circulating tumor cells, endothelial progenitors, and mature apoptotic endothelial cells  applicable to both groups. 
 
Abbreviated Title:  Ph2Sunitinib Thymoma/Thymic Ca CTEP Protocol #: 9174  
Version Date:  04/30/2020  
 
 71 17.2  SAMPLE SIZE/ACCRUAL RATE 
12-C-0118 used a Simon 2- stage design with an accrual ceiling of 52 (Group 1) based on the 
assumption that the individual cohorts for thymoma and thymic carcinoma would proceed to the 
second stage with accrual ceilings of 25 and 24 evaluable patients respectively (plus an additional 3 patients to allow for a small number of inevaluable patients.) However, the results from the study demonstrated only 1 PR in the thymoma cohort among the first 16 evaluable patients, and hence accrual was halted at 16 patients as previously specified and di d not proceed 
to the accrual ceiling of 25 patients for this cohort (2 or more responses needed to be observed to proceed to 25 patients.) However, in the thymic carcinoma cohort more than 1 PR was observed in the first 9 evaluable patients. Hence, accrual  proceeded to the second stage with an accrual 
ceiling of 24 patients in this cohort. The total accrual in study 12-C-0118 was therefore 16+25 =41 patients. Therefore, a total of 11 slots remained unfilled in the original study due to the inability of the thymoma cohort to proceed to the second- stage of accrual.  
 
In Amendment E, (version date 05/12/14), we provide a justification to evaluate sunitinib in 
patients with thymic carc inoma while discontinuing evaluation of this drug in patients with 
thymoma. Further, we would like to evaluate sunitinib in thymic carcinoma using a modified 
dosing schedule in an additional 15 patients (Group 2). Hence, we would like to utilize the 9 unfilled thymoma slots from the original study, add 6 new slots (to obtain 15 slot s for the new 
thymic carcinoma  cohort, Group 2) and retain 2 slots for inevaluable patients for an accrual 
ceiling of 52+6=58 patients.  It is anticipated that approximately 3 patients per month overall may enroll on this trial. Group 1 accrual was completed in less than  two years.  Thus, Group 2 accrual should be completed with  
approximately one additional year, thereby completing overall trial accrual in  a total of  three 
years. Progression free and overall survival will also be determined for each group s eparately, 
using Kaplan-Meier curves, and reported as a secondary endpoint.   
17.3  S
TRATIFICATION FACTORS  
 
  N/A   
 
17.4  ANALYSIS OF SECONDARY ENDPOINTS  
We will follow all patients from the  time that they are enrolled in the trial until the time of death. 
Demographic information such as age, gender and race will be tabulated. Durations of response, 
progression free survival, and overall survival will be determined actuarially using the Kaplan -
Meier method. The results of this analysis may be compared in an informal manner to any similarly defined curves available from other published studies in comparable patients with the same disease. Correlative studies are exploratory, hence statistical power calculations will not be provided. Expression levels of various proteins from pre - and post- treatment samples will be 
compared using an appropriate nonparametric test and pre -post differences between responders 
and non-responders using a Wilcoxon rank sum test. These latter evaluations will be considered exploratory and the resulting p- values will be  presented as being exploratory and without 
Abbreviated Title:  Ph2Sunitinib Thymoma/Thymic Ca CTEP Protocol #: 9174  
Version Date:  04/30/2020  
 
 72 adjustment for multiple comparisons.  
 
17.5 REPORTING AND EXCLUSIONS  
17.5.1 Evaluation of toxicity  
All patients will be evaluable for toxicity from the time of their first treatment with sunitinib . 
 
17.5.2 Evaluation of response  
All patients included in the study must be assessed for response to treatment, even if there are 
major protocol treatment deviations or if they are ineligible.  Each patient will be assigned one of the following categories:  1) complete response, 2) partial response, 3) stable disease, 4) progressive disease, 5) early death from malignant disease, 6) early death from toxicity, 7) early death because of other cause, or 9) unknown (not assessable, insufficient data).  [Note:  By arbitrary convention, category 9 usually designates the “unknown” status of any type of data in a clinical database.]  
 All of the patients who met the eligibility criteria (with the possible exception of those who received no study medication) should be included in the main analysis of the response rate.  Patients in response categories 4 -9 should be considered to have a treatment failure (disease 
progression).  Thus, an incorrect treatment schedule or drug administration does not result in exclusion from the analysis of the response rate.  Precise definitions for categories 4 -9 will be 
protocol specific.   All conclusions should be based on all eligible patients.  Subanalyses may then be performed on the basis of a subset of patients, excluding those for whom major protocol deviations have been identified ( e.g., early death due to other reasons, early discontinuation of treatment, major 
protocol deviations, etc.).  However, these subanalyses may not serve as the basis for drawing conclusions concerning treatment efficacy, and the reasons for excluding patients from the analysis should be clearly reported.  The 95% confidence intervals should also be provided.  
 
18 HUMAN SUBJECTS PROTECTIONS  
18.1 
 RATIONALE FOR SUBJECT SELECTION  
This study will be open to all individual with relapsed or refractory thymoma (Group 1 only) or 
thymic carcinoma  regardless of gender, ethnicity, or race provided that the aforementioned 
inclusion and exclusion criteria are met. To date, there is no inform ation that suggests that 
differences in drug metabolism or disease response would be expected in one sex, racial or ethnic group compared to another. Efforts will be made to extend accrual to each representative population, but in this preliminary study, a balance must be struck between patient safety considerations and limitations on the number of individuals exposed to potentially toxic and/or ineffective treatments on the one hand and the need to explore racial/ethnic aspects of clinical research on the other hand. If differences in outcome that correlate to ethnic identity are noted, accrual may be expanded or a follow -up study may be written to investigate those differences 
more fully.  
Abbreviated Title:  Ph2Sunitinib Thymoma/Thymic Ca CTEP Protocol #: 9174  
Version Date:  04/30/2020  
 
 73 This study will be recruited through internal referral, our local physician referral base, and  
through various cancer information hotlines (i.e., Clinical Studies Support Center, 1-800-
4Cancer).  
 For safety reasons, only pregnant women and children are excluded from this study. Pregnant women are excluded from this study because sunitinib angiogenesis inhibitor with the potential for teratogenic or abortifacient effects . Patients with HIV and  immunosuppression [CD4 count < 
institutional LLN (334 cells/uL)]  are excluded from the study due to potential for sunitinib 
induced myelosuppression which could place these patients at increased risk of lethal infections. Sunitinib metabolism is predominantly mediated by CYP3A4 and concurrent treatment with CYP3A4 inducers and inhibitors may affect sunitinib metabolism. Hence patients with HIV who are being treated with drugs which are inhibitors or inducers of CYP3A4 are also excluded from the study.   
Patients with evidence of severe or uncontrolled systemic disease, including active or  
uncontrolled infection, immune deficiencies, Hepatitis B, Hepatitis C, uncontrolled diabetes, 
uncontrolled hypertension, symptomatic congestive heart failure, unstable angina pectoris, myocardial infarction within the past 6 months, uncontrolled cardiac arrhythmia, stroke/cerebrovascular accident wit hin the past 6 months, or psychiatric illness/social situations 
that would limit compliance with study requirements)  are excluded due to the possibility that 
sunitinib may  worsen their condition and the likelihood that the underlying condition may 
obscure the attribution  of adverse events with respect to sunitinib. Patients with symptomatic 
brain metastases will be excluded from trial secondary to poor prognosis.    
18.2 
 PARTICIPATION OF CHILDREN  
Patients under the age of 18 will be excluded from study due to the low occurrence of these 
oncologic histologies in the pediatric population. In addition, the risk of exposure to an investigational agent without proven benefit in the targeted histologies supports excluding children until additional safety and efficacy data is available.  
 
18.3 P
ARTICIPATION OF SUBJECTS UNABLE TO GIVE CONSENT  
Adults unable to give consent are excluded from enrolling in the protocol.  However re-consent 
may be necessary and there is a possibility, though unlikely, that subjects could become decisionally impaired. For this reason and because there is a prospect of direct benefit from research participation (section 18.5), all subjects ≥ age 18 will be offered the opportunity to fill in their wishes for research and care, and assign a substitute decision maker on the “NIH Advance Directive for Health Care and Medical Research Participation” form so that another person can make decisions about their medical care in the event that they become incapacitated or cognitively impaired during the course of the study. Note: The PI or AI will contact the NIH Ability to Consent Assessment Team for evaluation as needed for the following: an independent assessment of whether an individual has the capacity to provide consent; assistance in identifying and assessing an appropriate surrogate when indicated; and/or an assessment of the capacity to appoint a surrogate.  For those subjects that become incapacitated and do not have a pre-determined substitute decision maker, the procedures described in NIH HRPP SOP 14E for 
Abbreviated Title:  Ph2Sunitinib Thymoma/Thymic Ca CTEP Protocol #: 9174  
Version Date:  04/30/2020  
 
 74 appointing a surrogate decision maker for adult subjects who are (a) decisionally impaired, and 
(b) who do not have a legal guardian or durable power of attorney, will be followed.  
18.4 E
VALUATION OF BENEFITS AND RISKS/DISCOMFORTS  
Patients should realize that we are hopeful that they may gain benefit from this study, but there is 
no objective evidence to support our optimism at this time. The potential benefit to a patient who enters study is a reduction in the bulk of his/her tumor, which may or may not have a favorable impact on symptoms and/or survival. Potential risks include the possible occurrence of any of a range of side effects t hat are listed in the pharmaceutical section and the consent document. The 
procedure for protecting against or minimizing risks will be to medically evaluate patients on a regular basis as described earlier.  
 
18.5 
 RISKS/BENEFITS ANALYSIS  
Sunitinib has been extensively studied and approved for use in several other malignancies. 
Previous studies and in clinical experience have demonstrated that sunitinib has an acceptable 
toxicity profile. For adults and adults unable to consent, there is more than minimal risk associated with the treatment offered in this study with the prospect for direct benefit.  The potential benefit of disease stabilization, tumor  shrinkage or reduction of symptoms provided by 
sunitinib justifies the risk in this high risk  patient population of advanced thymic malignancies. 
 
18.6 
 CONSENT AND ASSENT PROCESS AND DOCUMENTATION  
An associate or principal investigator on the trial will inform patients of the purpose, alternatives,  
treatment plan, research objectives and follow -up of this trial. The patient will be provided an 
IRB-approved consent for review and signature and his/her questions will be answered. After a 
decision is made to enroll into the study, a signature will be obtained from the patient at a 
subsequent visit. The original of the signed informed consent will be placed in the patient's medical record.  All patients must have a signed informed consent form and an on-study 
(confirmation of eligibility) form filled out and signed by a participating investigator before entering on study.  Telephone Consent : 
When re -consent is required due to an amendment, the patient can be consented via telephone if 
needed for logistical reasons. Telephone consent will be obtained and documented per OHSRP/IRBO and CCR policies and procedures.  
Abbreviated Title:  Ph2Sunitinib Thymoma/Thymic Ca CTEP Protocol #: 9174  
Version Date:  04/30/2020  
 
 75 19 REFERENCES  
1. Engels EA, Pfeiffer RM. Malignant thymoma in the United States: demographic patterns 
in incidence and associations with subsequent malignancies. Int J Cancer. 
2003;105(4):546-551. 
2. Giaccone G, Wilmink H, Paul MA, van der Valk P. Systemic treatment of m alignant 
thymoma - A decade experience at a single institution. Am J Clin Oncol-Canc. 2006;29(4):336-344. 
3. Falkson CB, Bezjak A, Darling G, et al. The management of thymoma: a systematic 
review and practice guideline. J Thorac Oncol. 2009;4(7):911-919. 
4. Rosai J SL. Histological typing of tumours of the thymus. 2nd edition ed. New York: 
Springer; 1999. 
5. Okumura M, Ohta M, Tateyama H, et al. The World Health Organization histologic 
classification system reflects the oncologic behavior of thymoma: a clin ical study of 273 
patients. Cancer. 2002;94(3):624-632. 
6. Okumura M, Miyoshi S, Fujii Y, et al. Clinical and functional significance of WHO 
classification on human thymic epithelial neoplasms: a study of 146 consecutive tumors. Am J Surg Pathol. 2001;25(1):103-110. 
7. Detterbeck FC. Clinical value of the WHO classification system of thymoma. Ann Thorac Surg. 2006;81(6):2328-2334. 
8. Greene MA, Malias MA. Aggressive multimodality treatment of invasive thymic carcinoma. J Thorac Cardiovasc Surg. 2003;125(2):434-436. 
9. Ogawa K, Toita T, Uno T, et al. Treatment and prognosis of thymic carcinoma: a 
retrospective analysis of 40 cases. Cancer. 2002;94(12):3115-3119. 
10. Eng TY, Fuller CD, Jagirdar J, Bains Y, Thomas CR, Jr. Thymic carcinoma: state of the 
art revi ew. Int J Radiat Oncol Biol Phys. 2004;59(3):654-664. 
11. Masaoka A, Monden Y, Nakahara K, Tanioka T. Follow-up-Study of Thymomas with 
Special Reference to Their Clinical Stages. Cancer. 1981;48(11):2485-2492. 
12. Maggi G, Casadio C, Cavallo A, Cianci R, M olinatti M, Ruffini E. Thymoma - Results of 
241 Operated Cases. Annals of Thoracic Surgery. 1991;51(1):152-156. 
13. Gawrychowski J, Rokicki M, Gabriel A, Lackowska B, Czyzewski D. Thymoma - the 
usefulness of some prognostic factors for diagnosis and surgic al treatment. Eur J Surg 
Oncol. 2000;26(3):203-208. 
14. Lewis JE, Wick MR, Scheithauer BW, Bernatz PE, Taylor WF. Thymoma. A 
clinicopathologic review. Cancer. 1987;60(11):2727-2743. 
15. Fornasiero A, Daniele O, Ghiotto C, et al. Chemotherapy for invasive thymoma. A 13-
year experience. Cancer. 1991;68(1):30-33. 
16. Loehrer PJ, Sr., Kim K, Aisner SC, et al. Cisplatin plus doxorubicin plus 
cyclophosphamide in metastatic or recurrent thymoma: final results of an intergroup trial. The Eastern Cooperative Oncology Group, Southwest Oncology Group, and Southeastern Cancer Study Group. J Clin Oncol. 1994;12(6):1164-1168. 
17. Giaccone G, Ardizzoni A, Kirkpatrick A, Clerico M, Sahmoud T, van Zandwijk N. 
Cisplatin and etoposide combination chemotherapy for locally advanced or metastatic thymoma. A phase II study of the European Organization for Research and Treatment of Cancer Lu ng Cancer Cooperative Group. J Clin Oncol. 1996;14(3):814-820. 
18. Berruti A, Borasio P, Gerbino A, et al. Primary chemotherapy with adriamycin, cisplatin, 
Abbreviated Title:  Ph2Sunitinib Thymoma/Thymic Ca CTEP Protocol #: 9174  
Version Date:  04/30/2020  
 
 76 vincristine and cyclophosphamide in locally advanced thymomas: a single institution 
experience. Br J  Cancer. 1999;81(5):841-845. 
19. Loehrer PJ, Sr., Jiroutek M, Aisner S, et al. Combined etoposide, ifosfamide, and 
cisplatin in the treatment of patients with advanced thymoma and thymic carcinoma: an intergroup trial. Cancer. 2001;91(11):2010-2015. 
20. Loehrer PJ YC, Dropcho S et al. A phase II trial of pemetrexed in patients with recurrent 
thymoma or thymic carcinoma J Clin Oncol 24(18S): abstract 7079. 
21. Lemma GL, Lee JW, Aisner SC, et al. Phase II study of carboplatin and paclitaxel in 
advanced thymom a and thymic carcinoma. J Clin Oncol. 2011;29(15):2060-2065. 
22. Loehrer PJ, Sr., Wang W, Johnson DH, Aisner SC, Ettinger DS, Eastern Cooperative 
Oncology Group Phase IIT. Octreotide alone or with prednisone in patients with advanced thymoma and thymic carcinoma: an Eastern Cooperative Oncology Group Phase II Trial. J Clin Oncol. 2004;22(2):293-299. 
23. Giaccone G, Rajan A, Ruijter R, Smit E, van Groeningen C, Hogendoorn PC. Imatinib 
mesylate in patients with WHO B3 thymomas and thymic carcinomas. J Thorac Oncol. 
2009;4(10):1270-1273. 
24. Giaccone G, Rajan A, Berman A, et al. Phase II study of belinostat in patients with 
recurrent or refractory advanced thymic epithelial tumors. J Clin Oncol. 2011;29(15):2052-2059. 
25. Kurup A BM, Dropcho S et al. Phase II study of gefitinib treatment in advanced thymic 
malignancies. J Clin Oncol 2005; 23(Pt 1): (Abstr 7068). 
26. Gordon MS, Battiato LA, Gonin R, Harrison-Mann BC, Loehrer PJ, Sr. A phase II trial 
of subcutaneously administered recombinant human interleukin- 2 in patients with 
relapsed/refractory thymoma. J Immunother Emphasis Tumor Immunol. 1995;18(3):179-184. 
27. Palmieri G, Merola G, Federico P, et al. Preliminary results of phase II study of 
capecitabine and gemcitabine (CAP -GEM) in patients with metastatic pretreated thymic 
epithelial tumors (TETs). Ann Oncol. 2010;21(6):1168-1172. 
28. Bedano PM, Perkins S, Burns M, et al. A phase II trial of erlotinib plus bevacizumab in 
patients with recurrent thymoma or thymic carcinoma. J Clin Oncol (Meeting Abstracts). 2008;26(15_suppl):19087-. 
29. Kawashima Y, Inoue A, Sugawara S, et al. Phase II study of amrubicin (AMR) and 
carboplatin (CBDCA) for invasive thymoma (IT) and thymic carcinoma (TC): NJLCG0803. ASCO Meeting Abstracts. 2013;31(15_suppl):7530. 
30. Mendel DB, Laird AD, Xin XH, et al. In vivo antitumor activity of SU11248, a novel 
tyrosine kinase inhibitor targeting vascular endothelial growth factor and platelet-derived growth factor receptors: Determination of a pharmacokinetic/pharmacodynamic relationship. Clin Cancer Res. 2003;9(1):327-337. 
31. Gan HK, Seruga B, Knox JJ. Sunitinib in solid tumors. Expert Opin Inv Drug. 
2009;18(6):821-834. 
32. Mena AC, Pulido EG, Guillen-Ponce C. Understanding the molecular- based mechanism 
of action of the tyrosine kinase inhibitor: sunitinib. Anticancer Drugs. 2010;21 Suppl 1:S3-11. 
33. Motzer RJ, Michaelson MD, Redman BG, et al. Activity of SU11248, a multitargeted 
inhibitor of vascular endothelial growth factor receptor and platelet-derived growth factor 
Abbreviated Title:  Ph2Sunitinib Thymoma/Thymic Ca CTEP Protocol #: 9174  
Version Date:  04/30/2020  
 
 77 receptor, in patients with metastatic renal cell carcinoma. J Clin Oncol. 2006;24(1):16-
24. 
34. Demetri GD, van Oosterom AT, Garr ett CR, et al. Efficacy and safety of sunitinib in 
patients with advanced gastrointestinal stromal tumour after failure of imatinib: a randomised controlled trial. Lancet. 2006;368(9544):1329-1338. 
35. Izzedine H, Buhaescu I, Rixe O, Deray G. Sunitinib mal ate. Cancer Chemother 
Pharmacol. 2007;60(3):357-364. 
36. Goodman VL, Rock EP, Dagher R, et al. Approval summary: sunitinib for the treatment 
of imatinib refractory or intolerant gastrointestinal stromal tumors and advanced renal cell carcinoma. Clin Cancer Res. 2007;13(5):1367-1373. 
37. Rock EP, Goodman V, Jiang JX, et al. Food and Drug Administration drug approval 
summary: Sunitinib malate for the treatment of gastrointestinal stromal tumor and advanced renal cell carcinoma. Oncologist. 2007;12(1):107-113. 
38. Chow LQM, Eckhardt SG. Sunitinib: From rational design to clinical efficacy. Journal of 
Clinical Oncology. 2007;25(7):884-896. 
39. Abrams TJ, Lee LB, Murray LJ, Pryer NK, Cherrington JM. SU11248 inhibits KIT and 
platelet -derived growth factor receptor beta in preclinical models of human small cell 
lung cancer. Molecular Cancer Therapeutics. 2003;2(5):471-478. 
40. Abrams TJ, Murray LJ, Pesenti E, et al. Preclinical evaluation of the tyrosine kinase 
inhibitor SU11248 as a single agent and in combination with IFIF standard of care"' therapeutic agents for the treatment of breast cancer. Molecular Cancer Therapeutics. 2003;2(10):1011-1021. 
41. Rosen L, Mulay M, Long J, et al. Phase I trial of SU011248, a novel tyrosine kinase 
inhibitor in advanced solid tumors. Journal of Clinical Oncology. 2003;21(23):284s-284s. 
42. Faivre S, Delbaldo C, Vera K, et al. Safety, pharmacokinetic, and antitumor activity of 
SU11248, a novel oral multitarget tyrosine kinase inhibitor, in patients with cancer. J Clin Oncol. 2006;24(1):25-35. 
43. Fiedler W, Serve H, Dohner H, et al. A phase 1 study of SU11248 in the treatment of 
patients with refractory or resistant acute myeloid leukemia (AML) or not amenable to conventional therapy for the disease. Blood. 2005;105(3):986-993. 
44. O'Farrell AM, Abrams TJ, Yuen HA, et al. SU11248 is a novel FLT3 tyrosine kinase 
inhibitor with potent activity in vitro and in vivo. Blood. 2003;101(9):3597-3605. 
45. Sweeney CJ, Chiorean EG, Verschraegen CF, et al. A Phase I Study of Sunitinib Plus 
Capecitabine in Patients With Advanced Solid Tumors. Journal of Clinical Oncology. 2010;28(29):4513-4520. 
46. Chow L, Yonker DL, Laurie SA et al. Sunitinib (SU) in combination with pemetrexed (P) 
in patients (pts) with advanced solid malignancies: a phase I dose escalation study. J Clin Oncol 26: 2008 (May 20 suppl; abstr 3566)  
47. Traynor AM SA, Schiller JH et al Phase I dose- escalation and pharmacokinetic (PK) 
study of sunitinib (SU) plus docetaxel (D) in patients (pts) with advanced solid tumors (STs). J Cli n Oncol 26: 2008 (May 20 suppl; abstr 3564)  
48. Brell JM BJ, Cooney MM et al. Phase I study of sunitinib malate continuously dosed and 
standard -infusion gemcitabine in solid tumors. J Clin Oncol 26: 2008 (May 20 suppl; 
abstr 13533)  
Abbreviated Title:  Ph2Sunitinib Thymoma/Thymic Ca CTEP Protocol #: 9174  
Version Date:  04/30/2020  
 
 78 49. Heath EI BG, Cohen JR et al. Phase I study of sunitinib in combination with carboplatin 
(C) plus paclitaxel (P) in patients (pts) with advanced solid tumors (STs). J Clin Oncol 
26: 2008 (May 20 suppl; abstr 3565)  
50. Rugo HS LJ, Melisko M et al. Phase I study of sunitinib (SU) in combination with 
metronomic dosing of cyclophosphamide and methotrexate (CM) in patients with metastatic breast cancer (MBC). J Clin Oncol 28:15s, 2010 (suppl; abstr 1067)  
51. Patel PH, Senico PL, Curiel RE, Motzer RJ. Phase I Study Combining Trea tment with 
Temsirolimus and Sunitinib Malate in Patients with Advanced Renal Cell Carcinoma. Clin Genitourin Canc. 2009;7(1):24-27. 
52. Feldman DR, Baum MS, Ginsberg MS, et al. Phase I Trial of Bevacizumab Plus Escalated Doses of Sunitinib in Patients With  Metastatic Renal Cell Carcinoma. Journal 
of Clinical Oncology. 2009;27(9):1432-1439. 
53. Motzer RJ, Hudes G, Wilding G, et al. Phase I Trial of Sunitinib Malate plus Interferon-
alpha for Patients with Metastatic Renal Cell Carcinoma. Clin Genitourin Canc. 
2009;7(1):28-33. 
54. Rini BI, Garcia JA, Cooney MM, et al. A phase I study of sunitinib plus bevacizumab in 
advanced solid tumors. Clin Cancer Res. 2009;15(19):6277-6283. 
55. Motzer RJ, Hutson TE, Tomczak P, et al. Overall Survival and Updated Results for 
Sunitinib Compared With Interferon Alfa in Patients With Metastatic Renal Cell 
Carcinoma. Journal of Clinical Oncology. 2009;27(22):3584-3590. 
56. Motzer RJ, Hudes GR, Ginsber g MS, et al. Phase I/II Trial of Sunitinib Plus Gefitinib in 
Patients With Metastatic Renal Cell Carcinoma. Am J Clin Oncol-Canc. 2010;33(6):614-618. 
57. Demetri GD DJ, Fletcher JA et al. SU11248, a multi-targeted tyrosine kinase inhibitor, can overcome imatinib (IM) resistance caused by diverse genomic mechanisms in patients (pts) with metastatic gastrointestinal stromal tumor (GIST). Journal of Clinical Oncology, 2004 ASCO Annual Meeting Proceedings (Post-Meeting Edition) Vol 22, No 14S (July 15 Supplement), 2004: 3001  
58. Dileo P VDAA, Manola J et al. Qualitative assessment of 18FDG -PET correlates with 
clinical benefit in patients (pts) with imatinib mes ylate (IM) -resistant GIST treated with 
the multi-targeted tyrosine kinase inhibitor SU11248. Proc Am Soc Clin Oncol Gastrointestinal Cancers Symposium A8. 2005. 
59. Demetri GD, van Oosterom AT, Garrett CR, et al. Efficacy and safety of sunitinib in 
patient s with advanced gastrointestinal stromal tumour after failure of imatinib: a 
randomised controlled trial. Lancet. 2006;368(9544):1329-1338. 
60. Burstein HJ, Elias AD, Rugo HS, et al. Phase II study of sunitinib malate, an oral 
multitargeted tyrosine kinase  inhibitor, in patients with metastatic breast cancer 
previously treated with an anthracycline and a taxane. Journal of Clinical Oncology. 2008;26(11):1810-1816. 
61. Socinski MA, Novello S, Brahmer JR, et al. Multicenter, phase II trial of sunitinib in 
previously treated, advanced non- small-cell lung cancer. Journal of Clinical Oncology. 
2008;26(4):650-656. 
62. Gallagher DJ MM, Gerst SR et al. Final results of a phase II study of sunitinib in patients 
(pts) with relapsed or refractory urothelial carcinoma ( UC). J Clin Oncol 26: 2008 (May 
20 suppl; abstr 5082)  
Abbreviated Title:  Ph2Sunitinib Thymoma/Thymic Ca CTEP Protocol #: 9174  
Version Date:  04/30/2020  
 
 79 63. Kulke MH, Fuchs CS. Activity of Sunitinib in Patients With Advanced Neuroendocrine 
Tumors REPLY. Journal of Clinical Oncology. 2009;27(2):320-320. 
64. Carr LL, Mankoff DA, Goulart BH, et al. Phase II Study of Daily Sunitinib in FDG- PET-
Positive, Iodine- Refractory Differentiated Thyroid Cancer and Metastatic Medullary 
Carcinoma of the Thyroid with Functional Imaging Correlation. Clin Cancer Res. 
2010;16(21):5260-5268. 
65. Vigil CE CA, Williams CA et al. Phase II study of sunitinib malate (SM) in subjects with metastatic and/or surgically unresectable non- GIST soft tissue sarcomas. J Clin Oncol 
26: 2008 (May 20 suppl; abstr 10535)  
66. Moehler M HJ, Lordick F et al. Sunitinib in patients with chemo- refractory metastatic 
gastric cancer: Preliminary results of an open -label, prospective nonrandomized 
multicenter Aio phase II trial. Proc Am Soc Clin Oncol Gastrointestinal Cancers Symposium  A61. 
67. Chaskis C SJ, Michotte A et al. A phase II trial of sunitinib in patients with recurrent 
high-grade glioma. ASCO Meeting Abstracts  26:A13001. 2008. 
68. Choong NW CE, Kozloff MF et al. Phase II trial of sunitinib in patients with recurrent 
and/or metastatic squamous cell carcinoma of the head and neck (SCCHN). A SCO 
Meeting Abstracts  26:A6064. 2008. 
69. Zhu A.X SD, di Tomaso E et al Sunitinib monotherapy in patients with advanced 
hepatocellular carcinoma (HCC): Insights from a multidisciplinary phase II study. ASCO Meeting Abstracts  26:A4521. 2008. 
70. Saltz LB,  Rosen LS, Marshall JL, et al. Phase II trial of sunitinib in patients with 
metastatic colorectal cancer after failure of standard therapy. J Clin Oncol. 
2007;25(30):4793-4799. 
71. Chan KR GS, Laudadio M et al. A pilot study using sunitinib malate as therapy in 
patients with stage IV uveal melanoma. . J Clin Oncol 26: 2008 (May 20 suppl; abstr 9047)  
72. Stadler WM. New targets, therapies, and toxicities: Lessons to be learned. Journal of 
Clinical Oncology. 2006;24(1):4-5. 
73. Robert C, Soria JC, Spatz A, et al. Cutaneous side-effects of kinase inhibitors and 
blocking antibodies. Lancet Oncol. 2005;6(7):491-500. 
74. Suwattee P, Chow S, Berg BC, Warshaw EM. Sunitinib: a cause of bullous palmoplantar 
erythrodysesthesia, periungual erythema, and mucositis. Arch  Dermatol. 
2008;144(1):123-125. 
75. Schmidinger M, Zielinski CC, Vogl UM, et al. Cardiac toxicity of sunitinib and sorafenib 
in patients with metastatic renal cell carcinoma. J Clin Oncol. 2008;26(32):5204-5212. 
76. Telli ML, Witteles RM, Fisher GA, Sriniv as S. Cardiotoxicity associated with the cancer 
therapeutic agent sunitinib malate. Ann Oncol. 2008;19(9):1613-1618. 
77. Khakoo AY, Kassiotis CM, Tannir N, et al. Heart failure associated with sunitinib 
malate: a multitargeted receptor tyrosine kinase inhibitor. Cancer. 2008;112(11):2500-2508. 
78. Chu TF, Rupnick MA, Kerkela R, et al. Cardiotoxicity associated with tyrosine kinase 
inhibitor sunitinib. Lancet. 2007;370(9604):2011-2019. 
79. Rini BI, Tamaskar I, Shaheen P, et al. Hypothyroidism in patients wit h metastatic renal 
cell carcinoma treated with sunitinib. J Natl Cancer Inst. 2007;99(1):81-83. 
Abbreviated Title:  Ph2Sunitinib Thymoma/Thymic Ca CTEP Protocol #: 9174  
Version Date:  04/30/2020  
 
 80 80. Atkinson BJ, Kalra S, Wang X, et al. Clinical outcomes for patients with metastatic renal 
cell carcinoma treated with alternative sunitinib schedules. The Journal of urology. 2014;191(3):611-618. 
81. Kondo T, Takagi T, Kobayashi H, et al. Superior Tolerability of Altered Dosing Schedule 
of Sunitinib with 2- Weeks -on and 1- Week -off in Patients with Metastatic Renal Cell 
Carcinoma--Comparison to Standard Dosing Schedule of 4- Weeks -on and 2- Weeks -off. 
Japanese journal of clinical oncology. 2014;44(3):270-277. 
82. Faivre S, Demetri G, Sargent W, Raymond E. Molecular basis for sunitinib efficacy and 
future clinical development. Nat Rev Drug Discov. 2007;6(9):734-745. 
83. Bello CL, Sherman L, Zhou J, et al. Effect of food on the pharmacokinetics of sunitinib 
malate (S U11248), a multi-targeted receptor tyrosine kinase inhibitor: results from a 
phase I study in healthy subjects. Anticancer Drugs. 2006;17(3):353-358. 
84. DuBois SG SS, Ingle AM et al. A pediatric phase I trial and pharmacokinetic (PK) study 
of sunitinib:  A Children’s Oncology Group Phase I Consortium study. J Clin Oncol 26: 
2008 (May 20 suppl; abstr 3561)  
85. Washington C EM, Bello C et al. The effect of ketoconazole (KETO), a potent CYP3A4 
inhibitor, on SU011248 pharmacokinetics (PK) in Caucasian and Asian healthy subjects. 
Proc Am Soc Clin Oncol 22: 2003 (abstr 553)  
86. Bello C HB, Sherman L et al. Effect of rifampin on the pharmacokinetics of SU11248 in 
healthy volunteers. ASCO Meeting Abstracts  23:A3078. 
87. Folkman J. What Is the Evidence That Tumors Are Angiogenesis Dependent. J Natl 
Cancer I. 1990;82(1):4- 6. 
88. Cherrington JM, Strawn LM, Shawver LK. New paradigms for the treatment of cancer: 
The role of anti-angiogenesis agents. Adv Cancer Res. 2000;79:1-38. 
89. Tomita M, Matsuzaki Y, Edagawa M, et al. Correlation between/tumor angiogenesis and 
invasiveness in thymic epithelial tumors. J Thorac Cardiov Sur. 2002;124(3):493-498. 
90. Sasaki H, Yukiue H, Kobayashi Y, et al. Elevated serum vascular endothelial growth 
factor and basic fibroblast growth factor levels in patients with thymic epithelial neoplasms. Surg Today. 2001;31(11):1038-1040. 
91. Pietras K, Sjoblom T, Rubin K, Heldin CH, Ostman A. PDGF receptors as cancer drug 
targets. Cancer Cell. 2003;3(5):439-443. 
92. Marx A, Rieker R, Toker A, Langer F, Strobel P. Thymic carcinoma: is it a separate 
entity? From molecular to clinical evidence. Thorac Surg Clin. 2011;21(1):25-31 v-vi. 
93. Girard N. Targeted therapies for thymic malignancies. Thorac Surg Clin. 
2011;21(1):115-123, viii. 
94. Girard N, S hen RL, Guo TH, et al. Comprehensive Genomic Analysis Reveals Clinically 
Relevant Molecular Distinctions between Thymic Carcinomas and Thymomas. Clin Cancer Res. 2009;15(22):6790-6799. 
95. Yoh K, Nishiwaki Y, Ishii G, et al. Mutational status of EGFR and KIT in thymoma and 
thymic carcinoma. Lung Cancer. 2008;62(3):316-320. 
96. Tsuchida M, Umezu H, Hashimoto T, et al. Absence of gene mutations in KIT-positive 
thymic epithelial tumors. Lung Cancer. 2008;62(3):321-325. 
97. Strobel P, Bargou R, Wolff A, et al. Sunitinib in metastatic thymic carcinomas: 
laboratory findings and initial clinical experience. Br J Cancer. 2010;103(2):196-200. 
98. Cimpean AM, Ceausu R, Encica S, Gaje PN, Ribatti D, Raica M. Platelet -derived growth 
Abbreviated Title:  Ph2Sunitinib Thymoma/Thymic Ca CTEP Protocol #: 9174  
Version Date:  04/30/2020  
 
 81 factor and platelet -derived growth factor receptor-alpha expression in the normal human 
thymus and thymoma. Int J Exp Pathol. 2011;92(5):340-344. 
99. Fiedler W, Giaccone G , Lasch P, et al. Phase I trial of SU14813 in patients with advanced 
solid malignancies. Ann Oncol. 2011;22(1):195-201. 
100. Azad A, Herbertson RA, Pook D, White S, Mitchell PL, Tebbutt NC. Motesanib 
diphosphate (AMG 706), an oral angiogenesis inhibitor, demonstrates clinical efficacy in 
advanced thymoma. Acta Oncol. 2009;48(4):619-621. 
101. Bedano PM PS, Burns M, Kessler K, Nelson R, Schneider BP, Risley L, Dropcho S and 
Loehrer PJ. A phase II trial of erlotinib plus bevacizumab in patients with recurrent thymoma or thymic carcinoma J Clin Oncol 26(Suppl): No 19087. 
102. Isambert N FG, Zanetta S, Falandry C, Soussan Lazard K, Fumoleau P. A phase I dose 
escalation and pharmacokinetic (PK) study of intravenous aflibercept (VEGF trap) plus docetaxel (D) in pat ients (pts) with advanced solid tumors: Preliminary results. . J Clin 
Oncol 2008; 26(Suppl), (Abstract 3599)  
103. Rosen LS, Kurzrock R, Mulay M, et al. Safety, pharmacokinetics, and efficacy of AMG 
706, an oral multikinase inhibitor, in patients with advanced solid tumors. Journal of Clinical Oncology. 2007;25(17):2369-2376. 
104. Bisagni G, Rossi G, Cavazza A, Sartori G, Gardini G, Boni C. Long Lasting Response to 
the Multikinase Inhibitor Bay 43- 9006 (Sorafenib) in a Heavily Pretreated Metastatic 
Thymic C arcinoma. Journal of Thoracic Oncology. 2009;4(6):773-775. 
105. Chuah C, Lim TS, Lim AST, et al. Dasatinib induces a response in malignant thymoma. 
Journal of Clinical Oncology. 2006;24(34):E56-E58. 
106. Li XF, Chen Q, Huang WX, Ye YB. Response to sorafeni b in cisplatin -resistant thymic 
carcinoma: a case report. Med Oncol. 2009;26(2):157-160. 
107. Buti S, Donini M, Sergio P, et al. Impressive Response With Imatinib in a Heavily 
Pretreated Patient With Metastatic c-KIT Mutated Thymic Carcinoma. J Clin Oncol. 2011;29(33):e803-805. 
108. Disel U, Oztuzcu S, Besen AA, et al. Promising efficacy of sorafenib in a relapsed 
thymic carcinoma with C -KIT exon 11 deletion mutation. Lung Cancer. 2011;71(1):109-
112. 
109. Girard N. Thymic tumors: relevant molecular data in the clinic. J Thorac Oncol. 2010;5(10 Suppl 4):S291-295. 
110. Carmeliet P, Jain RK. Angiogenesis in cancer and other diseases. Nature. 
2000;407(6801):249-257. 
111. Salgia R. Prognostic significance of angiogenesis and angiogenic growth factors in 
nonsmall cell lung cancer. Cancer. 2011;117(17):3889-3899. 
112. Jubb AM, Oates AJ, Holden S, Koeppen H. Predicting benefit from anti-angiogenic 
agents in malignancy. Nat Rev Cancer. 2006;6(8):626-635. 
113. Deprimo SE, Bello CL, Smeraglia J, et al. Circulating protein biomarkers of 
pharmacodynamic activity of sunitinib in patients with metastatic renal cell carcinoma: modulation of VEGF and VEGF-related proteins. J Transl Med. 2007;5:32. 
114. Rini BI. New strategies in kidney cancer: therapeutic advances through understanding the 
molecular basis of response and resistance. Clin Cancer Res. 2010;16(5):1348-1354. 
115. Faivre S, Demetri G, Sargent W, Raymond E. Molecular basis for sunitinib efficacy and 
future clinical development. Nature Reviews Drug Discovery. 2007;6(9):734-745. 
Abbreviated Title:  Ph2Sunitinib Thymoma/Thymic Ca CTEP Protocol #: 9174  
Version Date:  04/30/2020  
 
 82 116. Shojaei F, Lee JH, Simmons BH, et al. HGF/c- Met acts as an alternative angiogenic 
pathway in sunitinib- resistant tumors. Cancer Res. 2010;70(24):10090-10100. 
117. Ko JS, Zea AH, Rini BI, et al. Sunitinib mediates reversal of myeloid-derived suppressor 
cell accumulation in renal cell carcinoma patients. Clin Cancer Res. 2009;15(6):2148-
2157. 
118. Finke JH, Rini B, Ireland J, et al. Sunitinib reverses type-1 immune suppression and 
decreases T -regulatory cells in renal cell carcinoma patients. Clin Cancer Res. 
2008;14(20):6674-6682. 
119. Finke J, Ko J, Rini B, Rayman P, Ireland J, Cohen P. MDSC as a mechanism of tumor 
escape from sunitinib mediated anti-angiogenic therapy. International immunopharmacology. 2011;11(7):856-861. 
120. Kobayashi M, Kubo T, Komatsu K, et al. Changes in peripheral blood immune cells: 
their prognostic significance in metastatic renal cell carcinoma patients treated with molecular targeted therapy. Med Oncol. 2013;30(2):556. 
121. Baitsch L, Baumgaertner P, Devevre E, et al. Exhaustion of tumor- specific CD8(+) T 
cells in metastases from melanoma patients. The Journal of clinical investigation. 2011;121(6):2350-2360. 
122. Brahmer JR, Tykodi SS, Chow LQ, et al. Safety and activity of anti- PD-L1 antibody in 
patients with advanced cancer. N Engl J Med. 2012;366(26):2455-2465. 
123. Topalian SL, Hodi FS, Brahmer JR, et al. Safety, activity, and immune correlates of anti-
PD-1 antibody in cancer. The New England journal of medicine. 2012;366(26):2443-
2454. 
124. Bocci G, Man S, Green SK, et al. Increased plasma vascular endothelial growth factor 
(VEGF) as a surrogate marker for optimal therapeutic dosing of VEGF receptor-2 monoclonal antibodies. Cancer Res. 2004;64(18):6616-6625. 
125. Peters BA, Diaz LA, Polyak K, et al. Contribution of bone marrow- derived endothelial 
cells to human tumor vasculature. Nat Med. 2005;11(3):261-262. 
126. Mancuso P, Burlini A, Pruneri G, Goldhirsch A, Martinelli G, Bertolini F. Resting and 
activated endothelial cells are increased in the peripheral blood of cancer patients. Blood. 2001;97(11):3658-3661. 
127. Beerepoot LV, Mehra N, Vermaat JSP, Zonnenberg BA, Gebbink MFGB, Voest EE. 
Increased levels of viable circulat ing endothelial cells are an indicator of progressive 
disease in cancer patients. Annals of Oncology. 2004;15(1):139-145. 
128. Kalka C, Masuda H, Takahashi T, et al. Vascular endothelial growth factor(165) gene 
transfer augments circulating endothelial progenitor cells in human subjects. Circ Res. 2000;86(12):1198-1202. 
129. Kalka C, Tehrani H, Laudenberg B, et al. VEGF gene transfer mobilizes endothelial progenitor cells in patients with inoperable coronary disease. Ann Thorac Surg. 2000;70(3):829-834. 
130. Beaudry P, Force J, Naumov GN, et al. Differential effects of vascular endothelial growth 
factor receptor -2 inhibitor ZD6474 on circulating endothelial progenitors and mature 
circulating endothelial cells: Implications for use as a surrogate marker of antiangiogenic activity. Clin Cancer Res. 2005;11(9):3514-3522. 
131. Monestiroli S, Mancuso P, Burlini A, et al. Kinetics and viability of circulating 
endothelial cells as surrogate angiogenesis marker in an animal model of human 
Abbreviated Title:  Ph2Sunitinib Thymoma/Thymic Ca CTEP Protocol #: 9174  
Version Date:  04/30/2020  
 
 83 lymphoma. Cancer Res. 2001;61(11):4341-4344. 
132. Schuch G, Heymach JV, Nomi M, et al. Endostatin inhibits the vascular endothelial 
growth factor-induced mobilization of endothelial progenitor cells. Cancer Res. 
2003;63(23):8345-8350. 
133. Capillo M, Mancuso P, Gobbi A, et al. Continuous infusion of endostatin inhibits 
differentiation, mobilization, and clonogenic potential of endothelial cell progenitors. Clin Cancer Res. 2003;9(1):377-382. 
134. Farace F, Gross -Goupil M, Tournay E, et al. Levels of circulating 
CD45(dim)CD34(+)VEGFR2( +) progenitor cells correlate with outcome in metastatic 
renal cell carcinoma patients treated with tyrosine kinase inhibitors. Br J Cancer. 2011;104(7):1144-1150. 
135. Vroling L VdVA, De Haas RR, Schuurhuis GJ, Van Cruijsen H CD34bright/CD133neg 
candidate circulating endothelial progenitor cells (ccEPCs) are a potential biomarker 
during treatment with sunitinib or bevacizumab. Proceedings of the 99th AACR Annual 
Meeting, San Diego (CA) 2008, Abstract 4956. 
136. Rafii S. Circulating endothelial precursors: mystery, reality, and promise. Journal of Clinical Investigation. 2000;105(1):17-19. 
137. Khan SS, Solomon MA, McCoy JP, Jr. Detection of circulating endothelial cells and 
endothelial progenitor cells by flow cytometry. Cytometry B Clin Cytom. 2005;64(1):1-8. 
138. Furstenberger G, von Moos R, Lucas R, et al. Circulating endothelial cells and 
angiogenic serum factors during neoadjuvant chemotherapy of primary breast cancer. Br J Cancer. 2006;94(4):524-531. 
139. Hill JM, Zalos G, Halcox JP, et al. Circulating endothelial progenitor cells, vascular 
function, and cardiovascular risk. N Engl J Med. 2003;348(7):593-600. 
140. Xin H, Zhang C, Herrmann A, Du Y, Figlin R, Yu H. Sunitinib inhibition of Stat3 
induces renal cell carcinoma tumor cell apoptosis and reduces immunosuppressive cells. Cancer Res. 2009;69(6):2506-2513. 
141. Ozao -Choy J, Ma G, Kao J, et al. The novel role of tyrosine kinase inhibitor in the 
reversal of immune suppression and modulation of tumor microenvironment for immune-based cancer therapies. Cancer Res. 2009;69(6):2514-2522. 
142. Deeken J, Rudek M, Moore P. A Phase I/PK study of Sunitinib With Highly Active 
Antiretroviral Therapy (HAART) HIV+ Patients with Solid Tumors: AIDS Malignancy Consortium Study 061. 13th International Conference on Malignancies in AIDS and Other Acquired Immunodeficiencies, Bethesda, MD. 2011. 
143. Rieker RJ, Hoegel J, Morresi- Hauf A, et al. Histologic classification of thymic epithelial 
tumors: comparison of established cl assification schemes. Int J Cancer. 2002;98(6):900-
906. 
144. Kuo TT. Tumours of the thymus. In: Travis WD, Brambilla E, Muller- Hermelink HK, et 
al., editors. World Health Organization Classification of Tumors: Pathology and Genetics of Tumors of the Lung, Pleura, Thymus and Heart. Lyon, France: IARC Press; pp. 146–248, 2004. 
145. Eisenhauer EA, Therasse P, Bogaerts J, et al. New response evaluation criteria in solid 
tumours: revised RECIST guideline (version 1.1). Eur J Cancer. 2009;45(2):228-247. 
   
Abbreviated Title:  Ph2Sunitinib Thymoma/Thymic Ca CTEP Protocol #: 9174  
Version Date:  04/30/2020  
 
 84  
20 APPENDIX A : PERFORMANCE STATUS CRITERIA 
 
ECOG Performance Status Scale Karnofsky Performance Scale  
Grade  Descriptions  Percent  Description  
0 Normal activity.  Fully active, able 
to carry on all pre- disease 
performance without restriction.  100 Normal, no complaints, no evidence 
of disease.  
90 Able to carry on normal activity; 
minor signs or symptoms of disease.  
1 Symptoms, but ambulatory.  Restricted in physically strenuous activity, but ambulatory and able to carry out work of a light or sedentary nature ( e.g., light 
housework, office work). 80 Normal activity with effort; some signs or symptoms of disease. 
70 Cares for self, unable to carry on normal activity or to do active work. 
2 In bed <50% of the time.  
Ambulatory and capable of all self-care, but unable to carry out 
any work activities.  Up and about 
more than 50% of waking hours.  60 Requires occasional assistance, but 
is able to care for most of his/her 
needs.  
50 Requires considerable assistance and 
frequent medical care.  
3 In bed >50% of the time.  Capable 
of only limited self -care, confined 
to bed or chair more than 50% of 
waking hours.  40 Disabled, requires special care and 
assistance.  
30 Severely disabled, hospitalization 
indicated.  Death not imminent.  
4 100% bedridden.  Completely 
disabled.  Cannot carry on any self-care.  Totally confined to bed 
or chair.  20 Very sick, hospitalization indicated. 
Death not imminent.  
10 Moribund, fatal processes 
progressing rapidly.  
5 Dead.  0 Dead.  
         
  
Abbreviated Title:  Ph2Sunitinib Thymoma/Thymic Ca CTEP Protocol #: 9174  
Version Date:  04/30/2020  
 
 85 21 APPENDIX B : NEW YORK HEART ASSOCIATION CLASSIFICATION OF 
CARDIAC DISEASE  
 
 
 
Class  Functional Capacity  Objective Assessment  
I Patients with cardiac disease but without resulting limitations of 
physical activity.  Ordinary physical activity does not cause undue 
fatigue, palpitation, dyspnea, or anginal pain.  No objective evidence of 
cardiovascular disease.  
II Patients with cardiac disease resulting in slight limitation of 
physical activity.  They are comfortable at rest.  Ordinary physical 
activity results in fatigue, palpitation, dyspnea, or anginal pain.  Objective evidence of 
minimal cardiovascular 
disease.  
III Patients with cardiac disease resulting  in marked limitation of 
physical activity.  They are comfortable at rest.  Less than 
ordinary activity causes fatigue, palpitation, dyspnea, or anginal 
pain. Objective evidence of 
moderately severe cardiovascular disease.
 
IV Patients with cardiac disease  resulting in inability to carry on any 
physical activity without discomfort.  Symptoms of heart failure 
or the anginal syndrome may be present even at rest.  If any 
physical activity is undertaken, discomfort is increased.  Objective evidence of 
severe car diovascular 
disease.  
 
                      
Abbreviated Title:  Ph2Sunitinib Thymoma/Thymic Ca CTEP Protocol #: 9174  
Version Date:  04/30/2020  
 
 86  
22 APPENDIX C : DRUGS KNOWN TO BE ME TABOLIZED BY SELECTED CYP450 
ISOENZYMES  
 
Cytochrome P450 (CYP) Enzyme  
 
CYP3A4 Substrates, Inhibitors, and Inducers  
 
      3A4 Substrates  
Albuterol  
Alfentanil  
Alprazolam  
Amlodipine  
Amprenavir  
Aprepitant  
Aripiprazole  
Atazanavir  
Atorvastatin 
Benzphetamine  
Bisoprolol  
Bortezomib  
Bosentan  
Bromazepam  
Bromocriptine  
Buprenorphine  
Buspirone  
Busulfan  
Carbamazapine  
Cerivastatin  
Chlordiazepoxide  
Chloroquine  
Chlorpheniramine  
Cisapride  
Citalopram  
Clarithromycin  
Clobazam  
Clonazepam  
Clorazepate  
Cocaine  
Colchicine  
Cyclophosphamide  
Cyclosporine  
Dantrolene  
Dapsone  
Delavirdine  
Diazepam  
Digitoxin  
Dihydroergotamine  
Diltiazem  
Disopyramide  Docetaxel  
Doxepin 
Doxorubicin  
Doxycycline  
Efavirenz  
Eletriptan  
Enalapril  
Eplerenone  
Ergoloid mesylates  
Ergonovine  
Ergotamine  
Erythromycin  
Escitalopram  
Estradiol  
Estrogens, conj., synthetic 
Estrogens, conj., equine Estrogens, conj., esterified  
Estrone  
Estropipate  
Ethinyl estradiol  
Ethosuximide  
Etoposide  
Felbamate  
Felodipine  
Fentanyl  
Flurazepam  
Flutamide  
Fosamprenavir  
Fulvestrant  
Gefitinib  
Halofantrine  
Haloperidol  
Ifosfamide  
Imatinib  
Indinavir  
Irinotecan  
Isosorbide dinitrate  
Isosorbide mononitrate  
Isradipine  
Itraconazole  
Ketamine  Ketoconazole  
Lansoprazole  
Letrozole  
Levomethadyl acetate  
hydrochloride  
Levonorgestrel  
Lidocaine  
Losartan  
Lovastatin  
Medroxyprogesterone Mefloquine  
Mestranol  
Methadone  
Methylergonovine  
Methysergide  
Miconazole  
Midazolam  
Miglustat Mirtazapine  
Modafinil  
Montelukast  
Moricizine  
Nateglinide  
Nefazodone  
Nelfinavir  
Nevirapine  
Nicardipine  
Nifedipine  
Nimodipine  
Nisoldipine  
Nitrendipine  
Norethindrone  
Norgestrel  
Ondansetron  
Paclitaxel  
Pergolide  
Phencyclidine  
Pimozide  
Pioglitazone  
Primaquine  
Progesterone  Quetiapine  
Quinidine  
Rabeprazole Repaglinide Rifabutin  
Rifampin  
Ritonavir  
Saquinavir  
Sertraline  
Sibutramine  
Sildenafil 
Simvastatin 
Sirolimus  
Sufentanil  
Tacrolimus  
Tamoxifen Tamsulosin  
Telithromycin  
Teniposide  
Terbinafine  
Tetracycline  
Theophylline  
Tiagabine  
Ticlopidine  
Tolterodine  
Toremifene  
Trazodone  
Triazolam  
Trimethoprim  
Trimipramine  
Troleandomycin  
Vardenafil  
Venlafaxine  
Verapamil  
Vinblastine  
Vincristine  
Vinorelbine  
Zolpidem  
Zonisamide  
Zopiclone
 
Abbreviated Title:  Ph2Sunitinib Thymoma/Thymic Ca CTEP Protocol #: 9174  
Version Date:  04/30/2020  
 
 87  
3A4 Inhibitors  
Acetominophen  
Acetazolamide  
Amioderone  
Amlodipine  
Amprenavir  
Anastrozole  
Aprepitant  
Atazanavir  
Atorvastatin 
Azelastine  
Azithromycin 
Betamethasone  
Bortezomib  
Bromocriptine  
Caffiene  
Cerivastatin  
Chloramphenicol  
Chlorzoxazone  
Cimetadine  
Ciprofloxacin Cisapride  
Clarithromycin  
Clemastine  
Clofazimine  
Clotrimazole  
Clozapine  
Cocaine  
Cyclophosphamide  
Cyclosporine  
Danazol  
Delavirdine  
Desipramine  
Dexmedetomidine  
Diazepam  
Diclofenac 
Dihydroergotamine  Diltiazem  
Disulfiram  
Docetaxel  
Doxorubicin  
Doxycycline  
Drospirenone  
Efavirenz  
Enoxacin  
Entacapone  
Ergotamine  
Erythromycin  
Ethinyl estradiol  
Etoposide  
Felodipine  
Fentanyl  
Fluconazole Fluoxetine  
Fluvastatin  
Fluvoxamine  
Fosamprenavir  
Glyburi de 
Grapefruit juice  
Haloperidol  
Hydralazine  
Ifosfamide  
Imatinib  
Indinavir  
Irbesartan  
Isoniazid  
Isradapine  
Itraconazole  
Ketoconazole  
Lansoprazole  
Lidocaine  
Lomustine  
Losartan  Lovastatin  
Mefloquine  
Mestranol  
Methadone  
Methimazole  
Methoxsalen  
Methylprednisolone  
Metronidazole  
Miconazole  
Midazolam  
Mifepristone  
Mirtazapine  
Mitoxantrone  
Modafinil  
Nefazodone  
Nelfinavir  
Nevirapine  
Nicardipine  
Nifedipine  
Nisoldipine  
Nitrendipine  
Nizatidine  
Norfloxacin  
Olanzapine  
Omeprazole  
Orphenadrine  
Oxybutynin  
Paroxetine  
Pentamidine  
Pergolide  
Phencyclidine  
Pilocarpine  
Pimozide  
Pravastatin  
Prednisolone  
Primaquine  Progesterone  
Propofol  
Propoxyphene  
Quinidine  
Quinine  
Quinupristin  
Rabeprazole Risperidone  
Ritonavir  
Saquinavir  
Selegiline  
Sertraline  
Sildenafil Sirolimus  
Sulconazole 
Tacrolimus  
Tamoxifen 
Telithromycin  
Teniposide  
Testosterone  
Tetracycline  
Ticlopidine  
Tranylcypromine  
Trazodone  
Troleandomycin  
Valproic acid  
Venlafaxine  
Verapimil  
Vinblastine  
Vincristine  
Vinorelbine  
Zafirlukast  
Ziprasidone  
 
 
 
 3A4 Inducers  
Aminoglutethimide  
Carbamazapine  
Efavirenz  
Etravirine  
Fosphenytoin  
St. John’s wort  Nevirapine  
Oxcarbazepine  
Pentobarbital  
Phenobarbital  Phenytoin  
Primidone  
Rifabutin  
Rifampin  Rifapentine  
 
 
When Study Agent  is co-administered with drugs classified as  “substrates,” the plasma concentration of the substrate is high. 
When Study Agent  is co-administered with drugs classified as ‘inhibitors,’ plasma concentrations of the Study Agent will be  
high.  When Study Agen t is co-administered with drugs classified as “inducers,” the plasma concentration of the Study Agent  
will be low.   
In general, drug interactions occur significantly between substrates and either inhibitors or inducers of the same enzymes 
usually classified as “strong” substrates, inhibitors, or inducers.  
These lists are not all- inclusive.  Check additional references or sources.  
 
 (Adapted from Cytochrome P -450 Enzymes and Drug metabolism. In: Lacy CF, Armstrong LL, Goldman MP, Lance LL eds. 
Drug Informat ion Handbook 12TH ed. Hudson, OH; LexiComp Inc. 2004: 1619 -1631.)  
 
(1)  Malhorta et al. (2000). Clin Pharmacol Ther. 69:14 -23 
 
(2)  Mathijssen et al. (2002). J Natl Cancer Inst. 94:1247 -1249 
      Frye et al. (2004). Clin Pharmacol Ther. 76:323 -329 
 
Abbreviated Title:  Ph2Sunitinib Thymoma/Thymic Ca CTEP Protocol #: 9174  
Version Date:  04/30/2020  
 
 88 23 APPENDIX D : PATIENT’S MEDICATION DIARY  
 
Today’s date: Patient’s name: Patient’s study ID:  
 Patient’s Medication D iary - Group 1  
 
 INSTRUCTIONS TO THE PATIENT:  
1. Complete one form for each 6 week -period while you take sunitinib. 
2. You will take your dose of sunitinib by mouth each day in the morning. You will take ____12.5 mg capsules and/or  ____ 25 mg capsules or ___50 mg capsule. You may take the capsules with or without food as you wish. 3. Record the date, the number of capsules of each size you took, and when you took them.  
4. Record the daily dose onto the diary, including missed, skipped, or vomited doses. If you vomit after taking the tablets, the dose is replaced only if the tablets can actually be seen and counted. If you miss a dose, you should resume with the next scheduled dose. 5. If you have any comments or notice any side effects, please record them in the Comments column. 6. Wash your hands with soap and water after touching the capsule(s). Do not share this medication with anyone. 
7. Please return unused sunitinib capsules (or empty bottles) and this form to your 
physician when you go for your next appointment.  
Day 
 Date  
 Time 
of 
daily 
dose 
 # of capsules 
taken   BP 
readings Comments  
12.5 
mg  25 mg  
 50 mg  
1        
2        
3        
4        
5        
6        
7        
8        
9        
10        
11        
12        
13        
14        
15        
Abbreviated Title:  Ph2Sunitinib Thymoma/Thymic Ca CTEP Protocol #: 9174  
Version Date:  04/30/2020  
 
 89 16        
17        
18        
19        
20        
21        
22        
23        
24        
25        
26        
27        
28        
29-42     Drug holiday  
 Physician’s Office will complete this section:  
1. Date patient started protocol treatment 
__________________________________________ 2. Date patient was removed from study ________________________________________ 3. Patient’s planned total daily dose ____________________________________________ 4. Total number of tablets taken this month  ___________________________________ 
5. Physician/Nurse/Data Manager’s Signature 
                     
Abbreviated Title:  Ph2Sunitinib Thymoma/Thymic Ca CTEP Protocol #: 9174  
Version Date:  04/30/2020  
 
 90 Today’s date: 
Patient’s name: Patient’s study ID:  
 
Patient’s Medication Diary - Group 2 
 
 INSTRUCTIONS TO THE PATIENT:  
1. Complete one form for each 3 week -period while you take sunitinib. 
2. You will take your dose of sunitinib by mouth each day in the morning. You will take ____12.5 mg capsules and/or  ____ 25 mg capsules or ___50 mg capsule. You may take the capsules wi th or without food as you wish. 
3. Record the date, the number of capsules of each size you took, and when you took them.  
4. Record the daily dose onto the diary, including missed, skipped, or vomited doses. If you vomit after taking the tablets, the dose is replaced only if the tablets can actually be seen and counted. If you miss a dose, you should resume with the next scheduled dose. 5. If you have any comments or notice any side effects, please record them in the Comments column. 6. Wash your hands with soap and water after touching the capsule(s). Do not share this medication with anyone. 
7. Please return unused sunitinib capsules (or empty bottles) and this form to your 
physician when you go for your next appointment.  
Day 
 Date  
 Time 
of 
daily dose 
 # of capsules 
taken   BP 
readings Comments  
12.5 
mg  25 mg  
 50 mg  
1        
2        
3        
4        
5        
6        
7        
8        
9        
10        
11        
12        
13        
14        
15-21    Drug holiday  
 Physician’s Office will complete this section:  
1. Date patient started protocol treatment 
__________________________________________  
Abbreviated Title:  Ph2Sunitinib Thymoma/Thymic Ca CTEP Protocol #: 9174  
Version Date:  04/30/2020  
 
 91 2. Date patient was removed from study 
________________________________________ 
3. Patient’s planned total daily dose 
____________________________________________ 4. Total number of tablets taken this month  ___________________________________ 
5. Physician/Nurse/Data Manager’s Signature  
       
                         
  
Abbreviated Title:  Ph2Sunitinib Thymoma/Thymic Ca CTEP Protocol #: 9174  
Version Date:  04/30/2020  
 
 92  
24 APPENDIX E : CTEP MULTICENTER GUIDELINES  
 
If an institution wishes to collaborate with other participating institutions in performing a 
CTEP sponsored research protocol, then the following guidelines must be followed. 
 
Responsibility of the Protocol Chair  
• The Protocol Chair will be the single liaison with the CTEP Protocol and Information Office (PIO).  The Protocol Chair is responsible for the coordination, development, submission, and approval of the protocol as well as its subsequent amendments.  The protocol must not be rewritten or modified by anyone other than the Protocol Chair.  There will be only one version of the protocol, and each participating institution will use that document.  The Protocol Chair is responsible for assuri ng that all participating 
institutions are using the correct version of the protocol. 
• The Protocol Chair is responsible for the overall conduct of the study at all participating institutions and for monitoring its progress.  All reporting requirements to C TEP are the 
responsibility of the Protocol Chair.  
• The Protocol Chair is responsible for the timely review of Adverse Events (AE) to assure safety of the patients.  
• The Protocol Chair will be responsible for the review of and timely submission of data for study analysis. 
 
Responsibilities of the Coordinating Center 
• Each participating institution will have an appropriate assurance on file with the Office for Human Research Protection (OHRP), NIH.  The Coordinating Center is responsible 
for assuring that each participating institution has an OHRP assurance and must maintain copies of IRB approvals from each participating site.  
•  Prior to the activation of the protocol at each participating institution, an OHRP form 310 (documentation of IRB approval) must be submitted to the CTEP PIO. 
• The Coordinating Center is responsible for central patient registration.  The Coordinating 
Center is responsible for assuring that IRB approval has been obtained at each 
participating site prior to the first patient registration from that site.  
• The Coordinating Center is responsible for the preparation of all submitted data for review by the Protocol Chair.  
• The Coordinating Center will maintain documentation of AE reports.  There are two options for AE reporting: (1) participating institutions may report directly to CTEP with a copy to the Coordinating Center, or (2) participating institutions report to the Coordinating Center who in turn report to CTEP.  The Coordinating Center will submit AE reports to the Protocol Chair for timely review.  
   
Audits may be accomplished in one of two ways: (1) source documents and research records for selected patient s are brought from participating sites to the Coordinating Center for audit, 
Abbreviated Title:  Ph2Sunitinib Thymoma/Thymic Ca CTEP Protocol #: 9174  
Version Date:  04/30/2020  
 
 93 or (2) selected patient records may be audited on- site at participating sites.  If the NCI 
chooses to have an audit at the Coordinating Center, then the Coordinating Center is 
responsible for having all source documents, research records, all IRB approval documents, 
NCI Drug Accountability Record forms, patient registration lists, response assessments scans, x -rays, etc. available for the audit.  
 
Agent Ordering 
• Except in very unusual circumstances, each participating institution will order DCTD-supplied investigational agents directly from CTEP.  Investigational agents may be ordered by a participating site only after the initial IRB approval for the site has been forwarded by the Coordinating Center to the CTEP PIO.  
 
       
Abbreviated Title:  Ph2Sunitinib Thymoma/Thymic Ca CTEP Protocol #: 9174  
Version Date:  04/30/2020  
 
 94 25 APPENDIX F : COLLECTION/RECORDING  OF BLOOD PRESSURE 
INFORMATION 
 
1.0 General Guidelines  
1.1          Frequency of monitoring.   Blood pressure (BP) should be monitored at baseline, and then weekly  
thereafter ; i.e., at every clinic visit, and at home  on weeks when there is no clinic visit.   
1.2          Data recording.  All required data should be recorded in the appropriate CRF or on the patient’s blood 
pressure monitoring diary, as appropriate.  The following data are required at baseline and at each 
subsequent assessment : 
• Assessment date and time  
• Pulse  
• Systolic and diastolic BP  
 
1.3         Risk factors for hypertension (assess and record data in baseline history/physical CRF)  
• Diabetes (type 1 or type 2)  
• Renal disease (specify on CRF)  
• Endocrine condition associated with HTN (specify on CRF)  
• Use of steroids or NSAIDs (specify all concomitant meds)  
• Underlying cardiovascular condition – specify ( i.e., ischemic heart disease) 
  
2.0         Baseline data collection  (at study entry)  
       2.1      All patients  
• Current BP  
• Proteinuria, if present  
 
      2.2  Patients with preexisting hypertension ( i.e., those for whom “hypertension” is entered as a concomitant 
condition at study entry, or those who are currently receiving therapy with antihypertensive medication) – 
also record:  
• Date of HTN diagnosis (original)  
• Type HTN (ess ential or secondary)  
• CTCAE grade of HTN (at time of study entry)  
• Trade name, drug class*, dose, dose frequency, start/stop dates/ongoing of the following:  
- Antihypertensive agents taken at study entry  
- Antihypertensive agents taken in past (e.g., discontinued for toxicity, lack of efficacy)  
 3.0       Follow up BP data collection (during study)  
      3.1  All patients  (at each clinic visit)  
• Current BP  
• Proteinuria, if present  
 
     3.2  Patients with treatment- emergent hypertension [defined as BP increase of  >20 mmHg (diastolic) OR 
systolic BP >139 OR diastolic BP > 90  (if previously normal or grade 1 per CTCAE v5 ) – record at time 
of hypertension diagnosis and at all subsequent clinic visits:  
• BP changes from baseline (or from previous assessment) (specify C TCAE grade changes)  
• Hypertension- related symptoms as reported by patient ( e.g., headache)  
• Other relevant changes associated with development of hypertension ( e.g., ECG 
abnormalities)  
• Trade name, drug class*, dose, dose frequency, start/stop dates/ongoing of currently prescribed antihypertensive agents  
 
     3.3  Patients with pre -existing hypertension at study entry – record at each clinic visit  
• BP changes from previous clinic visit (specify CTCAE grade changes)  
Abbreviated Title:  Ph2Sunitinib Thymoma/Thymic Ca CTEP Protocol #: 9174  
Version Date:  04/30/2020  
 
 95 • Hypertension- related symptoms r eported by patient ( e.g., headache)  
• Other relevant changes associated with development of hypertension ( e.g., ECG 
abnormalities)  
• Changes in antihypertensive medications since last assessment ( e.g., dose change, 
add/discontinue drug)  
 
*Classes of antihypertensive drugs include ACE inhibitors, calcium channel blockers, alpha blockers, beta blockers, 
diuretics, angiotension II receptor antagonists.  
  
Abbreviated Title:  Ph2Sunitinib Thymoma/Thymic Ca CTEP Protocol #: 9174  
Version Date:  04/30/2020  
 
 96 26 APPENDIX G : MANAGEMENT OF SUNITINIB -INDUCED HYPERTENSION  
 
Recommended Hypertension Monitoring and Management  
(BP in mmHg)  
 
 
Grade  
(CTCAE v 5) Antihypertensive  
Therapy  Blood Pressure 
Monitoring  Sunitinib  
Dose Modification  
Persistent Grade 1  
Pre-hypertension  
Systolic 120- 139 
Diastolic 80 -90 
  Standard       
 No change  
Persistent Grade 2 - 
Moderate 
Systolic 140- 159  
Diastolic 90 -99  
   
Protocol -specific 
guidance supersedes any other management guidelines, including 
CTCAE v 5  Step 1) Initiate LA DHP 
CCB treatment and if 
needed, after 24 -48 hr Rx,  
increase dose in stepwise  fashion every 24- 48 hours  
until BP is controlled or at max dose of Rx
 
 
Step 2) If BP still not 
controlled, add another 
antihypertensive Rx, a BB, ACE1, ARB, or ABB; increase dose of this drug as described in step 1  
 
 
Step 3) If BP still not 
controlled, add 3rd drug 
from the list of antihypertensives in step 2; increase dose of this drug as described in step 1  
 Step 4) If BP still not controlled, consider either 1 dose reduction of sunitinib or stopping 
sunitinib  
 
NOTE:  Stopping or 
reducing the dose of 
sunitinib is expected to cause a decrease in BP 
The treating physician 
should monitor the patient 
for hypotension and adjust 
the number and dose of 
antihypertensive 
medication(s)  accordingly.  
 BP should be 
monitored as 
recommended by the 
treating p hysician  No change except as 
described in step 4  
Abbreviated Title:  Ph2Sunitinib Thymoma/Thymic Ca CTEP Protocol #: 9174  
Version Date:  04/30/2020  
 
 97 Persistent Grade 3 
Severe  
Systolic >160 
Diastolic >100  
 
Protocol -specific 
guidance supersedes 
any other management 
guidelines, including CTCAE v 5 HOLD sunitinib until 
systolic BP < 159 and 
diastolic BP < 99.  
  
BP management is identical to that for Grade 
2 (see steps 1 -4 above)  
with 2 major exceptions:  
1)  If systolic BP >180 or 
diastolic BP >110 and 
the patient is 
symptomatic: optimal 
management with 
intensive IV support in ICU; STOP sunitinib and notify hospital staff that stopping sunitinib 
may result in a decrease 
in BP  
 and  
2) If systolic BP >180 or 
diastolic BP >110 and 
the patient is 
asymptomatic,  
2 new anti -hypertensives 
must be given together in step 1 (and dose escalated appropriately as in step 1).  
 
NOTE:  Stopping or 
reducing the dose of sunitinib is expected to cause a decrease in BP The trea ting physician 
should monitor the patient 
for hypotension and adjust 
the number and dose of 
antihypertensive 
medication(s)  accordingly  BP should be 
monitored as recommended by the treating physician unless the patient is 
symptomatic with   
systolic BP >180 or 
diastolic BP >110 in 
which case, 
monitoring should 
be intensive.  
  HOLD sunitinib until 
systolic BP < 159 and 
diastolic BP  
<99. 
 In most circumstances, if   
BP cannot be 
controlled after an optimal trial of anti-hypertensive medications, consider either  1 
dose reduction of sunitinib or stopping sunitinib.  
HOWEVER,  
if the patient 
requires 
hospitalization for 
management of 
symptomatic  
systolic BP >180 or 
diastolic BP >110,  
permanently discontinue sunitinib or if BP is controlled, re-start sunitinib at 1 
lower dose level after 
consultation with the 
study Principal 
Investigator  
    
 
Grade 4  
Life-threatening 
consequences of 
hypertension  
 Optimal management 
with intensive IV support in ICU; STOP sunitinib and notify hospital staff that stopping sunitinib may 
result in a decrease in 
BP Intensive  Permanently 
discontinue sunitinib 
or if BP is controlled, re-start sunitinib at 1 
lower dose level after 
consultation with the 
study Principal 
Investigator  
 
Abbreviations : dihydropyridine calcium -channel blockers (DHP -CCB), selective beta blockers (BB), angiotensin 
converting enzyme inhibitors (ACEI), angiotensin II receptor blockers (ARB), alpha beta blocker (ABB)  
• *See table below for suggested antihypertensive medications by class  
• If pati ents require a delay of >2 weeks for management of hypertension, discontinue protocol therapy  
• If patients require >2 dose reductions, discontinue protocol therapy  
Abbreviated Title:  Ph2Sunitinib Thymoma/Thymic Ca CTEP Protocol #: 9174  
Version Date:  04/30/2020  
 
 98 • Patients may have up to 2 drugs for management of hypertension prior to any dose reduction in  sunitinib  
• 24-48 hours should elapse between modifications of anti -hypertensive therapy  
• Hypertension should be graded using CTCAE v 5. 
 
Oral Antihypertensive Medications  
 
Agents in bold characters are suggested as optimal choices to avoid or minimize potential drug -
interactions with sunitinib through CYP450. 
Agent  
class  
Agent  Initial  
dose Intermediate 
dose Maximum  
dose Hepatic  
metabolism  
Dihydro -
pyridine  
Calcium -
Channel 
Blockers  
(DHP CCB)  nifedipine XL  30 mg daily  60 mg daily  90 mg daily  CYP 3A4 
substrate  
amlodipine  2.5 mg daily  5 mg daily  10 mg daily  CYP 3A4 
substrate  
felodipine  2.5 mg daily  5 mg daily  10 mg daily  CYP 3A4 substrate 
and inhibitor  
Selective 
β Blockers  
(BB)  metoprolol  25 mg  
twice daily  50 mg  
twice daily  100 mg  
twice daily  CYP 2D6 substrate  
atenolol  25 mg daily  50 mg daily  100 mg daily  No 
acebutolol  100 mg  
twice daily  200-300 mg 
twice daily  400 mg  
twice daily  Yes (CYP450 
unknown)  
bisoprolol  2.5 mg daily  5-10 mg daily  20 mg daily  Yes (CYP450 
unknown)  
Angiotensin  
Converting  
Enzyme  
Inhibitors  
(ACEIs)  
 captopril  12.5 mg 3x 
daily  25 mg 3x daily  50 mg 3x daily  CYP 2D6 substrate  
enalapril  5 mg daily  10-20 mg daily  40 mg daily  CYP 3A4 substrate  
ramipril  2.5 mg daily  5 mg daily  10 mg daily  Yes (CYP450 
unknown)  
lisinopril  5 mg daily  10-20 mg daily  40 mg daily  No 
fosinopril  10 mg daily  20 mg daily  40 mg daily  Yes (CYP450 
unknown)  
Rarely used:  
perindopril   
4 mg daily   
none   
8 mg daily   
Yes, but not 
CYP450  
Rarely used:  
quinapril  10 mg daily  20 mg daily  40 mg daily  No 
Angiotensin II 
Receptor 
Blockers  
(ARBs)  losartan  25 mg daily  50 mg daily  100 mg daily  CYP 3A4 substrate  
candesartan  4 mg daily  8-16 mg daily  32 mg daily  CYP 2C9 substrate  
irbesartan  75 mg daily  150 mg daily  300 mg daily  CYP 2C9 substrate  
telmisartan  40 mg daily  none  80 mg daily  Yes, but not 
Abbreviated Title:  Ph2Sunitinib Thymoma/Thymic Ca CTEP Protocol #: 9174  
Version Date:  04/30/2020  
 
 99 Agent  
class  
Agent  Initial  
dose Intermediate 
dose Maximum  
dose Hepatic  
metabolism  
CYP450  
valsartan  80 mg daily  none  160 mg daily  Yes, but not 
CYP450  
α and β 
Blocker  labetolol  100 mg twice 
daily  200 mg twice 
daily  400 mg twice 
daily  CYP 2D6 substrate 
and inhibitor  
 
Abbreviated Title:  Ph2Sunitinib Thymoma/Thymic Ca CTEP Protocol #: 9174  
Version Date:  04/30/2020  
 
 100 27 APPENDIX H 
 
Instructions to site investigators:  Photocopy the following two pages back- to-back and provide 
the sheet to your patients at the time of enrollment.  The third page following contains a wallet-
sized information card for the patient to carry at all times.   
Abbreviated Title:  Ph2Sunitinib Thymoma/Thymic Ca CTEP Protocol #: 9174  
Version Date:  04/30/2020  
 
 101  
INFORMATION ON POSSIBLE INTERACTIONS WITH OTHER AGENTS FOR PATIENTS AND THEIR CAREGIVERS AND NON- STUDY HEALTH CARE TEAM  
 The patient _________________ is enrolled on a clinical trial using the experimental agent sunitinib. This clinical trial is sponsored by the National Cancer Institute. This form is addressed to the patient, but includes important information for others who care for this patient.   Sunitinib interacts with many drugs that are processed by your liver. Because of this, it is very important to tell your study doctors about all of your medicine before you start this study. It is also very important to tell them if you stop taking any regular medicine, or if you start taking a new medicine while you take part in this study. When you talk about your medicine with your study doctor, include medicine you buy without a prescription at the drug store (over- the counter  
remedy), or anything that you buy from the health food store or grocery store (herbal 
supplement).  
 Many health care prescribers can write prescriptions. You must also tell your other prescribers (doctors, physicians’ assistants or nurse practitioners) that you are taking part in a clinical trial. Bring this paper with you. These are the thing s that you and they need to know:  
 
• Sunitinib is metabolized (converted in the body) by a liver enzyme called CYP3A4. 
Sunitinib must be used very carefully with other medicines that need this liver enzyme to be 
effective or to be cleared from your system.  
• You and healthcare providers who prescribe drugs for you must be careful about adding 
or removing any drug in this category.  
• Before you start the study, your study doctor will work with your regular prescriber to switch any medicines that are considered “strong inducers/inhibitors or substrates of CYP3A4.” 
• Your regular prescribers should look at this web site http://medicine.iupui.edu/clinpharm/ddis/table.asp to see if any medicine they want to prescribe is on a list of drugs to avoid.   
• Please be very careful! Over -the-counter drugs have a brand name on the label—it’s 
usually big and catches your eye. They also have a generic name—it’s usually small and printed on the ingredient list. Find the generic name (your pharmacist can help) and look at the table on the back of this page. Be careful. 
 
• You should not take St. John’s wort or grapefruit juice with sunitinib.  
 • You should not receive steroids unless they are absolutely necessary; tell your study 
doctor if you are taking, have a prescription for, or have been given steroids. 
 
• You should not take drugs that affect your heart rhythm.  Tell your study doctor if you 
are taking, have a prescription for, or have been given such heart medications. 
 
Other medicines can be a problem with your study drugs.  
Abbreviated Title:  Ph2Sunitinib Thymoma/Thymic Ca CTEP Protocol #: 9174  
Version Date:  04/30/2020  
 
 102 • You should check with your doctor or pharmacist whenever you need to use an over-the-
counter medicine or herbal supplement.  
 
• Your regular prescriber should check a medical reference or call your study doctor before 
prescribing any new medicine for you. Your study doctor’s name is  
 ________________________________ and he or she can be contacted at   ________________________________.  
 
                                   
Abbreviated Title:  Ph2Sunitinib Thymoma/Thymic Ca CTEP Protocol #: 9174  
Version Date:  04/30/2020  
 
 103 
 
      
  
INFORMATION ON POSSIBLE DRUG INTERACTIONS  
You are enrolled on a clinical trial using the experimental agent 
sunitinib .  This clinical trial is sponsored by the NCI.   Sunitinib  
interacts with drugs that are processed by your liver.  Because of this, 
it is very important to:  
 Tell your doctors if you stop taking regular medicine or if you start 
taking a new medicine.  
 Tell all of your prescribers (doctor, physicians’ assistant, nurse practitioner, pharmacist) that you are taking part in a clinical trial.  
 Check with your doctor or pharmacist whenever  you need to use 
an over- the-counter medicine or herbal supplement.  
 
  
 Sunitinib  interacts with a specific liver enzyme called CYP3A4 , and 
must be used very carefully with other medicines that interact with 
this enzyme.  
 Before you start the study, your study doctor will work with your 
regular prescriber to switch any medicines that are considered 
“strong inducers/inhibitors or substrates of CYP3A4 .” 
 Before prescribing new medicines, your regular prescribers should 
go to http://medicine.iupui.edu/clinpharm/ddis/table.asp for a list 
of drugs to avoid, or contact your study doctor.   
 Your study doctor’s name is ______________  and can be 
contacted at ______________ .  
 
Abbreviated Title:  Ph2Sunitinib Thymoma/Thymic Ca CTEP Protocol #: 9174  
Version Date:  04/30/2020  
 
 104 28 APPENDIX I : LIST OF PRESCRIPTION  AND OVER THE COUNTER 
MEDICATIONS THAT MAY INTERACT WITH SUNITINIB (SUTENT ®) 
 
 
   
 
   
 
   
 
    
 
   
 
   
 
   
 
   
 
   
 
   
 
   
 
   
 
    
 
 Acetaminophen    
Acetazolamide  
Albuterol  
Alfentanil  
Alprazolam  
Aminoglutethimide  
Amioderone  
Amlodipine  
Amprenavir  
Aprepitant  
Aripiprazole  
Atazanavir  
Atorvastatin 
Azelastine  
Azithromycin 
Benzphetamine  
Betamethasone  
Bisoprolol  
Bortezomib  
Bosentan  
Bromazepam  
Bromocriptine  
Buprenorphine  
Buspirone  
Busulfan  
Caffeine  
Carbamazapine  
Cerivastatin  
Chloramphenicol  
Chlordiazepoxide  
Chloroquine  
Chlorpheniramine  
Chlorzoxazone  
Cimetadine  
Ciprofloxacin 
Cisapride  
Citalopram  
Clarithromycin  
Clemastine  
Clobazam  
Clofazimine  
Clonazepam  
Clorazepate  
Clotrimazole  
Clozapine  
Cocaine  
Colchicine  
Cyclophosphamide  
Cyclosporine  
Danazol  
Dantrolene  
Dapsone  
Delavirdine  
Desipramine  
Dexmedetomidine  
Diazepam  
Diclofenac Digitoxin  
Dihydroergotamine  
Diltiazem  
Disopyramide  
Disulfiram  
Docetaxel  Doxepin  
Doxorubicin  
Doxycycline  
Drospirenone  
Efavirenz  
Eletriptan  
Enalapril  
Enoxacin  
Entacapone  
Eplerenone  
Ergoloid mesylates  
Ergonovine  
Ergotamine  
Erythromycin  
Escitalopram  
Estradiol  
Estrogens, conj., synthetic 
Estrogens, conj., equine 
Estrogens, conj., esterified  
Estrone  
Estropipate  
Ethinyl estradiol  
Ethosuximide  
Etoposide  
Felbamate  
Felodipine  
Fentanyl  
Fluconazole 
Fluoxetine  
Flurazepam  
Flutamide  
Fluvastatin  
Fluvoxamine  
Fosamprenavir  
Fosphenytoin  
Fulvestrant  
Gefitinib  
Glyburide  
Grapefruit juice  
Halofantrine  
Haloperidol  
Hydralazine  
Ifosfamide  
Imatinib  
Indinavir  
Irbesartan  
Irinotecan  
Isoniazid  
Isosorbide dinitrate  
Isosorbide mononitrate  
Isradipine  
Itraconazole  
Ketamine  
Ketoconazole  
Lansoprazole  
Letrozole  
Levomethadyl acetate  
hydrochloride  
Levonorgestrel  
Lidocaine  
Lomustine  
Losartan  
Lovastatin  Medroxyprogesterone Mefloquine  
Mefloquine  
Mestranol  
Methadone  
Methimazole  
Methoxsalen  
Methylergonovine  
Methylprednisolone  
Methysergide  
Metronidazole  
Miconazole  
Midazolam  
Mifepristone  
Miglustat Mirtazapine  
Mitoxantrone  
Modafinil  
Montelukast  
Moricizine  
Nateglinide  
Nefazodone  
Nelfinavir  
Nevirapine  
Nicardipine  
Nifedipine  
Nimodipine  
Nisoldipine  
Nitrendipine  
Nizatidine  
Norethindrone  
Norfloxacin  
Norgestrel  
Olanzapine  
Omeprazole  
Orphenadrine  
Oxcarbazepine  
Oxybutynin  
Ondansetron  
Paclitaxel  
Paroxetine  
Pentobarbital  
Pergolide  
Phencyclidine  
Phenobarbital   
Phenytoin Pilocarpine  
Pimozide  
Pioglitazone  
Pravastatin  
Prednisolone  
Primaquine  
Primidone  
Progesterone  
Propofol  
Propoxyphene  
Quetiapine  
Quinidine  
Quinine  
Quinupristin  
Rabeprazole Repaglinide Rifabutin  
Rifampin  
Abbreviated Title:  Ph2Sunitinib Thymoma/Thymic Ca CTEP Protocol #: 9174  
Version Date:  04/30/2020  
 
 105  
  
Rifapentine   
Risperidone  
Ritonavir  
Saquinavir  
Selegiline  
Sertraline  
Sibutramine  
Sildenafil  
Simvastatin  
Sirolimus  
St. John’s wort   
Sufentanil  
Sulconazole  
Tacrolimus  
Tamoxifen  
Tamsulosin  
Telithromycin  
Teniposide  
Terbinafine  
Testosterone  
Tetracycline  
Theophylline  
Tiagabine  
Ticlopidine  
Tolterodine  
Toremifene  
Tranylcypromine  
Trazodone  
Triazolam  
Trimethoprim  
Trimipramine  
Troleandomycin  
Valproic acid  
Vardenafil  
Venlafaxine  
Verapamil  
Vinblastine  
Vincristine  
Vinorelbine  
Zafirlukast  
Ziprasidone  
Zolpidem  
Zonisamide  
Zopiclone  
 